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1. Introduction
Acute myeloid leukemia (AML) is a highly heterogeneous disease which it is 
thought to be the result of a multi-step process  of genetic transformations. This has 
a large impact on the clinical presentation of the disease, and on the development, 
the choice and management of therapy of patients with AML. This thesis describes 
various aspects of AML in the context of genome-wide expression profi ling, a 
promising new technique for new diagnostic approaches and therapeutic target 
discovery in AML. 
1.1 Hematopoiesis 
The formation of mature blood cells, or hematopoiesis, is characterized by the 
existence of pluripotent hematopoetic stem cells (HSC), which upon stimulation 
with different growth factors proliferate and differentiate into all functional end 
cells of the hematopoietic system (Figure 1).
1.1.1 Embryonal development of the hematopoietic system
In the fi rst phase post-conception, the fertilized egg proliferates and forms a 
blastocyst, a thin-walled hollow sphere made up of an outer layer of cells, a fl uid 
fi lled cavity and an inner cell mass containing pluripotent stem cells. In two 
weeks, blastocyst cells differentiate into three different functional germ layers, 
ectoderm, endoderm and mesoderm. Like muscle and central nervous system 
tissue, the hematopoietic tissues arise from the mesoderm layer. The hematopoietic 
system is established in a sequential way during development (Figure 2). In mice, 
hematopoietic stem cells or HSC can be found in the yolk sac as early as day E7. 
Until recently, these HSC were thought to originate from sites in the yolk sac (1). 
The hematopoietic system of birds and amphibians, however, was shown to arise 
from an area surrounding the dorsal aorta, gonads and pro-/mesonephros (AGM) 
(2, 3) and this observation was later on reproduced in vertebrates.  It is thought that 
yolk sac hematopoietic cells, i.e. primitive hematopoiesis, are transient blood cells 
only present during embryogenesis, whereas defi nitive hematopoiesis arises from 
the AGM-region (4-7). There are indications that HSCs colonizing the fetal liver are 
partially generated in the placenta (8).  Later in embryonic development, HSC from 
the AGM colonize the liver and subsequently the bone marrow, which will remain 
the site of hematopoiesis during adult life (9). 
1.1.2 Hematopoietic stem cells and hematopoiesis
All mature and functional end cells of the hematopoietic system, i.e. cells of 
bone marrow, blood, spleen and thymus, are derived, following proliferation, 
differentiation and maturation, from hematopoietic stem cells.  This process is 
under tight control of a network of proliferation and differentiation stimulating 
glycoproteins such as granulocyte macrophage-colony stimulating factor , KIT 
ligand  and erythropoetin (Figure 1) (10-16). In addition, HSC are tightly coupled with 
stromal and mesenchymal cells that constitute and produce the microenvironment. 
It is this microenvironment that produces a variety of stimulatory and inhibitory 
factors that control and determine HSC development (17, 18). 
Various progenitor and differentiated blood cell types are derived from the HSC 
and can be classifi ed into two major branches; a myeloid branch, giving rise to 
13
Introduction
granulocytes (neuthrophiles, eosinophils and basophils), monocytes/macrophages, 
erythrocytes and platelets; and a lymphoid branch from which B-cells and T-cells 
are derived (Figure 1). 
Pluripotency is a key feature of HSC. An additional criterium to qualify as true HSC 
is self-renewal capacity (10, 19, 20). HSC have a very high proliferation capacity; in 
fact, one cell can sustainably repopulate the entire hematopoietic system in mice in 
three months (21-23). Several marker proteins, such as c-KIT, CD34, macrophage 
antigen 1 and stem cell antigen 1, can be used to establish the origin of different 
Figure 1. Schematic representation of hematopoiesis. Different types of mature blood 
cells arise from the hematopoietic stem cells, passing through various different stages of 
progeny. These processes require distinct growth factors including different interleukines 
(IL), thrombopoeitin (TPO), granulocyte colony stimulating factor (GCSF) and macrofage 
colony stimulating factor (MCSF).
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HSCs (24).  Stem cell antigen 1 has been identifi ed as a marker for AGM HSC, where 
additional macrophage antigen 1 presence may predispose for liver colonization 
(25, 26). Using  markers, such as CD34, stem cell antigen 1, c-KIT and absence of 
LIN1, 0.1% of hematopoietic cells have been estimated as HSC (15). 
1.2 Acute myeloid leukemia
Leukemia (derived from the Latin terms leuko (white) and heme (blood)) is a 
disease in which the hematopoietic system completely or partially fails to produce 
functional blood cells.  In general, leukemia can be distinguished into myeloid 
leukemia and lymphoid leukemia, which relates to the type of progenitor cell 
from which the malignant cells are derived. Both can be further subdivided into 
acute and chronic forms. In chronic disease increased numbers of more mature 
malignant cells, which are partially functional, are present in the bone marrow and 
blood. In acute leukemia, immature blood cells accumulate in bone marrow and 
blood, which leads to complete disruption of normal hematopoiesis.
In the United States, incidence of AML is approximately 3 cases per 100.000 
inhabitants per year. This increases with age, up to 12.6 cases per 100.000 inhabitants 
older than 65 per year (27). Incidence in the Netherlands maybe somewhat less, with 
726 new cases in 1996, which translates to 1.8 new cases per 100.000 inhabitants per 
year (28).  With 65.000 people diagnosed with cancer annually, this makes AML 
one of the less frequently found cancers in the Netherlands (29).
1.2.1 Diagnosis and prognosis 
AML diagnosis and establishing prognosis is a multidisciplinary process in 
which morphology, cytology, immunophenotyping, cytogenetics and molecular 
Figure 2. Schematic representation of the origin of HSC in different stages of 
development. During development, hematopoiesis shifts from sites in the yolk sac to 
ultimately the bone marrow.
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diagnostics are combined. The primary diagnosis of AML is established through 
cytological and cytochemical identifi cation of leukemic blast cells in blood and bone 
marrow. Further, the myeloid lineage is confi rmed by immunophenotyping. These 
examinations serve as the basis for the French-American-British classifi cation (30-
33)., which does not harbor prognostic value. Recently, the French-American-British 
classifi cation has been replaced by the World Health Organization classifi cation (34, 
35). The latter classifi cation also incorporates cytogenetic and molecular analysis 
and uses clinical features e.g. preceding therapy or an antecedent hematological 
disease. The World Health Organization classifi cation has recently replaced the 
French-American-British classifi cation .  
Immunophenotyping is used to characterize the blast population and plays a role 
mainly in diagnosis rather than in prognosis. Using several monoclonal antibodies, 
such as CD34 (stem/progenitor cell marker), CD2, CD3 and CD5 (T-lymphoid 
markers), CD19, CD20 (B-lymphoid markers),  myeloperoxidase, CD14, CD15 
(monoblast/monocyte/macrophage markers) and glycophorin A (erythrocyte 
marker), cellular differentiation lineage of the leukemia is established. 
More traditional prognostic markers are known, e.g. age and white blood cell 
count per mm3 (36). The classifi cation of prognostic risk is commonly derived 
from the presence or absence of particular cytogenetic and molecular markers. 
For example, AMLs with recurrent balanced translocations such as inversion(16), 
translocation(15;17), translocation(8;21) are associated with a relatively favorable 
prognosis. In addition to the recurrent translocations, t(8;21), inv(16) and 
t(15;17), several other acquired deletions and amplifi cations, such as deletions of 
chromosome 5 or 7, or trisomy of chromosome 8 are frequently present in patients 
with AML (37-46). 
With remission induction therapy, 70-80% of young and middle-aged adults will 
successfully obtain a complete remission. On average, overall survival in AML is 
approximately 40% after 5 years for patients less than 60 years of age. Based on 
presence of inversion(16), translocation(15;17) or translocation(8;21), approximately 
20 percent of de novo AMLs is classifi ed as favorable prognosis. Patients with these 
abnormalities show an overall survival after 5 years of 60 to 70% and a complete 
remission rate of 90% (43). Presence of translocation(9;22), translocation(6;9), 
deletion(5) or (5q), deletion(7) or (7q) or translocation(11q23),  represents another 20 
percent of patients, who are usually classifi ed as having an unfavorable prognosis. 
Overall survival in these cases is approximately 15% (47, 48). 
Translocations of specifi c chromosomes are not only identifi ed by cytogenetics, but 
the resulting fusion mRNA transcripts are also detectable by molecular diagnostics. 
Molecular diagnostic techniques, such as Southern blotting and reverse transcriptase 
polymerase chain reaction, offer the advantage of relatively easy implementation, 
the possibility to detect cryptic chromosomal abnormalities as well as the advantage 
of measuring abnormal subpopulations with increased sensitivity. In addition to 
the detection of recurrent translocations, molecular diagnostics is also applied to 
detect genetic point mutations and small duplications and deletions (49-52).  
Not only large chromosomal aberrations have prognostic impact; several genetic 
mutations have been shown to impact on prognosis have been identifi ed. Mutations 
in the gene encoding CCAAT/enhancer binding protein alfa (CEBPα) defi ne 
AML with a relatively good response to treatment (51, 52) , while internal tandem 
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duplications and tyrosine kinase duplications in fms-related tyrosine kinase 3 gene 
(FLT3) are associated with a poor prognosis (53, 54). Other mutations, such as in the 
genes encoding tumor protein 53 (TP53), and Wilms’tumor suppressor  (WT1) and 
high expression of the brain and acute leukemia cytoplasmic gene (BAALC), WT1 
and ecotropic virus integration 1 (EVI1) are considered markers for unfavorable 
prognosis (55-57). An overview of prognostic markers and their prevalence is 
given in Table 1. 
Although not routinely applied at most institutions, autonomous growth of blast 
cells has also been shown to have prognostic impact (58, 59).
1.2.2 Treatment 
Survival rates for AML have increased during recent decennia. Currently, the 
5-years survival rate for AML patients under the age of 60 is approximately 40 
percent, coming from a value of only 15 percent in the 1970s (60). 
The fi rst goal of AML treatment is to induce a remission in order to restore normal 
hematopoiesis.  The second goal of treatment following the initial effort of leukemia 
eradication is to prevent relapse. This second phase of treatment may involve 
the use of additional chemotherapy or the application of hematopoietic stem cell 
transplantation. 
A special case is the treatment of acute promyelocytic leukemia, a subclass of 
acute myeloid leukemia.  Acute promyelocytic leukemia responds uniquely to 
the differentiation-inducing effects of trans-retinoic acid, usually administered in 
combination with chemotherapy. Retinoic acid is in fact a ligand of the retinoic 
acid receptor alfa protein, which is involved in the acute promyelocytic leukemia 
specifi c t(15;17) chimeric fusion protein (61). 
New developments in drug therapeutics include the development of small molecules 
targeting specifi c enzymes. An example of such a small molecule is imatinib, a 
drug originally developed for the treatment of chronic myeloid leukemia (62). Over 
90% of chronic myeloid leukemia cases presents with a reciprocal translocation of 
chromosomes 9 and 22. Imatinib specifi cally inhibits the Abelson murine leukemia 
tyrosine kinase, which is part of the fusion protein resulting from the t(9;22) 
translocation. Imatinib binds to the centrally located activation loop of the Abelson 
murine leukemia protein (63). This translocation is also infrequently (1-2%) seen in 
AML, thus in special cases of AML, imatinib may be applied. In AML, other small 
molecules are being developed, e.g. those that target FLT3 and RAS (64, 65).  
1.2.3 Pathogenesis
AML is a highly heterogeneous stem cell disease in which a variety of cytogenetic 
aberrations and molecular mutations can be involved. These abnormalities relate to 
different pathogenetic mechanisms affecting proliferation, differentiation,apoptosi
s, self-renewal and DNA repair. AML is not initiated by a single genetic event but it 
is thought to be the result of a multi-step process in which genetic transformations 
accumulate (66-68). 
Many routes of leukemogenesis are yet to be elucidated. During many years of 
scientifi c research the structural and functional consequences of balanced reciprocal 
translocations have been investigated. In AML, chromosomal translocations lead to 
the formation of chimeric fusion proteins. Examples of genes that generate fusion 
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Cytogenetic 
abnormality
Genes 
involved
Prognosis Frequency
t(8;21)(q22;q22) AML1-ETO Favourable 8-12%
inv(16)inv(16)(p11;q22) CBFβ-MYH11 Favourable 4-10%
t(15;17)(q22;q11) PML-RARα Unfavourable 8-12%
11q23 abnormalities MLL Unfavourable 4-6%
-5/5q Unknown Unfavourable 2-4%
-7/7q Unkown Unfavourable 6-8%
t(6;9)(q34;q11) DEK-CAN Unfavourable 1%
t(9-22)(q34;q11) BCR-ABL Unfavourable <1%
3q26 abnormalities EVI1 Unfavourable 1-3%
3q26 abnormalities Unknown Unfavourable 4-6%
+8 Unknown Unclear 8-10%
Table 1A. Cytogenetic abnormalities in AML
Marker Prognosis Frequency
FLT3 internal tandem duplication Unfavourable 25%
FLT3 tyrosine kinase domain Unclear 10-12%
High EVI1 expression Unfavourable 5-10%
TP53 mutation Unfavourable 3-5%
High BAALC and WT1 expression Unfavourable 30-40%
N-RAS mutation Unclear 8-12%
K-RAS mutation Unclear 3-5%
High ERG expression Unfavourable 25%
CEBPα Favourable 5-10%
Table 1B. Molecular markers added to cytogenetics with prognostic signifi cance
proteins are the PML-RARα gene (promyelocytic leukemia - retinoic acid receptor 
alfa), the AML1-ETO gene (acute myeloid leukemia – eight twenty-one) and the 
CBFβ–MYH11 gene (core binding factor beta - myosin heavy chain 11) in AMLs 
with t(15;17), t(8;21) and inv(16), respectively (69-72). 
PML, part of the PML-RARα fusion protein, in normal cells is present in nuclear 
structures called PML nuclear bodies. PML is involved in several processes, such 
as regulation of cyclin D1 via interaction with eukaryotic translation initiation 
factor 4E, as a tumor suppressor protein through regulation of nuclear body 
proteins and is also believed to have a role in TP53-dependent as well as TP53-
independent apoptosis pathways (73-78). PML has also been proposed to function 
as a transcriptional regulator via interaction with pRb in the nuclear bodies, thereby 
displaying an inhibitory effect on the pRb-regulated activation of the glucocorticoid 
receptor (79), and its interaction with Pu.1, leading to transcriptional repression of 
the Pu.1-dependent epidermal growth factor receptor gene promoter. Decreased 
expression of Pu.1 has been shown to induce AML in mice (80). However, there 
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has been no direct experimental evidence supporting a direct effect of PML on 
transcriptional regulation, and it is important to note that PML nuclear bodies do 
not associate with sites of active transcription and do not localise with nascent 
DNA (81). Under normal physiological conditions, RARα dimerizes with retinoic-
X-receptors to form a complex that act as nuclear retinoid receptors (82). The 
PML-RARα fusion protein is a dominant negative RARα mutant, indicating that 
it can bind to retinoic-X-receptors with stronger affi nity than the wild-type (83) 
and it has been shown that in absence of retinoic acid, the complex can repress 
transcriptional activation through histone deacetylation (84, 85). It is therefore 
thought that oncogenic retinoic acid receptors mediate leukemogenesis through 
aberrant chromatin acetylation. However, the PML-RARα fusion in itself is not 
suffi cient to cause leukemia in genetically modifi ed mice, indicating the necessity 
for additional defects (86). 
Both components of the heterodimeric transcription factor CBF, the Core Binding 
Factor complex (CBF), are disrupted in recurrent chromosomal translocations 
observed in AML. AML1 (RUNX1, CBFA2), encodes the α-unit of CBF and is fused 
to ETO in the t(8;21) translocation.  The β-unit of CBF is encoded by the CBFβ gene, 
which is involved in the inv(16) abnormality.  The α-unit of CBF binds to DNA 
while the β-unit has a stabilizing role and does not have direct DNA contact (87). 
CBF recognizes a core DNA sequence TGT/cGGT, which is present in regulatory 
elements of several cellular promoters and enhancers of various hematopoietic-cell 
specifi c genes (88, 89). It has been noted that apart from the core binding sequence, 
adjacent binding sites for lineage-specifi c transcription factors, such as CEBPα and 
ETS family members, are also important and may direct transcription of lineage-
specifi c genes (90, 91). These observations support the hypothesis that CBF may 
function as a transcriptional organizer that recruits specifi c factors into a complex 
that affects lineage-specifi c transcription (92). ETO, which is fused to AML1 as 
a result of t(8;21), is normally part of a complex, including histone deacetylase 
proteins, that mediates transcriptional repression  (93, 94). The fusion protein 
AML1-ETO is capable of recruiting histone deacetylase proteins, resulting in the 
transcriptional repression of CBF targets such as interleukin 3 and granulocyte-
macrophage colony stimulating factor (95). The fusion protein CBFβ-MYH11 can 
interfere with CBF DNA binding by sequestering the CBFα subunit, although the 
CBFβ-MYH11-CBFα complex retains the ability to bind DNA (96, 97). It is also 
possible that the fusion exerts its effect via local interference in transcriptional 
processes (96, 98). However, t(8;21) and inv(16)/t(16;16), respectively, do not cause 
frank leukemia, indicating that in these leukemias other  abnormalities must be 
present (99-104). 
Disruption of transcription factors is commonly seen in AML. Mixed lineage leukemia 
gene (MLL), the gene implicated in cytogenetical abnormalities involving 11q23, is 
a regulator of homeobox (HOX) genes (105, 106). The transcription factor CEBPα, 
that is mutated in approximately 8% of AML patients, is essential for granulocytic 
differentiation (107). EVI1 is a DNA binding protein and is localized in the nucleus 
(108). EVI1 is involved in 3q26 abnormalities. As a result of juxtaposition of EVI1 to 
the regulatory elements of the ribophorin 1 gene, EVI1 is overexpressed. EVI1 may 
also be overexpressed in cases lacking 3q26 abnormalities (109). Ectopic expression 
of EVI1 in immature hematopoietic cells in vitro interferes with erythroid and 
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granulocytic development (110, 111). 
Internal tandem duplications and tyrosine kinase domain mutations are frequently 
seen in FLT3. These lead to constitutively active receptors that activate proteins 
involved in signaling pathways, such as STAT5A and PI3K (112, 113). Mutations in 
FLT3, NRAS and KRAS genes are considered to be secondary mutations. They do 
not appear to have a role in the initiation of the neoplastic transformation, but are 
thought to be required for progression (114). RAS proteins transduce signals from 
the extracellular environment (typically initiated by receptor tyrosine kinases) 
to the nucleus via downstream mediator proteins such as mitogen-activated 
protein kinases and phosphatidylinositol 3-kinase. Mutations in RAS lead to 
impaired guanosine tri-phosphate hydrolysis and increased signal transduction 
and are frequently involved in human cancer. Mutations in nucleophosmin were 
recently identifi ed and are found in approximately 35% of AML patients (115). 
Nucleophosmin is predominantly localized in the nucleus and is thought to act as 
a molecular chaperone, regulating the transport and assembly of pre-ribosomal 
proteins. 
As mentioned earlier, mice expressing AML-related fusion genes such as AML1-
ETO, CBFβ-MYH11 or PML-RARα only develop AML at very low frequency 
and with long latency, indicating the necessity of secondary events (101, 116, 
117).  Retroviral insertional mutagenesis offers a powerful experimental strategy 
to identify genes involved in cancer (118, 119). Due to integration of a virus in 
the genome, genes are disrupted, leading to increased or decreased expression, 
or disrupted gene products. When the virus integrates in a critical gene or in the 
regulatory sequences of a critical gene, this may cause cancer. Identifi cation of 
common sites of viral insertion is indicative of the presence of genes involved in 
leukemogenesis. In recent years, retroviral insertional mutagenesis has greatly 
benefi ted from the sequencing of the mouse genome and the development of fast 
polymerase chain reaction based strategies and (semi-)high throughput sequence 
protocols. This method has also been applied in leukemia as an approach to 
identifying leukemia genes and has resulted in lists of candidate proto-oncogenes 
(120, 121). 
1.3 High-throughput assessment of RNA expression patterns
1.3.1 History of cDNA microarrays
With several publications, Mark Schena and Patrick O. Brown of the Department 
of Biochemistry at the Stanford University were amongst the fi rst investigators 
who reported a new tool of expression monitoring: microarrays. (122-124). Base-
pairing (i.e., A-T and G-C for DNA; A-U and G-C for RNA) or complementary 
hybridization of nucleotide sequences is the underlying principle for microarrays. 
Transcriptomics, the high-throughput measurement of RNA expression using 
microarrays, has greatly benefi ted from the deciphering of the human genome 
sequence (125, 126). On the fi rst microarray, 1.0 kilobase (kb) cDNA (DNA 
complementary to RNA) sequences of 48 Arabidopsis expressed sequence tags were 
attached to a glass microscope slide. From total Arabidopsis mRNA, fl uorescently 
labeled probes were prepared and hybridized to an array at high stringency. Due 
to this fl uorescent label, each expressed sequence tag spot could be scanned using 
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a laser scanner and each intensity corresponded to the concentration of specifi c 
mRNA in the hybridization-mix (123).  Later, this system was refi ned such that 
two hybridization-mixtures competitively bound to the same array. This facilitated 
comparison of mRNAs concentrations in two mixtures (127). These arrays are 
known as dual-channel microarrays. The two mixtures carry different fl uorescent 
labels (Cy-3 and Cy-5) that are detected at different wavelengths. From that point, 
dual-channel array printing facilities were introduced at scientifi c institutes and 
microarrays were rapidly incorporated into scientifi c research. At the end of 1998, 
35 publications reported on microarray-technology. At the end of 2000, this number 
had exponentially increased to 413 publications and to date, more than 12.000 
articles concerned with microarrays have been published. However, the quality and 
content of the ‘home-made’ arrays greatly differed. To be able to compare results of 
different experiments in different institutions, standardization is needed. 
Affymetrix Inc has developed a second type of microarrays, i.e., single-channel 
microarrays. The Affymetrix platform interrogates RNA expression using 
much shorter oligonucleotides (20-80 bp). It is produced using advanced photo-
lithography instead of high-speed robotics (an overview of this process is 
described in section 1.3.3) (128).  An important feature of the technique is that 
one single biological sample is hybridized to the array, which gives a quantitative 
measurement of mRNA concentrations. Other techniques for manufacturing 
microarrays have been developed, e.g. inkjet printing of oligonucleotides (Agilent) 
and piezoelectric dispensic robots which couple oligonucleotides to a glass slide 
covered with a polymer fi lm (Motorola/Amersham Codelink™) (129, 130). 
Affymetrix GeneChips® have become a particularly frequently used platform, and 
currently furnish a standard in transcriptomics research. 
1.3.2 History of oligonucleotide arrays 
In 1991, Fodor and colleagues published an article about the light-directed 
synthesis of a 1024-peptide array (131). In subsequent years, this technique was 
optimized and focus shifted towards oligonucleotide arrays.  In 1994, a study was 
published on the use of oligonucleotide arrays for the use of rapid DNA sequence 
analysis (132, 133). Although DNA sequence analysis using array technology has 
also proven to be feasible, this technique initially focused on the analysis of mRNA 
expression (128, 134). Currently, DNA sequence analysis is increasingly applied.
Golub et al. made use of Affymetrix GeneChips to classify AML and ALL samples, 
while Winzeler et al functionally characterized the Saccharomyces cerevisiae 
genome (135, 136). Both articles are now recognized as landmark studies, with 
currently 3254 and 902 citations, respectively.  
The fi rst commercially available oligonucleotide array was introduced in 1998 
and consisted of four different arrays and represented 8000 genes (137). Due to 
shrinkage of feature size and more accurate data present in the sequence databases, 
allowing decreasing the number of probes per probe set, the number of genes 
present on subsequent platforms increased. Currently available oligonucleotide 
arrays contain approximately 55.000 probe sets, representing approximately 19.000 
genes. 
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1.3.3 Synthesis and design of oligonucleotide arrays
Affymetrix oligonucleotides arrays, i.e., silicium slides of 1.28 cm by 1.28 cm, 
contain 25-mer oligonucleotides or probes. They are organized around probe sets 
and each probe set measures expression of a single gene. A probe set consists of 11 
to 15 probes which are exactly complementary to cDNA (Perfect Match probes, PM) 
and a similar number of probes in which the middle, or 13th, nucleotide has been 
altered (MisMatch probes, MM) (Figure 3).  All probes have been designed in the 
anti-sense direction. The group of probes corresponding to a given gene generally 
spans a region of about 600 bases at 3’-end of the start site of the gene, known as the 
target sequence. Most genes are represented by multiple probe sets, up to 16 probe 
sets for one gene, allowing some redundancy in cases of genes for which different 
sequences existed in different databases. Moreover, potential splice variants can be 
interrogated this way. The full-length genes are selected from different databases. 
For the HGU133 set, sequence clusters were abstracted from UniGene build 133 
(April 2001), which were refi ned by comparison to other GenBank, RefSeq and 
dbEST. 
Arrays are synthesized in a photolithographic process, which combines techniques 
from semiconductor fabrication, solid phase and combinatorial chemistry and 
robotics.  Probes on the array are built by transmitting light to specifi c locations. 
Washing the array surface using specifi c nucleotide mixes sequentially generates 
the oligonucleotide requested on all positions. In earlier arrays, probes of the same 
probe set were synthesized at the same physical location. To prevent local biases, 
probes are currently randomly divided over the chip.
To analyze mRNA expression, RNA is isolated from the sample source. Subsequent 
steps are synthesis of cDNA of the RNA source, generation of biotin-labeled 
Figure 3. Overview of Affymetrix GeneChip design. 11 To 15 Perfect Match and 
Mismatch probes are combined in one probe set, representing one gene. Intensity values of 
a probe set are summarized into an expressionvalue.
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antisense mRNA, fragmentation of the resulting cRNA and hybridization of the 
cRNA fragments on the array. After hybridization, the array is stained with a 
fl uorescent molecule (streptavidin-phycoerythrin) that binds to the biotin-cRNA. 
Scanning the chip with a confocal laser results in light emission, which is converted 
into intensity signals. 
1.3.4 Preprocessing intensity data: expression measurement
The fi rst step in the analysis process of oligonucleotide array data is to construct 
expression levels from intensity values. Multiple perfect match and mismatch 
probes measure expression for each gene. An expression level is obtained by 
arithmetically combining all probes in a probe set.  Several non-biological 
factors, such as stronger local hybridization or cross-hybridization of mRNA, can 
infl uence intensity. This may result in different background intensities and other 
methodological variation (138, 139). Therefore, the data have to be normalized 
before different experiments can be compared. Combining probe intensity signals 
can be done in several ways. Affymetrix has developed an algorithm of which the 
latest version was implemented in their analysis package Microarray Analysis 
Suite 5.0 (MAS5.0),which is called MAS5. This method normalizes intensities 
using a global scaling procedure and measures expression using a one-step 
Tukey biweight algorithm, which is defi ned as the anti-log of a robust average of 
differences between log(perfect match) and log(mismatch) (140). However, the a-
specifi city of the mismatch probes has been under debate and therefore, alternative 
methods have been developed (141). One of the fi rst alternatives was the dChip-
method, which scales the intensity data towards the median intensity in a group 
of arrays and then uses model-based index estimates, giving variable weight to 
perfect match-mismatch probe pairs of a probe set based on variance between 
arrays, to measure expression (142). Irizarry et al. introduced RMA (robust multi-
array average), later followed by GCRMA (GC robust multi-array average) (143, 
144). RMA, often preceded by quantile normalization (143, 145), applies a median 
polish procedure to PM intensities only in summarization. GCRMA is based on 
a similar model as RMA but takes into account the effect of stronger bonding of 
G/C pairs (146, 147). Other normalization and summarization methods have been 
developed, such as the variance stabilizing normalization (VSN) (148), which are 
less frequently applied. The choice which method is to be preferred is far from 
straightforward and several attempts have been done to assess and compare the 
effects of different pre-processing and normalization techniques (149-152). 
1.3.5 Analysis and applications of gene expression profi les 
Expression profi ling has several biologically relevant applications. Microarrays 
have been used to identify cell cycle regulating genes in Saccharomyces cerevisiae 
and human cells by hybridizing cycle synchronized samples (153-156). A common 
application is to compare biological samples treated with and without a particular 
external factor, e.g. the comparative transcriptome analysis of murine skin tissue 
treated with and without ultraviolet light (157). Thus, expression signatures can be 
obtained of genes involved in particular cellular processes. Other examples of the 
utility of expression profi ling include identifi cation of genes involved in erythroid 
differentiation by comparing different lineages (158) or identifi cation of target genes 
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of CEPBα by comparing CEBPα-induced and non-induced cell populations (159). 
Expression profi ling of all specimens from patient cohorts can serve the objective 
of identifying different prognostic factors or identifying different disease subtypes. 
Gene expression profi ling has for instance been applied to classify different types 
of myeloid leukemia (160), to predict outcome of  central nervous tumors (161) 
and to predict de probability of developing metastasis in mamma tumors (162). 
Although model-based and patient cohort studies address different research 
questions, largely similar analysis methods are often applied. 
As microarray research generates lots of data, specifi c analysis methods are required. 
To identify general patterns and structure in data, cluster analysis and principal 
component analysis are often applied (163, 164). These analyses classify data in 
different categories based on similarities, thereby identifying groups of related 
genes or samples (163, 164). When no prior knowledge is imposed on the data, the 
analysis is designated unsupervised. Supervised analysis refers to an analysis in 
which prior knowledge of the samples is taken into account. An example of this 
type of analysis is the identifi cation of genes, which are differentially expressed in 
predefi ned subgroups of samples. In cancer research, this type of analysis can be 
used to identify genes that are potentially pathogenically relevant. Algorithms have 
been developed for this purpose, such as the Signifi cance Analysis of Microarrays 
algorithm (165) or Bayesian methods (166), are being applied. Another type of 
supervised analysis is prediction analysis, or classifi cation of samples. This can 
be performed to identify genes that are selectively expressed in a particular class 
of samples. Complementary to Signifi cance Analysis of Microarrays, Prediction 
Analysis of Microarrays (167) has been developed for this purpose. Machine 
learning algorithms such as support vector machines, are also regularly applied 
(168). If a set of genes is found to be predictive for a particular class of samples, it 
could be applied in a clinical setting to predict the identity of subsequent samples. 
1.4 Outline of this thesis
AML is a heterogeneous disease with a variable response to treatment (169). 
Classifi cation of AML is currently based on a combination of different laboratory 
techniques. Previously, expression profi ling has been shown to be able to distinguish 
myeloid from lympoid leukemia, and distinct subtypes within these diseases (136, 
160, 170, 171). 
The fi rst goal of the work described in this thesis is to investigate whether expression 
profi ling can be used to classify distinct AML subgroups with one comprehensive 
assay. Chapter 2 describes the results of an expression profi ling study using the 
bone marrow and blood specimens of a cohort of 285 de novo AML patients. 
Several statistical pre-processing methods exist to combine data obtained with 
oligonucleotide arrays into gene expression levels (140, 142, 143). Different pre-
processing methods may lead to different expression estimates and may therefore 
have an infl uence on the outcome of both supervised and unsupervised analyses. 
Chapter 3 describes an assessment of the magnitude of this effect. 
Recently, Falini and colleagues described the abberant cytoplasmic location of 
a new oncogene, i.e. nucleophosmin or NPM1, in approximately 35% of AML 
patients (115). Nucleophosmin is thought to function mainly as a molecular 
chaperone of proteins, facilitating the transport of ribosomal proteins through the 
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nuclear membrane. Mutations in NPM1 were described to result in its abnormal 
cytoplasmic location. Chapter 4 describes the presence, nature, and expression 
characteristics and the clinical prognostic value of these mutations in a cohort of 
275 AML patients.  
A variety of genes are differentially expressed in different subtypes of AML. 
Differentially expressed genes could be involved in the pathogenesis of AML, but 
could also relate to phenotypic variations of different leukemias, e.g. related to the 
maturation status. Chapter 5 specifi cally describes a methodology to distinguish 
pathogenetically relevant genes among large sets of differentially expressed genes 
in clinical AML by including results from retrovirally induced mouse leukemias. 
Acute interpretation of data obtained by unsupervised analysis of large scale 
expression profi ling studies is currently frequently performed by visually 
combining sample-gene heatmaps and sample characteristics. In Chapter 6, we 
present an implementation of an integration method for such visualizations.
At the end, the results described in this thesis are discussed (Chapter 7). 
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2.1  Abstract
2.1.1  Background
In patients with acute myeloid leukemia (AML) a combination of methods must 
be used to classify the disease, make therapeutic decisions, and determine the 
prognosis. However, this combined approach provides correct therapeutic and 
prognostic information in only 50 percent of cases. 
2.1.2 Methods
We determined the gene-expression profi les in samples of peripheral blood or 
bone marrow from 285 patients with AML using Affymetrix U133A GeneChips 
containing approximately 13,000 unique genes or expression-signature tags. Data 
analyses were carried out with Omniviz, signifi cance analysis of microarrays, and 
prediction analysis of microarrays software. Statistical analyses were performed 
to determine the prognostic signifi cance of cases of AML with specifi c molecular 
signatures.
2.1.3 Results
Unsupervised cluster analyses identifi ed 16 groups of patients with AML on the 
basis of molecular signatures. We identifi ed the genes that defi ned these clusters 
and determined the minimal numbers of genes needed to identify prognostically 
important clusters with a high degree of accuracy. The clustering was driven by 
the presence of chromosomal lesions (e.g., t(8;21), t(15;17), and inv(16)), particular 
genetic mutations (CEBPα), and abnormal oncogene expression (EVI1). We identifi ed 
several novel clusters, some consisting of specimens with normal karyotypes. A 
unique cluster with a distinctive gene-expression signature included cases of AML 
with a poor treatment outcome.
2.1.4 Conclusions
Gene-expression profi ling allows a comprehensive classifi cation of AML that 
includes previously identifi ed genetically defi ned subgroups and a novel cluster 
with an adverse prognosis.
2.2 Introduction
Acute myeloid leukemia (AML) is not a single disease but a group of neoplasms with 
diverse genetic abnormalities and variable responses to treatment. Cytogenetics 
and molecular analyses can be used to identify subgroups of AML with different 
prognoses. For instance, the translocations inv(16), t(8;21), and t(15;17) herald a 
favorable prognosis, whereas other cytogenetic aberrations indicate poor-risk 
leukemia (1-5). Abnormalities involving 11q23, t(6;9), or 7(q) are defi ned as poor-
risk markers by some groups (2,3) and as intermediate- risk markers by others 
(3-5). These inconsistencies and the absence of cytogenetic abnormalities in a 
considerable proportion of patients argue for refi nement of the classifi cation 
of AML. Additional reasons for extending the molecular analyses of AML are 
exemplifi ed by fi ndings regarding the gene for fms-like tyrosine kinase 3 (FLT3), the 
gene encoding ectotropic viral integration 1 site (EVI1), and the gene for CCAAT/
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enhancer binding protein alpha (CEBPα). An internal tandem duplication in FLT3, a 
hematopoietic growth factor receptor, is the most common molecular abnormality 
in AML (6,7). The presence of such mutations in FLT3 and elevated expression of 
the transcription factor EVI1 confer a poor prognosis, (6-8) whereas mutations in 
CEBPα are associated with a good outcome (9,10). Molecular classifi cation based on 
DNA-expression profi ling offers a powerful way of distinguishing myeloid from 
lymphoid cancer and subclasses within these two diseases (11-14). DNA-microarray 
analysis has the potential to identify distinct subgroups of AML with the use of 
one comprehensive assay, to classify cases that currently resist categorization by 
means of other methods, and to identify subgroups with favorable or unfavorable 
prognoses within genetically defi ned subclasses. The goals of this study of 285 
adults with AML were to use gene expression profi les to identify established and 
novel subclasses of AML and otherwise unrecognized cases of poor-risk AML.
2.3 Methods
2.3.1  Patients and cell samples
Eligible patients had received a diagnosis of primary AML, which had been 
confi rmed by means of a cytologic examination of blood and bone marrow (Table 
1). All patients were treated according to the protocols of the Dutch–Belgian 
Hematology–Oncology Cooperative group (available at www.hovon.nl) (15-17). 
All subjects provided written informed consent. A total of 285 patients provided 
bone marrow aspirates or peripheral-blood samples at the time of diagnosis and 
8 healthy control subjects provided peripheral-blood samples or bone marrow 
aspirates. Blasts and mononuclear cells were purifi ed by Ficoll–Hypaque (Nygaard) 
centrifugation and cryopreserved. CD34+ cells from three control subjects 
were sorted by means of a fl uorescence-activated cell sorter. The AML samples 
contained 80 to 100 percent blast cells after thawing, regardless of the blast count 
at diagnosis. 
2.3.2 Isolation and quality control of RNA
After thawing, cells were washed once with Hanks’balanced-salt solution. High-
quality total RNA was extracted by lysis with guanidinium thiocyanate followed 
by cesium chloride–gradient purifi cation (18). RNA levels, quality, and purity were 
assessed with the use of the RNA 6000 Nano assay on the Agilent 2100 Bioanalyzer 
(Agilent). None of the samples showed RNA degradation (ratio of 28S ribosomal 
RNA to 18S ribosomal RNA of at least 2) or contamination by DNA.
2.3.3 Gene profi ling and quality control
Samples were analyzed with the use of Affymetrix U133A GeneChips. Each gene 
on this chip is represented by 10 to 20 oligonucleotides, termed a “probe set.” 
The intensity of hybridization of labeled messenger RNA (mRNA) to these sets 
refl ects the level of expression of a particular gene. The U133A GeneChip contains 
22,283 probe sets, representing approximately 13,000 genes. We used 10 μg of total 
RNA to prepare antisense biotinylated RNA. Single-stranded complementary 
DNA (cDNA) and double-stranded cDNA were synthesized according to the 
manufacturer’s protocol (Invitrogen Life Technologies) with the use of the 
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Glossary
Centroid: In a self-organizing topologic map of gene expression, the centroid 
     corresponds to the center of a cluster.
Chromosomal abnormalities
     t(8;21): One of the commonest cytogenetic abnormalities in AML; produces a hybrid      
     gene by fusing AML1 on the long arm of chromosome 21 with ETO on the long arm 
     of chromosome 8.
     inv(16): Inversion of a segment of chromosome 16 that produces the CBFβ-MYH11 
     fusion.
     t(15;17): Reciprocal translocation of genetic material between the long arms of 
     chromosomes 15 and 17 that produces the PML-RARα fusion gene, typical of acute 
     promyelocytic leukemia.
     11q23: A chromosomal region that becomes rearranged with various partner 
     chromosomal regions in diverse forms of leukemia, involving the MLL gene.
     t(6;9): A rare translocation often found in young patients and sometimes associated 
     with basophilia.
     -7(q): Loss of the long arm of chromosome 7, on monosomy 7.
French–American–British (FAB) classifi cation: An internationally agreed-on method of   
     classifying acute leukemia by morphologic means. There are eight subtypes, ranging     
     from M0 (myeloblasts) to M7 (megakaryoblasts).
Gene-expression profi ling: Determination of the level of expression of thousands of  
     genes through the use of microarrays. Messenger RNA extracted from the test tissue   
     or cells and labeled with a fl uorescent dye is tested for its ability to hybridize to the 
     spotted nucleic acids.
Microarray or GeneChip: A robotically spotted array of thousands of complementary 
     DNAs or oligonucleotides.
Patient-clustering technique: A method of grouping patients with similar patterns of 
     gene expression.
Pearson’s correlation coeffi cient: A statistical measure of the strength of the relationship 
     between variables.
Pearson’s Correlation Visualization tool of Omniviz: Omniviz is a commercial 
     multifunctional statistical package used for analysis of microarray data. It allows the 
     visual representation of gene-expression profi les of patients in a Pearson’s Correlation 
    View.
Prediction analysis of microarrays (PAM): A statistical technique that identifi es a 
    subgroup of genes that best characterizes a predefi ned class.
Probe set: A group of 10 to 20 oligonucleotides; each set corresponds to one gene.
Signifi cance analysis of microarrays (SAM): A statistical method used in microarray 
    analyses that identifi es genes that are signifi cantly differentially expressed between 
    groups of patients on the  basis of a change in the level of gene expression relative to 
    the standard deviation of repeated measurements.
Supervised analysis: An analysis of the results of microarray profi ling that takes 
    external factors into account.
Unsupervised analysis: An analysis of the results of microarray profi ling that does not 
    take external factors such as survival or clinical signs into account.
10-Fold cross-validation: A validation method that works as follows: the model is fi tted 
    on 90 percent of the samples, and the class of the remaining 10 percent is then 
    predicted. This procedure is repeated 10 times, with each part playing the role of the 
    test samples and the error of all 10 parts added together to compute the overall error. 
    The error within the validation set refl ects the number of samples wrongfully 
    predicted to be in this set.
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T7-(deoxythymidine)24-primer (Genset). In vitro transcription was performed 
with biotin-11-cytidine triphosphate and biotin-16-uridine triphosphate (Perkin–
Elmer) and the MEGAScript T7 labeling kit (Ambion). Double-stranded cDNA and 
complementary RNA (cRNA) were purifi ed and fragmented with the GeneChip 
Sample Cleanup module (Affymetrix). Biotinylated RNA was hybridized to 
the Affymetrix U133A GeneChip (45°C for 16 hours). Staining, washing, and 
scanning procedures were carried out as described in the GeneChip Expression 
Analysis technical manual (Affymetrix). All GeneChips were visually inspected 
for irregularities. The global method of scaling, or normaliza tion, was applied, 
and the mean (±SD) difference between the scaling, or normalization, factors of 
all GeneChips (293 samples; 285 from patients with AML, 5 from subjects with 
normal bone marrow,and 3 from subjects with CD34+ cell samples) was 0.70±0.26. 
All additional measures of quality  — the percentage of genes present (50.6±3.8), 
the ratio of action 3’ to 5’ (1.24±0.19), and the ratio of GAPDH 3’ to 5’ (1.05±0.14) 
— indicated a high overall quality of the samples and assays. Detailed clinical, 
cytogenetic, and molecular cytogenetic information is available at the Gene 
Expression Omnibus (www.ncbi.nlm.nih.gov/geo, accession number GSE1159). 
2.3.4 Data normalization, analysis, and visualization
All intensity values were scaled to an average value of 100 per GeneChip according 
to the method of global scaling, or normalization, provided in the Affymetrix 
Microarray Suite software, version 5.0 (MAS5.0). Since our methods reliably 
identify samples with an average intensity value of 30 or more but do not reliably 
discriminate values between 0 and 30, these values were set to 30. This procedure 
affected 31 percent of all intensity values, of which 64 percent were fl agged as 
absent by the MAS5.0 software, 3 percent were fl agged as marginal, and 33  percent 
were fl agged as present according to the MAS5.0 software. For each probe set, the 
geometric mean of the hybridization intensities of all samples from the patients 
was calculated. The level of expression of each probe set in every sample was 
determined relative to this geometric mean and logarithmically transformed (on a 
base 2 scale) to ascribe equal weight to gene-expression levels with similar relative 
distances to the geometric mean. Deviation from the geometric mean refl ects 
differential gene expression. The transformed expression data were subsequently 
imported into Omniviz software, version 3.6 (Omniviz), signifi cance analysis of 
microarrays (SAM) software, version 1.21, and prediction analysis of microarrays 
(PAM) software, version 1.12.
2.3.5 Use of Pearson’s Correlation and Visualization Tool
The Omniviz package was used to perform and visualize the results of unsupervised 
cluster analysis (an analysis that does not take into account external information 
such as the morphologic subtype or karyotype). Genes (probe sets) whose level of 
expression differed from the geometric mean (refl ecting up- or down-regulation) in 
at least one patient were selected for further analysis. The clustering of molecularly 
recognizable specifi c groups of patients was investigated with each of the selected 
probe sets with the use of the Pearson’s Correlation and Visualization tool of 
Omniviz (provided in Fig. B, C, D, E, F, G, and H in Supplementary Appendix 1, 
available with the full text of this article at www.nejm.org). 
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Characteristic Value
Sex - no.(%)
          Male                    137 (48)
          Female                    148 (52)
Age group - no. (%)
          <35yr                      76 (27)
          35 - 60 yr                    177 (62)
          ≥60 yr                      32 (11)
Age - yr
          Median                         44
          Range                      15 - 78
White-cell count - x 10-3/mm3
          Median                         28
          Range                    0.3 - 582
Banoe marrow blast count - %
          Median                         66
          Range                       0 - 98
Platelet count - x 10-3/mm3
          Median                        45
          Range                     3 - 931
French-American-British classifi cation - no. (%)
          M0                             6 (2)
          M1                    63 (22)
          M2                    66 (23)
          M3                    19 (7)
          M4                    53 (19)
          M5                    65 (23)
          M6                      3 (1)
          Not determined                    10 (4)
Cytogenetic abnormalities - no. (%)*
          t(15;17)                    18 (6)
          t(8;21)                    22 (8)
          inv(16)/t(16;16)                    19 (7)
          +8                    26 (9)
          +11                      7 (2)
          +21                      2 (1)
          -5                      3 (1)
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Characteristic Value
Cytogenetic abnormalities - no. (%)* continued
          -5(q)                      1 (<1)
          -7                    13 (5)          
          -7(q)                      7 (2)
          3(q)                      6 (2)
          t(6;9)                      4 (1)
          t(9;22)                      2 (1)
          t(11q23)                    19 (7)
          Complex karyotype (>3 
          chromosomal abnormalities)
                   11 (4)
          Other abnormal karyotypes                    60 (21)
          Normal karyotype                  119 (42)
          Not determined                    10 (4)
Molecular abnormalities - no. (%)
  Mutation
          FLT3 internal tandem duplication                    78 (27)
          FLT3 tyrosine kinase domain                    33 (12)
          N-RAS                    26 (9)
          K-RAS                      9 (3)
          CEBPα                    17 (6)
          Overexpression EVI1                    23 (8)
* All patients with a specifi c cytogenetic abnormality were included in the analysis, 
  irrespective of the presence of additional abnormalities. A summary of the frequencies 
  and percentages of the cytogenetic and molecular abnormalities for each of the assigned 
  clusters can be found in Table Q of Supplementary Appendix 1 (available with the full 
  text of this chapter at www.nejm.org). Some samples had more than one abnormality.
Table 1. Clinical and molecular characteristics of the 285 patients with newly 
diagnosed AML.
2.3.6 The SAM Method
All supervised analyses were performed with the use of SAM software (19). A 
supervised analysis correlates gene expression with an external variable such as 
the karyotype or the duration of survival. SAM calculates a score for each gene on 
the basis of the change in expression relative to the SD of all 285 measurements. 
The criteria for identifying the top 40 genes for an assigned cluster were a minimal 
difference in gene expression between the assigned cluster and the other AML 
samples by a factor of 2 and a q value of less than 2 percent. The q value for each 
gene represents the probability that it is falsely called signifi cantly deregulated.
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2.3.7 The PAM Method
All supervised class-prediction analyses were performed by applying PAM software 
in R (version 1.7.1).20 The method of the nearest shrunken centroids identifi es a 
subgroup of genes that best characterizes a predefi ned class. The prediction error 
was calculated by means of 10-fold cross validation (see the Glossary) within the 
training set (two thirds of the patients) followed by the use of a second validation 
set (one third of the patients). All genes identifi ed by the SAM and PAM methods 
are listed in Supplementary Appendix 1 (Tables A1 to P1 and R). 
2.3.8 Reverse-transcriptase polymerase chain reactions and sequence
  analyses
Reverse-transcriptase–polymerase-chain-reaction (RT-PCR) assays and sequence 
analyses for internal tandem duplication and tyrosine kinase domain mutations in 
FLT3 and mutations in NRAS, KRAS, and CEBPα, as well as real-time PCR for EVI1 
were performed as described previously (8,9,21,22). AML samples of the clusters 
characterized by favorable cytogenetic characteristics (t(8;21), t(15;17), and inv(16)) 
were analyzed for the expression of fusion genes by real-time PCR (Supplementary 
Appendix 1).
2.3.9 Statistical analysis
Statistical analyses were performed with Stata Statistical Software, release 7.0. 
Actuarial probabilities of overall survival (with failure defi ned as death from 
any cause) and event-free survival (with failure defi ned as incomplete remission 
[set at day 1], relapse, or death during a fi rst complete remission) were estimated 
according to the Kaplan–Meier method.
2.4 Results
2.4.1 Visual correlation of gene expression
All specimens of AML were classifi ed into subgroups with the use of unsupervised 
ordering (i.e., without taking into account hematologic, cytogenetic, or other 
external information). Optimal clustering of these specimens was reached with 
the use of 2856 probe sets (a probe set consists of 10 to 20 oligonucleotides); 2856 
sets represent 2008 annotated genes and 146 expressed-sequence tags, which are 
short sequences of unknown genes (Fig.1A and Table 2, and Fig. B, C, D, E, F, 
G, and H in Supplementary Appendix 1). Sixteen distinct groups of patients with 
AML were identifi ed on the basis of strong similarities in gene-expression profi les. 
Figure 1A, a Pearson’s correlation view, shows these clusters as red squares along 
the diagonal. A red rectangle indicates positive pairwise correlations (equality in 
gene expression between clusters) and a blue rectangle indicates negative pairwise 
correlations (inequality in gene expression between clusters) (Fig. 1A, and Fig. A in 
Supplementary Appendix 1). The fi nal Omniviz Correlation View was adapted so 
that cytologic, cytogenetic, and molecular features were plotted directly adjacent 
to the original diagonal. This arrangement allowed the visualization of groups of 
patients with similar patterns of gene expression along with relevant clinical and 
genetic fi ndings (Fig. 1B). Distinct clusters of t(8;21), inv(16), and t(15;17) were readily 
identifi ed with 1692 probe sets (Table 2). Identifi cation of clusters with mutations 
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in FLT3, monosomy 7, or overexpression of EVI1 required 2856 probe sets (Table 2, 
and Fig. B, C, D, E, F, G, and H in Supplementary Appendix 1). When more genes 
were used, the compact pattern of clustering vanished (Table 2). When included in 
the Omniviz Correlation View analyses (2856 probe sets), all fi ve samples of bone 
marrow and three CD34+ samples from control subjects gathered within clusters 8 
and 10, respectively. Genes characteristic of each of the 16 clusters were obtained 
by means of supervised analysis (distinctions on the basis of predefi ned classes), 
with the use of the SAM method. The expression profi les of the top 40 genes of 
each cluster are plotted in Figure 1B beside the correlation view. The SAM analyses 
identifi ed 599 discriminating genes (Tables A1 to P1 in Supplementary Appendix 
1); we were unable to identify a distinct gene profi le for cluster 14.
2.4.2 Recurrent translocations
CBFβ-MYH11
All AML samples with inv(16), which causes the CBFβ-MYH11 fusion gene, 
gathered within cluster 9 (Fig. 1B, and Table I in Supplementary Appendix 1). Four 
specimens within this cluster were not known to harbor an inv(16), but molecular 
analysis and Southern blotting revealed that their leukemic cells had the CBFβ-
MYH11 fusion gene (Table I and Fig. I in Supplementary Appendix 1). SAM analysis 
revealed that MYH11 was the most discriminative gene for this cluster (Table I1 
and Fig. J in Supplementary Appendix 1). Interestingly, a low level of expression of 
CBFβ was correlated with this cluster, perhaps because of the decreased expression 
or deletion of the MYH11-CBFβ alternate fusion gene or down-regulation of the 
normal CBFβ allele by the CBFβ-MYH11 fusion protein. 
PML-RARa
Cluster 12 contained all cases of acute promyelocytic leukemia (APL) with t(15;17) 
(Fig. 1B, and Table L in Supplementary Appendix 1), including one patient (Patient 
322) who had previously received a diagnosis of APL with PML-RARa on the basis 
of RT-PCR alone. SAM analyses revealed that genes for hepatocyte growth factor 
(HGF), macrophage-stimulating 1 growth factor (MST1), and fi broblast growth 
factor 13 (FGF13) were specifi c for this cluster. In addition, cluster 12 could be 
separated into two subgroups: one with a high and the other with a low white-cell 
count (Fig. K in Supplementary Appendix 1). This subdivision corresponds to the 
presence of FLT3 internal tandem duplication mutations (Fig. 1B).
AML1-ETO
All specimens from patients with the t(8;21) that generates the AML1-ETO fusion 
gene grouped within cluster 13 (Fig. 1B, and Table M in Supplementary Appendix 
1). SAM identifi ed ETO as the most discriminative gene for this cluster (Table M1 
and Fig.L in Supplementary Appendix 1).
2.4.3 11q23 abnormalities
Cases with 11q23 abnormalities were scattered among the 285 samples, although 
two subgroups were apparent: cluster 1 and cluster 16 (Fig. 1B, and Tables A and 
P in Supplementary Appendix 1). Cluster 16, with 11 total cases, contained 4 cases 
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of t(9;11) and 1 case of t(11;19). SAM analyses identifi ed a strong signature of up-
regulated genes in most cases in this cluster (Fig. 1B, and Table P1 in Supplementary 
Appendix 1). Although 6 of 14 cases within cluster 1 also had 11q23 abnormalities, 
this subgroup was more heterogeneous than cluster 16 (Fig. 1B).
Figure 1 (facing page). Correlation View of Specimens from 285 Patients with AML 
Involving 2856 Probe Sets (Panel A) and an Adapted Correlation View (2856 Probe 
Sets) (Right-Hand Side of Panel B), and the Levels of Expression of the Top 40 Genes 
That Characterized Each of the 16 Individual Clusters (Left-Hand Side of Panel 
B). In Panel A, the Correlation Visualization tool displays pairwise correlations between 
the samples. The colors of the cells relate to Pearson’s correlation coeffi cient values, with 
deeper colors indicating higher positive (red) or negative (blue) correlations. One hundred 
percent negative correlation would indicate that genes with a high level of expression in one 
sample would always have a low level of expression in the other sample and vice versa. Box 
1 indicates a positive correlation between clusters 5 and 9 and box 2 a negative correlation 
between clusters 5 and 12. The red diagonal line displays the intraindividual comparison 
of results for a patient with AML (i.e., 100 percent correlation). To reveal the patterns of 
correlation, we applied a matrix-ordering method to rearrange the samples. The ordering 
algorithm starts with the most highly correlated pair of samples and, through an iterative 
process, sorts all the samples into correlated blocks. Each sample is joined to a block in 
an ordered manner so that a correlation trend is formed within a block, with the most 
correlated samples at the center. The blocks are then positioned along the diagonal of the 
plot in a similar ordered manner. Panel B shows all 16 clusters identifi ed on the basis 
of the Correlation View. The French-American-British (FAB) classifi cation and karyotype 
based on cytogenetic analyses are depicted in the columns along the original diagonal of the 
Correlation View; FAB subtype M0 is indicated in black, subtype M1 in green, subtype M2 
in purple, subtype M3 in orange, subtype M4 in yellow, subtype M5 in blue, andsubtype 
M6 in gray; normal karyotypes are indicated ingreen, inv(16) abnormalities in yellow, 
t(8;21) abnormalitiesin purple, t(15;17) abnormalities in orange, 11q23 abnormalities in 
blue, 7(q) abnormalities in red, +8 aberrations in pink, complex karyotypes (those involving 
more than three chromosomal abnormalities) in black, and other abnormalities in gray. 
FLT3 internal tandem duplication (ITD) mutations, FLT3 mutations in the tyrosine kinase 
domain (TKD), NRAS, KRAS, and CEBPα mutations, and the overexpression of EVI1 are 
depicted in the same set of columns: red indicates the presence of a given abnormality, and 
green its absence. The levels of expression of the top 40 genes identifi ed by the signifi cance 
analysis of microarrays of each of the 16 clusters as well as in normal bone marrow (NBM) 
and CD34+ cells are shown on the left side. The scale bar indicates an increase (red) or 
decrease (green) in the level of expression by a factor of at least 4 relative to the geometric 
mean of all samples. The percentages of the most common abnormalities (those present in 
more than 40 percent of specimens) and the percentages of specimens in each cluster with a 
normal karyotype are indicated. 
A full-color version of this fi gure is provided on the CD.
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Variable Distribution
No. of probe sets 147 293 569 984 1692 2856 5071
Factor increase or 
decrease in regulation† >32 >22.6 >16 >11.3 >8 >5.6 >4
Chromosomal abnormalities
          t(8;21) ± + + + ++ ++ +
          inv(16) ± ± ± + ++ ++ +
          t(15;17) ± + ++ ++ ++ ++ +
          11q23 ± ± ± ± + + ±
          -7(q) ± ± ± ± ± + ±
Mutation
          FLT3 internal   
          tandem duplication ± ± ± ± ± ± ±
          FLT3 tyrosine   
          kinase domain - - - - - - -
          N-RAS - - - - - - -
          K-RAS - - - - - - -
          CEBPα - ± ± + + + +
Overexpression
          EVI1 - - - - ± + ±
* Two plus signs indicate that 100 percent of specimens were in a single cluster, a single 
   plus sign that specimens were in no more than two recognizable clusters, a plus–minus 
   sign that specimens were in more than two recognizable clusters, and a minus sign that 
 no clustering occurred. Four patients with AML with abnormalities involving 
  chromosome 5 were excluded. 
† The factor increase or decrease in the regulation of gene expression is relative to the 
 geometric mean by which the differentially expressed probe sets were selected.
Table 2. Evaluation of the Omniviz Correlation View results on the basis of the 
clustering of AML specimens with similar molecular abnormalities.*
2.4.4 CEBPα mutations
Mutations in CEBPα occur in approximately 7 percent of patients with AML, most 
with a normal karyotype, and predict a favorable outcome (9,10). Two clusters (4 
and 15) had a high frequency of CEBPα mutations (Fig. 1B). The sets of up-regulated 
or down-regulated genes in cluster 4 discriminated the specimens it contained 
from those in cluster 15 (Table D1 in Supplementary Appendix 1). The upregulated 
genes included the T-cell genes CD7 and the T-cell receptor delta locus, which may 
be ex- pressed by immature AML cells. (23,24). All but one of the top 40 genes of 
cluster 15 were down-regulated (Table O1 in Supplementary Appendix 1). These 
genes were also down-regulated in cluster 4 (Fig. 1B). The genes encoding alpha1-
catenin (CTNNA1), tubulin beta-5 (TUBB5), and Nedd4 family interacting protein 
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1 (NDFIP1) were the only down-regulated genes among the top 40 in both cluster 
4 and cluster 15.
2.4.5 Overexpression of EVI1
High levels of expression of EVI1, which occur in approximately 10 percent of cases 
of AML, predict a poor outcome (8). In cluster 10, 10 of 22 specimens (Table J in 
Supplementary Appendix 1) showed increased expression of EVI1, and 6 of these 
10 specimens had chromosome 7 abnormalities. In cluster 8, 4 of 13 specimens also 
had chromosome 7 aberrations (Table H in Supplementary Appendix 1), but since 
its molecular signature differed from that of cluster 10 (Fig. 1B), the high level of 
expression of EVI1 or EVI1-related proteins may have determined the molecular 
profi le of cluster 10. In the heterogeneous cluster 1, 5 of 14 specimens also had 
increased EVI1 expression. These specimens may have appeared outside cluster 10 
because their molecular signatures were most likely the result of the overexpression 
of EVI1 and an 11q23 abnormality.
2.4.6 FLT3 and RAS mutations
Samples from most patients in clusters 2, 3, and 6 harbored a FLT3 internal tandem 
duplication (Fig.1B). Almost all these patients had a normal karyotype. The presence 
of FLT3 internal tandem duplication seemed to divide clusters 3, 5, and 12 into two 
groups. Other individual specimens with a FLT3 internal tandem duplication were 
dispersed over the entire series; mutations in the tyrosine kinase domain of FLT3 
were not clustered. Likewise, mutations in codon 12, 13, or 61 of the small GTPase 
RAS (N-RAS and K-RAS) had no apparent signatures and did not aggregate in the 
Correlation View (Fig. 1B).
2.4.7 Other clusters
Specimens from patients with AML with a normal karyotype clustered into several 
subgroups within the assigned clusters (Fig. 1B). Most patients in cluster 11 had 
normal karyotypes and no consistent dditional abnormality. Cluster 5 contained 
mainly specimens from patients with AML of subtype M4 or M5, according to the 
French–American–British (FAB) classifi cation (Fig. 1B). Clusters 7, 8, 11, and 14 
were not associated with a FAB subtype but had distinct gene-expression profi les.
2.4.8 Class prediction of distinct clusters
We used the PAM method to validate the cluster specifi c genes identifi ed by the 
SAM method and to determine the minimal number of genes that can be used 
to predict karyotypic or other genetic abnormalities with biologic signifi cance in 
AML (Table 3). The 285 specimens were randomly divided into a training set (189 
specimens) and a validation set (96 specimens). All patients in the validation set 
who had favorable cytogenetic fi ndings were identifi ed with 100 percent accuracy 
with the use of only a few genes (Table 3). As expected from the SAM analyses, 
ETO for t(8;21), MYH11 for inv(16), and HGF for t(15;17) were among the best 
predictors of the cytogenetic abnormalities (Table R in Supplementary Appendix 
1). Cluster 10 (which involved EVI1 overexpression) was predicted with a high 
degree of accuracy, although with a higher 10-fold cross-validation error than that
46
Chapter 2
Abnormality Training 
Set  (n=189)
Validation 
Set  (n=96)
No. of probe 
sets used
No. of genes 
represented
                                                           no.of errors
t(8;21), leading to 
AML1-ETO (cluster 13) 0 0 3 2
t(15;17), leading to 
PML-RARα (cluster 12) 1 0 3 2
inv(16), leading to 
CBFβ-MYH11 (cluster 9) 0 0 1 1
11q23 (cluster 16) 3 3 31 25
EVI1 (cluster 10) 16 0 28 25
CEBPα (cluster 4) 8 2 13 8
CEBPα (cluster 15) 17 6† 36 32
CEBPα (cluster 4 and 15) 5 2 9 5
FLT3 internal tandem 
duplication 27 21 56 41
* Prediction analysis of microarrays was performed to defi ne the minimal numbers of 
  genes that could predict whether a specimen from a particular patient belonged in one of 
 the clusters (fi rst column). The group of patients was randomly segregated into a 
  training set (second column) and a validation set (third column). The 10-fold method 
  of cross-validation, applied on the training set, works as follows: the model is fi tted on 
  90 percent of the samples, and the class of the remaining 10 percent is then predicted. 
  This procedure is repeated 10 times, with each part playing the role of the test samples 
 and the error of all 10 parts added together to compute the overall error (second 
 column). The minimal numbers of probe sets or genes (fourth and fi fth columns, 
  respectively) that were identifi ed in the training were tested on the validation set (third 
 column). The error within the validation set (third column) refl ects the number of 
  samples wrongfully predicted in this set. The identities of the probe sets and genes are 
   provided in Table R of Supplementary Appendix 1. 
† After randomization none of the patients with CEBPα abnormalities in cluster 15 were 
  included in the validation set.  
Table 3. Results of class prediction analysis with the use of prediction analysis of 
microarrays.
in the groups with favorable cytogenetic fi ndings. In cluster 16 (involving 11q23 
abnormalities), samples from 3 of 96 patients were wrongfully identifi ed in the 
validation set. Since cluster 15 (involving CEBPα mutations) contained few samples, 
we combined both CEBPα-containing clusters. These combined clusters predicted 
the presence of CEBPα mutations within the validation set with 98 percent accuracy. 
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Figure 2. Kaplan–Meier Estimates of Overall Survival (Panel A), Event-free 
Survival (Panel B), and Relapse Rates after Complete Remission (Panel C) among 
Patients with AML with Specimens in Clusters 5, 9, 10, 12, and 13. Cluster 5 
was characterized by a French–American–British classifi cation of M4 or M5, cluster 9 
by inv(16) abnormalities, cluster 10 by a high level of expression of EVI1, cluster 12 by 
t(15;17) abnormalities, and cluster 13 by t(8;21) abnormalities. P values were calculated 
with the use of the log-rank test.
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We were unable to identify a signature that reliably identifi ed FLT3 internal tandem 
duplications.  
2.4.9 Survival analyses
Overall survival, event-free survival, and relapse rates were determined among 
patients whose specimens were within clusters containing more than 20 specimens 
in the Correlation View (clusters 5, 9, 10, 12, and 13) (Fig. 2). The mean (±SE) actuarial 
probabilities of overall survival and event-free survival at 60 months were 59±10 
percent and 55±11 percent, respectively, among patients with samples in cluster 
13; 57±12 percent and 47±11 percent, respectively, among those with samples in 
cluster 12; and 72±10 percent and 52±10 percent, respectively, among those with 
samples in cluster 9. Patients with samples in cluster 5 had an intermediate rate 
of overall survival (32±8 percent) and event-free survival (27±8 percent), whereas 
survival among patients with samples in cluster 10 was poorer (the overall survival 
rate was 18±9 percent, and the event free survival rate was 6±6 percent), mainly as 
a result of an increased incidence of relapse (Fig. 2C). 
2.5 Discussion
In this study of 285 patients with AML that was characterized by cytogenetic 
analyses and extensive molecular analyses, we used gene-expression profi ling to 
comprehensively classify the disorder. This method identifi ed 16 groups on the basis 
of unsupervised analyses involving Pearson’s correlation coeffi cient. Our results 
provide evidence that each of the assigned clusters represents true subgroups of 
AML with specifi c molecular signatures. 
We were able to cluster all cases of AML with t(8;21), inv(16), or t(15;17), including 
those that had not been identifi ed by cytogenetic examination, into three clusters 
with unique gene-expression profi les. Correlations between gene-expression 
profi les and prognostically favorable cytogenetic aberrations have been reported 
by others, (12,13) but we found that these cases can be recognized with a high 
degree of accuracy within a representative cohort of patients with AML. 
The SAM and PAM methods were highly concordant for the genes identifi ed 
within the assigned clusters, indicating that these clusters contained discriminative 
genes. For instance, clusters 4 and 15, with overlapping signatures, both included 
specimens with normal karyotypes and mutations in CEBPα. Multiple genes 
appeared to be down-regulated in both clusters but were unaffected in any other 
subgroup of AML. 
The discriminative genes identifi ed by SAM and PAM may reveal functional 
pathways that are critical for the development of AML. These methods of statistical 
treatment of the data identifi ed several genes that are implicated in specifi c 
subtypes of AML, such as the interleukin-5 receptor a (IL5Ra) gene in AML with 
t(8;21) abnormalities (25) and FLT3-STAT-5 targets — the gene for interleukin-2 
receptora (IL2Ra) (26) and the pim1 kinase gene (PIM1) (27)— in AML with FLT3 
internal tandem duplication mutations. 
Five clusters (5, 9, 10, 12, and 13) with 20 or more specimens were evaluated in 
relation to outcome of disease. As expected, clusters 9 (involving CBFβ-MYH11), 12 
(involving PML-RARα), and 13 (involving AML1-ETO) contained specimens with a 
relatively favorable prognosis. 
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Specimens in cluster 10 had a distinctly poor outcome. A randomly selected subgroup 
of patients with specimens in this cluster could be identifi ed with a high degree of 
accuracy with the use of a minimal number of genes. The high frequency of poor 
prognostic markers in this cluster (-7(q), -5(q), t(9;22), or high levels of expression 
of EVI1) is in accord with the poor outcome of patients in this cluster. Since this 
cluster is heterogeneous with regard to both known poor-risk markers and the 
presence or absence of these markers, the molecular signature of this cluster may 
signify a biochemical pathway that causes a poor outcome. The fact that normal 
CD34+ cells segregate into this cluster suggests that the molecular signature of 
treatment resistance resembles that of normal hematopoietic stem cells. 
The 44 patients with specimens in cluster 5 had an intermediate duration of 
survival. Since these specimens were of the FAB M4 or M5 subtype, it is possible 
that genes related to monocytes or macrophages were important in the clustering 
of these cases.  
In three clusters more than 75 percent of specimens had a normal karyotype 
(clusters 2, 6, and 11). Most of the patients with specimens in clusters 2 and 6 had 
FLT3 internal tandem duplication mutations, whereas patients with specimens 
in cluster 11, which had a discriminative molecular signature, did not have any 
consistent molecular abnormality.
Clusters 1 and 16 harbored 11q23 abnormalities, representing defects involving the 
mixed-lineage leukemia (MLL) gene. The different gene-expression profi les of these 
two clusters are most likely due to additional distinctive genetic defects. In cluster 
1, this additional abnormality may be a high level of expression of the oncogene 
EVI1, which was not apparent in cluster 16. Similarly, distinctive additional genetic 
defects may explain the separation of clusters 4 and 15, both of which contained 
specimens with CEBPα mutations, clusters 1 and 10, both of which had high levels 
of EVI1 expression, and clusters 8 and 10, both of which had  a high frequency of 
monosomy 7. 
Internal tandem duplications in FLT3 adversely affect the clinical outcome (6,7). The 
molecular signature associated with this  abnormality is not distinctive; however, 
the clustering of specimens with these abnormalities within assigned clusters (e.g., 
cluster 12) suggests that these internal  tandem duplications result in different 
biologic entities within the scope of AML.  
Our study demonstrates that cases of AML with known cytogenetic abnormalities 
and new clusters of AML with characteristic gene-expression signatures can be 
identifi ed with the use of a single assay. The applicability and performance of 
genome-wide analysis will advance with the availability of novel whole-genome 
arrays, improved sequence annotation, and the development of sophisticated 
protocols and software, allowing the analysis of subtle differences in gene 
expression and predictions of pathogenic pathways.
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3.1 Abstract
3.1.1 Background
Intensity values measured by Affymetrix microarrays have to be both normalized, 
to be able to compare different microarrays by removing non-biological variation, 
and summarized, generating the fi nal probe set expression values. Various pre-
processing techniques, such as dChip, GCRMA, RMA and MAS have been developed 
for this purpose. This study assesses the effect of applying different pre-processing 
methods on the results of analyses of large Affymetrix datasets. By focusing on 
practical applications of microarray-based research, this study provides insight 
into the relevance of pre-processing procedures to biology-oriented researchers.
3.1.2 Results
Using two publicly available datasets, i.e., gene-expression data of 285 patients 
with Acute Myeloid Leukemia (AML, Affymetrix HG-U133A GeneChip) and 
42 samples of tumor tissue of the embryonal central nervous system (CNS, 
Affymetrix HuGeneFL GeneChip), we tested the effect of the four pre-processing 
strategies mentioned above, on  (1) expression level measurements, (2) detection of 
differential expression, (3) cluster analysis and (4) classifi cation of samples. In most 
cases, the effect of pre-processing is relatively small compared to other choices 
made in an analysis for the AML dataset, but has a more profound effect on the 
outcome of the CNS dataset. Analyses on individual probe sets, such as testing for 
differential expression, are affected most; supervised, multivariate analyses such 
as classifi cation are far less sensitive to pre-processing. 
3.1.3 Conclusion
Using two experimental datasets, we show that the choice of pre-processing method 
is of relatively minor infl uence on the fi nal analysis outcome of large microarray 
studies whereas it can have important effects on the results of a smaller study. The 
data source (platform, tissue homogeneity, RNA quality) is potentially of bigger 
importance than the choice of pre-processing method.
3.2 Introduction
The analysis of gene expression data generated by microarrays, such as the high-
density oligonucleotide microarays produced by Affymetrix (Santa Clara, CA), is 
an often laborious process in which a basic understanding of molecular biology, 
computer science and statistics is required. In a typical microarray experiment, 
RNA obtained under various conditions (patients, treatments, disease states etc.) 
is hybridised to microarrays. By tagging the RNA with a fl uorescent marker, 
intensity values can be obtained that correspond to the amount of labeled RNA 
bound to the array. On the widely used Affymetrix platform, gene expression is 
measured using probe sets consisting of 11 to 20 perfect match (PM) probes of 25 
nucleotides, which are complementary to a target sequence, and a similar number 
of mismatch (MM) probes in which the 13th nucleotide has been changed. The 
MM probe measurements are thought to comprise most of the background cross-
hybridization and stray signal affecting the PM probes. 
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Normalization of probe intensity values is performed to remove any non-biological 
variation. The individual probe measurements are then summarized as probe set 
expression levels, as estimates of the amount of specifi c mRNA present in the 
biological sample. Normalization and probe set summarization are statistical 
procedures for which several methods have been developed. MicroArray Suite 
(MAS 5.0), a software package provided by Affymetrix, normalizes intensities 
using a global scaling procedure and measures expression using a one-step 
Tukey biweight algorithm, which is defi ned as the anti-log of a robust average 
of differences between log(PM) and log(MM) (1). The same algorithms are 
implemented in the software package currently provided by Affymetrix, GCOS. 
One of the fi rst alternatives to this approach was provided by Li and Wong with the 
dChip-method, which scales the intensity data towards the median intensity in a 
group of arrays and then uses model-based index estimates, giving variable weight 
to PM-MM probe pairs of a probe set based on variance between arrays, to measure 
expression (2). Irizarry et al. introduced RMA (robust multi-array average), later 
followed by GCRMA (GC robust multi-array average). RMA, often preceded by 
quantile normalization (3, 4), applies a median polish procedure to PM intensities 
only in summarization. GCRMA is based on a similar model as RMA but takes into 
account the effect of stronger bonding of G/C pairs (5, 6). An overview of these 
methods is shown in Table 1. Other normalization methods, such as the variance 
stabilizing normalization (VSN, (7)) and summarization methods, such as PLIER 
(8), have been developed, but are less frequently applied. 
Various studies have been published which assess the differences in outcome 
of these different data pre-processing methods (9-14). To validate and test pre-
processing methods, two publicly available datasets are commonly used. The Latin 
square dataset provided by Affymetrix (http://www.affymetrix.com/) contains 
spiked-in cRNA’s at several concentrations facilitating the assessment of the relation 
between mRNA concentration and expression value. The GeneLogic dilution 
series (obtainable on request, http://www.genelogic.com) gives an estimate of 
the relation between actual and measured differential expression. Based on these 
datasets, an online benchmark tool has been developed to encourage authors to test 
their method (http://affycomp.biostat.jhsph.edu) (15). This tool assesses quality of 
pre-processing using several parameters in fi ve different groups: (1) variability of 
expression across replicate arrays, (2) response of expression measure to changes in 
abundance of RNA, (3) sensitivity of fold-change measures to the amount of actual 
RNA sample, (4) accuracy of fold-change as a measure of relative expression and 
(5) usefulness of raw fold-change score for the detection of differential expression. 
Pronounced differences between different procedures have been shown to occur 
(4, 9, 11, 13). 
The studies on the Latin square and dilution data were performed using data 
generated specifi cally for this purpose, allowing comparisons of specifi c analyses, 
showing accurately which methods perform best. In effect, statistical properties 
of the various estimators are tested. Several authors noted that the use of two 
special-purpose datasets for calibration of statistical procedures creates a risk 
on overfi tting of the available data and therefore focused on using experimental 
data to compare methods with respect to the sets of differentially expressed genes 
found (9, 11, 14). This sometimes lead to contradictory results, where for instance a 
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Normalization method Summarization method
MAS
Global scaling – individual 
array normalization; moderate 
infl uence on expression 
levels, no effect on outliers. 
Non-parametric methods are 
potentially more reliable
Tukey biweight (robust average) 
– subtract MM from PM and 
adjust for negative values
dChip
Average median scaling - 
individual array normalization; 
moderate infl uence on expression 
levels, no effect on outliers. 
Non-parametric methods are 
potentially more reliable
Model-based index estimate 
– subtract MM from PM, but 
take indivual probe variability, 
assessed over all available 
arrays, into account
RMA
Quantile normalization – 
multiple array normalization; 
considerable infl uence on 
expression levels, with removal 
of outliers. Parametric methods 
are potentially more reliable
Median polish – only use MM 
for background adjustment; 
fi t parameters of linear model 
robustly using median polish, 
taking into account all available 
arrays
GCRMA
Quantile normalization – 
multiple array normalization; 
considerable infl uence on 
expression levels, with removal 
of outliers. Parametric methods 
are potentially more reliable
Median polish - only use MM 
for background adjustment; 
fi t parameters of linear model 
robustly using median polish, 
taking into account all available 
arrays; fi t extra GC-content 
parameter
Table 1. Overview of several pre-processing methods.
study using the Latin square dataset showed the MAS5.0 method to outperform 
the dChip method on detecting differentially expressed genes (13),  while a study 
on experimental data showed the opposite (9). Therefore, more work is needed to 
reliably establish how important the effect of choice of pre-processing method is in 
every-day practice, especially when analyses such as clustering and classifi cation 
are applied. 
In this paper, we focus on one practical application of microarrays: patient-cohort 
studies (16-20). In such studies, researchers typically select sets of genes that are 
differentially expressed between certain known conditions, a supervised analysis. 
Moreover, unsupervised techniques (not imposing any prior knowledge on the 
data) such as clustering are applied to detect biological relations between samples 
or genes by grouping them according to their expression profi les. Often the goal is 
to obtain a predictor (classifi er) for, for instance, prognostically relevant categories, 
using supervised analysis.
Given that different pre-processing procedures will infl uence the outcome of 
these analyses, several questions can be asked, such as: How well is expression 
measured using a number of different pre-processing methods? What is their effect 
on the detection of differentially expressed genes, clusters found and classifi cation 
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results? By focusing on practical applications of microarray studies, we hope to 
give insight into the relevance of different pre-processing procedures to biology-
oriented researchers. 
3.3 Materials and methods
3.3.1 Datasets
The two datasets used have been described before (17, 20). The fi rst dataset 
consists of microarray measurements taken on samples of 285 patients with acute 
myeloid leukemia (AML), of whom blasts and mono-nuclear cells were isolated 
from peripheral blood or bone marrow aspirates. The samples were hybridized on 
Affymetrix HG-U133A GeneChip microarrays. This dataset will be referred to as 
the AML dataset; it is available on the Gene Expression Omnibus website (http://
ncbi.nlm.nih.gov/geo, accession number GSE1159). The second dataset contains 
gene-expression data of 42 homogenized tumor tissues of the embryonal central 
nervous system (CNS), hybridized on Affymetrix HuGeneFL arrays. The dataset, 
referred to as the CNS dataset, is available at http://www.genome.wi.mit.edu/
MPR/CNS/.
3.3.2  Normalization and expression measurement
Both datasets were pre-processed with MAS, RMA, GCRMA and dChip, resulting 
in eight different datasets. MAS expression data combined with global scaling was 
obtained from the MAS 5.0 software, provided by Affymetrix (Affymetrix Inc., 
Santa Clara, CA). dChip pre-processing together with scaling of the data towards 
the median average expression value per chip was applied using software available 
from the authors (http:///www.dchip.org/). RMA and GCRMA pre-processing 
was performed together with quantile normalization using the Bioconductor 
v2.0 library available in the R software environment (http://www.bioconductor.
org/). 
3.3.3 Real-time quantitative PCR (RQ-PCR)
For the AML dataset only, a number of measured probe set expression levels were 
compared to available RQ-PCR measurements of the corresponding genes on 
subsets of the original dataset (with n varying between 208 and 277, as indicated 
in Supp. Table 2). Probe sets were selected for RQ-PCR measurement based on 
biological relevance to the study of leukemia; samples were selected based on 
availability of material. Eligible patients had a diagnosis of primary AML, confi rmed 
by cytological examination of blood and bone marrow. After informed consent, 
bone marrow aspirates or peripheral blood samples were taken at diagnosis. Blasts 
and mononuclear cells were purifi ed by Ficoll-Hypaque (Nygaard, Oslo, Norway) 
centrifugation and cryopreserved. The AML samples contained 80-100 percent 
blast cells after thawing, regardless of the blast count at diagnosis.
After thawing, cells were washed once with Hanks balanced salt solution. High 
quality total RNA was extracted by lysis with guanidinium isothiocyanate followed 
by cesium chloride gradient purifi cation. RNA concentration, quality and purity 
were examined using the RNA 6000 Nano assay on the Agilent 2100 Bioanalyzer 
(Agilent, Amstelveen, The Netherlands). None of the samples showed RNA 
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degradation (28S/18S rRNA ratio ≥ 2) or contamination by DNA.
cDNA was synthesized from 1μg of RNA using random hexamer priming, 
essentially as described (21). cDNA prepared from 50ng of RNA was used for all 
RQ-PCR amplifi cations. 
Real-time quantitative PCR amplifi cation was performed with the ABI PRISM 7700 
sequence Detector (Applied Biosystems, Nieuwerkerk aan den IJssel, Netherlands), 
using 50 µL mix containing 20 µM deoxyribonucleoside triphosphates (dNTPs; 
Amersham Pharmacia Biotech, Roosendaal, Netherlands); 15 pmol forward and 
reverse primer (Life Technologies); 3 mM MgCl2 (5 mM for the reference gene 
porphobilinogen deaminase [PBGD]); 10 pmol probe (Eurogentec, Maastricht, 
Netherlands); 5 µL 10 x buffer A and 1.25 U AmpliTaq Gold (Applied Biosystems). 
The primers and probe combinations for detection of EVI1 [EMBL:BX647613] (22), 
CEBPα [RefSeq:NM_004364.2] (23), TRKA [EMBL:M23102] (24) and PBGD [EMBL:
AB162702] (24) have been described. Primer and probe combinations used to 
determine the expression of MEIS1 [EMBL:AB040810] , HOXA7 [EMBL:AJ005814], 
PRDM1 [EMBL:AL358952], and PRDM2 [EMBL:U23736] are listed in Supp. Table 
1. Expression of HOXA9 [EMBL:BC006537], GMCSF [EMBL:X03021], P8 [EMBL:
AF135266] was measured with 1x SYBR Green I dye (Applied Biosystems). The 
primers used in the SYBR Green reactions are listed in Supp. Table 1. The thermal 
cycling conditions included 10 minutes at 95°C followed by 45 cycles of denaturation 
for 30 seconds at 95°C and annealing/extension at 60°C for 60 seconds.
To quantify the relative expression levels of the various genes in AML the Ct values 
were normalized for the endogenous reference PBGD (∆Ct = Cttarget - CtPBGD) and 
compared with a calibrator NBM cells from healthy volunteers, using the ∆∆Ct 
method (∆∆Ct = ∆Ct AML sample - ∆CtCalibrator). We used the ∆∆Ct value to calculate 
relative expression (2-∆∆Ct). 
A minimum threshold of 1 was applied, as well as log(2) transformation (25). 
Pearson correlation coeffi cients were calculated between the RQ-PCR data and 
the corresponding microarray-data pre-processed by the different procedures. 
Pearson correlation coeffi cients between data from the different procedures were 
also calculated, for each probe set present on the microarray. 
3.3.4 Data transformation
For each probe set, the geometric mean m of all expression values e over the 
different samples was calculated. The level of expression for a particular sample 
was subsequently determined as log2(e)-log2(m). This transformation was applied 
to all datasets and only transformed data was used for detection of differential 
expression, cluster analysis and classifi cation.
3.3.5 Differential expression
Tests for differential expression were performed on several biologically relevant 
groups, by comparing samples from a group to the remainder of the samples. Four 
groups were tested in the AML dataset: (1) samples with a recurrent mutation in 
the FLT3 gene (n = 78), (2) samples with inversion of chromosome 16, (inv(16), n 
= 23), (3) samples with translocation of chromosomes 15 and 17 (t(15;17), n = 19) 
and (4) samples with translocation of chromosomes 8 and 21 (t(8;21), n = 22). In the 
CNS dataset, four groups were tested as well: (1) samples with primitive neuro-
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ectodermal tumors (PNET, n = 8), (2) samples with medullablastomas (MED, n 
= 10), (3) samples with rhabdoid tumors (RHAB, n = 10) and (4) samples with 
malignant gliomas (GLIO, n = 10). 
Student’s t-test and Wilcoxon’s rank sum test were applied to each probe set (26). 
The resulting p-values were adjusted for multiple testing by Šidák step-down 
adjustment to control the Family-Wise Error Rate or FWER (27). The Signifi cance 
Analysis of Microarrays (SAM) permutation algorithm (Excel-version 1.21, 
available from http://www-stat.stanford.edu/~tibs/SAM/), controlling the False 
Discovery Rate (FDR), was also applied (28). SAM provides an estimate of the 
FDR known as a q-value. Each test was applied and lists of probe sets, considered 
signifi cantly differentially expressed at an FWER or FDR of 5%, were retrieved. 
For all possible combinations (i.e. MAS-dChip, MAS-RMA, MAS-GCRMA, dChip-
RMA, dChip-GCRMA and RMA-GCRMA) probe sets marked as signifi cantly 
differentially expressed by both methods were counted. To be able to compare 
different combinations, an overlap ratio R(A,B) was calculated between the number 
of probe sets detected as differentially expressed in both datasets A and B and the 
total number of unique probe sets detected in the two datasets:
   
where p is the number of probe sets signifi cant in both datasets, a is the number of 
signifi cant probe sets found in dataset A and b is the number of signifi cant probe 
sets found in dataset B.
3.3.6 Cluster analysis
Subsets of n probe sets (for the AML dataset, n = 3000; for CNS, n = 1000) were 
created by ranking probe sets by their standard deviation over all samples, and 
selecting the top n. Samples in all datasets (4 pre-processing methods) were 
clustered using k-means clustering and hierarchical clustering on both correlation 
distance matrices, in which the distance between two samples x and y is defi ned as 
1-ρxy; and Euclidean distance matrices, as used in (17). Hierarchical clustering was 
performed using single, average and complete linkage. To be able to compare all 
methods and datasets, the number of clusters was fi xed to the expected number 
of groups based on biological characteristics of the patient population, which was 
12 for the AML dataset and 5 for the CNS dataset. To investigate the infl uence of 
this setting, the AML dataset was also clustered into 2 and 20 clusters and the CNS 
dataset was clustered into 2 and 10 clusters, respectively. During each run of the 
k-means algorithm it was randomly restarted 1000 times, retaining the solution 
yielding minimum cluster within-scatter, in an attempt to avoid local minima.
Clustering results were compared using the Jaccard index. The Jaccard-index 
J(C1,C2) compares two clusterings C1 and C2 based on the number of similar sample 
pairs available in the clusters and results in a value between 0 (no similar pairs) and 
1 (all pairs are equal). It is estimated as  
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where n12 denotes the number of pairs of samples in the same cluster in C1 and 
assigned to the same cluster in C2, n1 denotes the number of pairs in the same cluster 
in C1, but in different clusters in C2 and n2 denotes the number of pairs in the same 
cluster in C2, but in a different cluster in C1.
The raw Jaccard index should be interpreted in the light of how stable C1 and C2 
actually are. If a clustering C, obtained using a certain pre-processing method, 
changes when one or a few samples are removed, it is to be expected that using a 
different pre-processing method will also have an impact. To estimate stability, for 
each pre-processing method 100 pairs of random subsets each containing 90% of 
the samples were clustered. Each individual subset was transformed as described 
and n = 3000 (or n = 1000 for the CNS dataset) probe sets were selected (these sets 
were 97.1% identical on average). In each pair, both subsets were then clustered, 
and the Jaccard index between these two clusterings was calculated using the 
samples present in both subsets. This resulted in 100 Jaccard indices, giving an 
impression of the variability due to transformation and subset selection. Finally, 
normal distributions were fi tted to the 100 Jaccard indices found. 
For a Jaccard index resulting from a comparison between two pre-processing 
methods M1 and M2, the cumulative distribution function (CDF) of the normal 
distribution for both pre-processing methods is used to arrive at two stability-
normalized Jaccard indices J1SN and J2SN. Figure 3A illustrates this. A value of  0.5 
for JiSN (in Figure 3A obtained at a Jaccard index of 0.48 for MAS or 0.62 for RMA) 
indicates that differences between pre-processing methods fall well within the 
range of clustering variability for pre-processing method Mi; values higher than that 
indicate that clustering differences due to pre-processing are in fact smaller than 
the average differences between clusterings on subsampled datasets. Although the 
notion of stability has been used before in clustering (e.g. (29)), we believe this 
normalized index to be novel.
Note that for the k-means algorithm, stability-normalised Jaccard indices are 
displayed in Figures 3B and 3C as mean and standard deviation over 10 runs of the 
algorithm, each run the result of 1000 restarts (see above).
3.3.7 Classifi cation
Three two-class problems were defi ned on the AML dataset: (1) samples with 
inversion of chromosome 16 (inv(16)) vs. all others, (2) samples with a mutation 
in the FLT3-gene vs. all others and (3) samples that showed continuous complete 
remission (CCR) vs. samples that did not.  These problems were selected in 
increasing order of expected diffi culty. In the case of the CNS dataset, four two-
class problems (PNET vs. others, MED vs. others, RHAB vs. others and GLIO vs. 
others) were defi ned. A number of classifi ers were trained on probe set subsets of 
increasing size (n = 10, 20, 50, 100, 200, 500, 1000). Probe sets were selected here 
using a signal-to-noise ratio (SNR) variation fi lter, i.e. |µ1-µ2| / √(σ12 + σ22) on the 
training set. Classifi ers used were nearest centroid (NC), nearest shrunken centroid 
(PAM) (30), LIKNON (31), k-nearest neighbour (k-NN), support vector classifi er 
with polynomial kernel of degree d (SVC-P) and radial basis function kernel of 
width σ (SVC-R) (32). The parameters k, d and σ were optimised by performing 
cross-validation (k: leave-one-out; d, σ: 10-fold) on the training set only. Both 
PAM and LIKNON provide their own feature selection algorithm, which selects 
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the optimal feature set within the set selected by the variation fi lter. In a single 
experiment, 90 percent of the samples (randomly selected) were used to train a 
classifi er after which the classifi er was tested on the remaining 10 percent. This 
experiment was repeated 100 times, resulting in an average performance and a 
standard deviation. 
3.4 Results and discussion
The aim of our work was to evaluate the effect of several microarray data pre-
processing methods on the outcome of analyses commonly applied in patient-
cohort studies. Four types of analysis were performed: (1) expression level 
measurement, (2) detection of differential expression (supervised), (3) cluster 
analysis (unsupervised) and (4) classifi cation of samples (supervised). These 
analyses were applied to two publicly available datasets, one of 285 acute myeloid 
leukemia (AML) samples profi led on Affymetrix HG-U133A GeneChips (17) and 
one consisting of 42 Affymetrix HuGeneFL GeneChips hybridized with central 
nervous system (CNS) tumor tissue (20). 
3.4.1 Comparing expression levels to RQ-PCR (AML dataset)
Pearson correlation coeffi cients between expression levels of EVI1, CEBPα, MEIS1, 
HOXA7, HOXA9, TRKA, PRDM1, PRDM2, P8 and GMCSF found in the AML 
dataset, measured by RQ-PCR and microarray after pre-processing using different 
methods, are listed in Table 2. The actual expression levels measured by RQ-PCR 
and the Affymetrix probe sets (using the different pre-processing methods) are 
listed in Supp. Table 2. Average correlation to RQ-PCR expression is 0.48-0.57 for 
the different methods with RMA (0.57 ± 0. 30) and GCRMA (0.57 ± 0.28) showing 
the highest correlation on average, dChip (0.48 ± 0.31) scoring lowest and MAS (0.52 
± 0.29) scoring intermediate. No signifi cant differences have been found between 
correlations of different pre-processing methods and RQ-PCR data and (taking RQ-
PCR as gold standard) no pre-processing method unequivocally performed best in 
measuring expression level. Correlation overall is moderate, but this result is likely 
to be infl uenced by different genomic location of RQ-PCR primers and Affymetrix 
probes, resulting in different expression values when alternative splicing occurs; 
by incorrect annotation of individual probe sets (such as 206848_at); and by 
suboptimal RQ-PCR primer and Affymetrix probe design. 
3.4.2 Comparing expression levels between pre-processing methods
Correlations are depicted in Figure 1A for the AML dataset and in Figure 1B for 
the CNS dataset for each probe set present on the microarray, ordered by average 
expression level over the four differently pre-processed datasets. Overall, a clear 
trend of increasing correlation at increasing expression levels is apparent, which  has 
been noticed before (15). Aside from a dense area of highly correlated genes with 
intermediate to high expression, in several comparisons, for instance that of RMA 
to MAS, a second more densely populated area is visible in the range of extremely 
low expression levels. These expression levels correspond to non-expressed genes 
(40-50% of all probe sets). At these levels, variability is relatively higher, resulting 
in moderate correlations. As the normalization method of RMA 
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Gene symbol Probe set ID MAS dChip RMA GCRMA
EVI1 215851_at 0.34 0.52 0.63 0.29
221884_at 0.64 0.87 0.88 0.45
P8 209230_s_at 0.09 0.15 0.16 0.00
PRDM1 217192_s_at 0.53 0.57 0.55 0.53
TRKA 208605_s_at 0.66 0.77 0.75 0.63
PRDM2 205277_at 0.21 0.25 0.28 0.25
203057_s_at 0.56 0.56 0.59 0.58
203056_s_at 0.57 0.59 0.59 0.55
216433_s_at 0.33 0.42 0.45 0.12
MEIS1 204069_at 0.88 0.90 0.90 0.86
HOXA9 214651_s_at 0.90 0.90 0.91 0.89
209905_at 0.91 0.91 0.90 0.90
HOXA7 206847_s_at 0.80 0.77 0.80 0.89
206848_at 0.01 0.02 0.02 0.04
CEBPα 204039_at 0.61 0.61 0.63 0.58
GMCSF 210229_s_at 0.20 0.32 0.10 0.15
Table 2. Correlation between expression levels measured by RQ-PCR and Affymetrix 
GeneChip on the AML dataset, after use of different pre-processing methods.
and GCRMA is the same (both using MM probes only for background correction) 
and their summarization methods are very similar, it is not surprising that these 
methods show the highest resemblance in measured expression. However, they 
show more agreement with MAS than with dChip (which was also seen when 
comparing microarray expression levels to RQ-PCR expression levels). Perhaps 
this has to do with the fact that dChip calculates expression on the original probe 
intensity values rather than the log-transformed ones used by the other methods. 
The CNS dataset shows similar trends, but the much higher level of variation 
suggests that sample size and/or quality of the platform and biological sample 
have a much more profound effect on estimated expression levels, than has the 
pre-processing method.
In conclusion, the AML dataset shows that variation in estimated expression levels 
exists between different pre-processing methods and that this variation is higher 
at lower mRNA concentrations. The clear trend of increasing correlation with 
increasing expression level suggests that pre-processing has an infl uence, but this 
concerns only a minority of probe sets.
Using the Affymetrix Latin square dataset, Rajagopalan noted that MAS and dChip 
perform equally well on estimating expression levels, with a small non-signifi cant 
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advantage for MAS (13). Although trends towards MAS seem visible in our study 
as well, MAS and dChip behave rather differently in the experimental dataset used 
here. 
Testing not only the Latin square dataset but also the GeneLogic dataset, Irizarry 
et al. conclude that RMA shows highest sensitivity and specifi city when compared 
to dChip and the AvDiff algorithm (10). As no method performs signifi cantly 
different in our study, these results are not confi rmed.
Figure 1: Correlation of expression values pre-processed by two methods. 
Pearson correlation coeffi cients of expression measurements calculated by two pre-
processing procedures are shown on the y-axis, probe sets ranked by average expression 
level over the four pre-processing methods are shown on the x-axis. Contours indicate 
equal density, as estimated using a Gaussian kernel density estimate, with kernel width 
optimised by leave-one-out maximum-likelihood. A. AML dataset. B. CNS dataset.
A
64
Chapter 3
3.4.3 Differential expression 
Signifi cance of differences in expression when comparing two conditions was 
calculated using three standard methods: the t-test; the Wilcoxon rank sum 
test, controlling the Family-Wise Error Rate (FWER); and Signifi cance Analysis 
of Microarrays (SAM), a test controlling the False Discovery Rate (FDR) using 
a statistic resembling that of the t-test (28). Different pre-processing methods 
were compared by assessing the overlap in the number of probe sets marked 
as differentially expressed by two pre-processing methods. We call a probe set 
differentially expressed below an FWER or FDR of 5%. In the AML-dataset, p-
values (FWER) and q-values (FDR) were computed for samples with recurrent 
FLT3 ITD mutations vs. the rest, inv(16) vs. the rest, t(15;17) vs. the rest and t(8;21) 
vs. the rest. In the CNS-dataset, p-values and q-values were computed for PNET-
, RHAB-, GLIO- and MED-samples vs. the rest, respectively. Although different 
subdivisions into conditions were thus compared, the outcomes are remarkably 
similar.
B
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Considering the AML dataset, the overlap between the probe sets selected on RMA 
and GCRMA pre-processed data is most striking, with a minimum R of 0.78 (average 
0.85, Table 3A, Supp. Tables 3A-C). Overall, the overlap between different pre-
processing methods is considerable: a minimum R of 0.56 (average 0.74) is found, 
independent of the statistical test used. The combination MAS-dChip comes up as 
least comparable (Table 3A, Supp. Tables 3A-C). MAS shows higher concordance 
with RMA and GCRMA than does dChip. No indications were found that R will 
increase for smaller FWER or FDR (data not shown).   
The overlap between probe set lists detected as differentially expressed is 
considerably less in the CNS dataset than in the AML dataset and there is more 
variation, which could be due to the higher amount of noise in this dataset and/or 
its smaller sample size. The RMA-GCRMA comparison results in an average R of 
0.56 (Table 3B, Supp. Tables 3D-F). Again, pre-processing with MAS will result in 
less differences with RMA pre-processing than with dChip (Table 3B, Supp. Tables 
3D-F).  Overall, average R is 0.40 for this dataset. When using q-values, again RMA 
and/or MAS often detect larger numbers of differentially expressed probe sets than 
dChip and GCRMA. Note also that the difference between the number of probe 
sets selected using the t-statistic and the Wilcoxon statistic is larger than for the 
AML dataset. This may be caused by outlier data on the HuGeneFL microarrays, 
to which the t-test is more susceptible.
In a study evaluating experimental datasets of 79 ovary tumors and 47 colon 
tumors profi led on the Affymetrix HG-U133A platform, Shedden et al. (9) show 
that dChip results are closer to those obtained using RMA than to those obtained 
using MAS, an observation not confi rmed by our results. Statistical tests on RMA 
and MAS pre-processed data detect the largest number of differentially expressed 
probe sets in most cases, where GCRMA and dChip select less, with a maximum 
difference in number of selected probe sets of 49.7% in the AML dataset (Supp. 
Table 3A, q-values). This does not confi rm the observations of Shedden et al., who 
found that dChip outperformed MAS and GCRMA in terms of sensitivity. Irizarry 
et al. (10) report that RMA performs better than dChip and the AvDiff algorithm 
in fi nding truly differentially expressed genes. No statement on the true nature of 
probe sets measured as differentially expressed here can be made. However, MAS 
and RMA score roughly equal numbers of probe sets as differentially expressed 
and both methods fi nd more probe sets to be differentially expressed than dChip 
and GCRMA, as in (10). 
Recently, Hoffmann et al. (11) stated that normalization will have a larger infl uence 
on the number of differentially expressed genes than the actual statistical test 
used. Although a direct comparison of (11) and our work is not possible due to 
differences in multiple testing correction, in our (much) larger datasets we observe 
a larger difference between the number of probe sets selected as a result of the 
multiple testing correction used (FWER or FDR) than as a result of the choice of 
pre-processing method. 
Overall, the overlap between sets of genes selected as differentially expressed is 
considerable when pre-processing the data using different methods and overlap 
increases when non-biological variation decreases. Using the current datasets, it is 
not possible to give indications of the quality of probe sets selected, due to the lack 
of ground truth.
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MAS dChip RMA GCRMA
SA
M
 q
-
va
lu
es
MAS 3185
dChip 0.68 2973
RMA 0.72 0.72 3649
GCRMA 0.73 0.70 0.86 3650
t-
te
st
p-
va
lu
es
MAS 458
dChip 0.66 354
RMA 0.68 0.70 419
GCRMA 0.69 0.71 0.83 472
W
ilc
ox
on
 
te
st
p-
va
lu
es
 MAS 337
dChip 0.72 295
RMA 0.75 0.79 322
GCRMA 0.75 0.79 0.87 344
Table 3A. Overlap R(A,B) between sets of genes marked as differentially expressed 
after pre-processing with different methods. p- and q-values for the signifi cance of 
difference in expression between samples from the AML dataset with recurrent FLT3 
mutation and samples without recurrent FLT3 mutation were calculated. The numbers 
on the diagonal represents the number of probe sets marked as differentially expressed after 
application of each method.
MAS dChip RMA GCRMA
SA
M
 q
-
va
lu
es
MAS 400
dChip 0.39 714
RMA 0.50 0.54 666
GCRMA 0.52 0.39 0.58 330
t-
te
st
p-
va
lu
es
MAS 224
dChip 0.36 303
RMA 0.43 0.51 159
GCRMA 0.47 0.37 0.55 123
W
ilc
ox
on
 
te
st
p-
va
lu
es
 MAS 17
dChip 0.41 17
RMA 0.46 0.29 18
GCRMA 0.45 0.26 0.5 14
Table 3B. CNS dataset, GLIO samples vs. others.
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3.4.4 Cluster analysis
Data resulting from different pre-processing methods was clustered by k -means 
(KM) and hierarchical clustering with single, average and complete linkage (HC/S, 
HC/A, HC/C). Clusterings of both the AML and CNS datasets were compared 
using the Jaccard index; results are shown in Figure 2 and Supp. Figure 1 (33). 
RMA and GCRMA results are often similar, which is to be expected. dChip results 
frequently differ from results obtained using other pre-processing methods. In 
general, KM, HC/A and HC/C on both datasets show Jaccard indices of 0.3-0.6. 
HC/S shows higher indices, but the actual resulting clusterings are very poor due 
to the well-known high susceptibility of this method to outliers (data not shown): 
almost all samples end up in a single cluster, the remaining samples form individual 
clusters. As an example, the confusion matrix in Table 4 shows that many clusters 
found using the MAS pre-processed dataset are also found reasonably well using 
the RMA pre-processed dataset (by k-means clustering into k = 12 clusters, on 
correlation distance, using 3000 probe sets). However, as there are 2716 sample 
pairs co-occurring in a cluster in both clustering results, 1099 sample pairs co-
occurring in a cluster in the MAS clustering result only and 1137 sample pairs co-
occurring in a cluster in the RMA result only, this leads to a Jaccard-index J of only 
2716 / (2716 + 1099 + 1137) = 0.55. 
In an attempt to quantify the sensitivity of clusterings found to small perturbations, 
stability-normalized Jaccard indices JSN were therefore calculated, indicating to what 
extent the Jaccard indices J found are out of the ordinary. Figure 3A illustrates 
Number of samples in RMA clusters
N
um
be
r o
f s
am
pl
es
 in
 M
A
S 
cl
us
te
rs
1 2 3 4 5 6 7 8 9 10 11 12
1 33 1 1 0 1 1 1 0 0 1 1 0
2 0 33 0 0 1 0 0 0 0 0 2 0
3 0 3 28 2 0 0 0 0 0 0 0 0
4 0 0 7 24 0 1 0 1 0 0 0 0
5 0 1 0 0 21 2 0 0 0 0 0 0
6 0 0 1 3 0 21 0 0 0 0 0 0
7 0 0 0 0 0 0 21 0 0 0 0 0
8 0 0 0 1 0 0 0 18 0 0 0 0
9 0 0 0 0 4 0 0 0 10 0 0 8
10 0 0 0 0 0 0 0 0 1 10 0 0
11 0 3 0 0 0 0 0 0 0 0 10 0
12 0 0 1 0 0 0 0 0 7 0 0 0
Table 4. Confusion matrix of  MAS and RMA clustering results. Clustering into k = 
12 clusters was performed using k-means clustering, using correlation distance on 3000 
probe sets. A cell at position (i,j) shows the number of samples assigned to cluster i on data 
pre-processed using MAS and to cluster j on data pre-processed using RMA. The Jaccard 
index between these two clusterings is 0.55.
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that for KM and the pair of pre-processing methods used (MAS and RMA), J = 0.55 
is actually better than the Jaccard index obtained on average on a slightly changed 
version of the MAS pre-processed dataset (JSN > 0.5), but worse than that obtained 
on average on a slightly changed version of the RMA pre-processed dataset (JSN < 
0.5). 
Figure 3B shows that for KM and HC/A, differences using MAS and (GC)RMA are 
actually roughly of the same order as differences between 90% subsamples of the 
MAS pre-processed dataset (i.e. the JSN is high for MAS). To a lesser extent, this also 
A
B
Figure 2: Jaccard indices of clustering results. Results were obtained using correlation 
distance on a fi xed number of probe sets, after different pre-processing procedures and by 
different clustering algorithms. A. AML dataset, k = 12 clusters, 3000 probe sets. B. CNS 
dataset, k = 5 clusters, 1000 probe sets.
A full-color version of this fi gure is provided on the CD.
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holds for dChip vs. (GC)RMA. However, these same differences are quite large 
in terms of the differences in clusterings between 90% subsamples of (GC)RMA 
(i.e. the JSN is low for (GC)RMA). The main cause for this is (GC)RMA’s higher 
stability: as it normalises over all arrays – unlike MAS and dChip – leaving out a 
small subset will have only a limited effect on probe set distributions, and hence on 
clustering results. When RMA and GCRMA results are compared to each other, a 
high JSN results as well. HC/C oftens shows lower values for J and JSN.
The CNS dataset (Figure 3C) largely tells the same story, although the JSN are 
somewhat larger, especially for k-means clustering. This is due to the smaller 
sample size: leaving out 10% of the samples relatively has more impact on the 
Jaccard indices.
Supp. Figures 1 and 2 illustrate the infl uence of the choice of the number of clusters 
(k) and the distance measure (correlation or Euclidean). Both datasets show the 
A
Figure 3A: Stability normalization of Jaccard index. Illustration of stability 
normalization for the Jaccard index of a particular k-means clustering (k = 12), obtained 
on MAS- and RMA-pre-processed versions of the AML dataset (correlation distance, 3000 
probesets). The dotted line corresponds to the Jaccard index between these clusterings 
(0.55). For both MAS and RMA, the CDF can be used to arrive at a stability normalized 
Jaccard index; in this case 0.90 and 0.16. The arrows indicate the Jaccard indices for which 
the normalised Jaccard index JSN = 0.5. The interpretation is that for MAS, the comparison 
to RMA falls well within what can be expected, for RMA less so.
A full-color version of this fi gure is provided on the CD.
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same effects. For lower k (k = 2), both Jaccard indices and stability-normalized 
Jaccard indices are much higher, as clusterings of data pre-processed by the various 
methods agree on structure clearly present in the data. For higher k (AML: k = 20, 
CNS: k = 10), Jaccard indices and stability-normalized Jaccard indices are similar to 
or even lower than those for the k chosen originally. Using Euclidean distance leads 
to slightly lower Jaccard indices, with an increase in difference between dChip and 
other methods. This may be the result of the negative values it produces (unlike 
MAS and (GC)RMA), which are thresholded at 0.1 in the data transformation steps. 
Due to the centering by the geometric mean this can lead to larger extreme probe 
set values over arrays.
In conclusion, clustering results are sensitive to the choice of pre-processing method. 
Figure 3C. CNS dataset: stability-normalized pairwise Jaccard indices of cluster 
labels assigned by the various methods. Clusterings into k = 5 clusters obtained using 
correlation distance on 1000 probe sets. Legend is shown in Figure 3D. For k-means, the 
grey bars indicate standard deviation over 10 repeated experiments.
B
C
D
Figure 3B. AML dataset: stability-normalized pairwise Jaccard indices of cluster 
labels assigned by the various methods. Clusterings into k = 12 clusters obtained using 
correlation distance on 3000 probe sets. Legend is shown in Figure 3D. For k-means, the 
grey bars indicate standard deviation over 10 repeated experiments.
Figure 3D. Legends to markers in Figures 3B-C.
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This sensitivity is smallest for small numbers of clusters k (i.e. when looking for 
clearly present structure) and when using correlation distance. Additionally, using 
(GC)RMA seems to result in more stable clusterings than using MAS or dChip.
3.4.5 Classifi cation
A number of different classifi cation problems defi ned on the datasets have been 
approached using several classifi ers trained on data of all pre-processing methods. 
Resulting performances are listed in Table 5 and Supp. Table 4. Results are reported 
only for the number of probe sets giving lowest average test set error over the 
four methods. Although this makes the performance estimates biased, it does not 
infl uence comparison between methods.
In the AML dataset, inversion of chromosome 16 is well predictable, with error 
rates smaller than 5% (Table 5a). Differences in error rate between classifi cation 
algorithms are very small: although the nearest centroid classifi er often performs 
worst, no algorithm performs signifi cantly better than others. More importantly, no 
pre-processing method scores signifi cantly better or worse than others (although 
MAS relatively often shows best results). Although predicted with a higher error 
rate, these observations are confi rmed on the FLT3 (Table 5B) and CCR (Table 5C) 
AML problems.
Interestingly, this also holds for the CNS dataset (Table 5D shows results for the 
MED problem; other results are shown in Supp. Table 4), although performances 
show much more variation and MAS no longer comes out best. Ofcourse, the CNS 
dataset is rather small, so obtaining good classifi ers is harder.
No classifi er or pre-processing method scores signifi cantly better than others. 
This can be explained by the fact that the probe sets on which classifi cation is 
based are already selected to give good classifi cation results: on differently pre-
processed datasets, different probe sets may be selected (in fact, the selected sets 
of n = 1000 probe sets show an overlap of 71% to 87%). The six classifi ers used 
seem to be equally susceptible to different pre-processing methods; that is, for each 
of them performance varies with pre-processing method used in at least some of 
the problems. For classifi cation, the choice of pre-processing method (and, for that 
matter, classifi cation algorithm) seems to be irrelevant.
3.5 Conclusion
Patient-cohort studies using microarrays are often performed to fi nd 
pathobiologically relevant relations between genes and patient classes. The 
Affymetrix platform has become increasingly popular for this type of study. 
Processing intensity values obtained using Affymetrix GeneChips remains a 
challenging task for many microarray researchers. Apart from the Affymetrix MAS 
procedure, several statistical procedures have been proposed to assess expression, 
such as dChip, RMA and GCRMA.  Our study has tried to estimate the effects of 
the choice of pre-processing method from a practical viewpoint. To this end, we 
have applied a number of analyses to two datasets, which we believe to represent 
two extremes in recent patient-cohort studies both in terms of sample size and of 
platform used.
The experimental results indicate that the normalization step in (GC)RMA has 
a larger effect on the data than the one in MAS and dChip, but this cannot be 
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MAS dChip RMA GCRMA
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) NC (50) 0.01(0.02) 0.02(0.02) 0.01(0.02) 0.02(0.03)
PAM (20) 0.01(0.02) 0.01(0.02) 0.01(0.02) 0.01(0.02)
LIKNON 
(10)
0.02(0.03) 0.02(0.03) 0.02(0.02) 0.02(0.02)
k-NN 
(50)
0.01(0.02) 0.01(0.02) 0.01(0.02) 0.01(0.02)
SVC/P 
(10)
0.02(0.03) 0.02(0.02) 0.02(0.03) 0.02(0.03)
SVC/RBF 
(10)
0.03(0.02) 0.02(0.02) 0.02(0.02) 0.02(0.02)
Table 5A. Performance of different classifi cation algorithms: AML dataset, inv(16) 
problem. Mean test set error (standard deviation) over 100 random splits of the original 
data into a training set (90%) and a test set (10%). Error is defi ned as average error per 
class, i.e. corresponding to assuming a prior probability of occurrence of a class of 50%. 
Classifi ers were trained for 10, 20, 50, 100, 250, 500 and 1000 probe sets selected by the 
variation fi lter; results shown here are for the number of probe sets resulting in the smallest 
average test set error over the four methods, indicated between brackets after the classifi er 
name. 
MAS dChip RMA GCRMA
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(n
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r o
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s 
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ed
) NC (10) 0.16(0.06) 0.19(0.09) 0.16(0.08) 0.26(0.08)
PAM (20) 0.14(0.06) 0.14(0.06) 0.14(0.06) 0.14(0.06)
LIKNON 
(20) 0.12(0.05) 0.11(0.05) 0.12(0.06) 0.13(0.05)
k-NN (200) 0.10(0.05) 0.11(0.05) 0.11(0.06) 0.13(0.06)
SVC/P (20) 0.12(0.05) 0.11(0.05) 0.13(0.06) 0.13(0.05)
SVC/RBF 
(100) 0.09(0.05) 0.10(0.05) 0.10(0.05) 0.14(0.05)
Table 5B. AML dataset, FLT3 problem.
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MAS dChip RMA GCRMA
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er
 
(n
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ed
) NC (1000) 0.34(0.09) 0.34(0.08) 0.33(0.08) 0.35(0.08)
PAM (10) 0.29(0.06) 0.30(0.06) 0.30(0.05) 0.30(0.06)
LIKNON 
(20) 0.27(0.08) 0.31(0.07) 0.31(0.08) 0.28(0.07)
k-NN (20) 0.28(0.07) 0.29(0.06) 0.30(0.06) 0.29(0.07)
SVC/P (20) 0.28(0.08) 0.31(0.07) 0.31(0.07) 0.28(0.06)
SVC/RBF 
(20) 0.28(0.05) 0.30(0.04) 0.30(0.04) 0.29(0.04)
Table 5C. AML dataset, CCR problem.
MAS dChip RMA GCRMA
C
la
ss
ifi 
er
 
(n
um
be
r o
f p
ro
be
 s
et
s 
us
ed
) NC (1000) 0.04(0.09) 0.03(0.09) 0.03(0.08) 0.07(0.13)
PAM 
(1000) 0.05(0.10) 0.07(0.13) 0.09(0.14) 0.06(0.13)
LIKNON 
(1000) 0.10(0.12) 0.06(0.11) 0.10(0.13) 0.18(0.18)
k-NN (500) 0.06(0.11) 0.06(0.12) 0.08(0.12) 0.04(0.10)
SVC/P 
(1000) 0.09(0.12) 0.05(0.11) 0.04(0.09) 0.07(0.12)
SVC/RBF 
(10) 0.17(0.13) 0.16(0.13) 0.17(0.14) 0.14(0.14)
Table 5D. CNS dataset, MED problem.
separated from the effect of applying different models for summarization. And, 
although the dChip and RMA summarization models are more related to each other 
than the MAS and RMA ones, MAS pre-processed data shows more similarity to 
RMA than does dChip. 
In practical terms, the question of which method will give expression value 
estimates closest to the actual data is still to be answered; this study has not 
attempted to answer it, because we have not used data with accompanying ground 
truth. We showed that results of various analyses are not always dependent on the 
choice of pre-processing method. Analyses such as calculating expression levels or 
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assessing differential expression are reasonably susceptible to differences between 
pre-processing methods; clustering as well, except when looking for clearly present 
structure (that is, using a small number of clusters); but classifi cation far less so. 
The message is that while care should be taken in assigning biological meaning to 
individual probe set measurements, this holds less for global statements about the 
data. 
Several other studies have been performed to assess the level of concordance in 
differential gene sets between pre-processing methods and noted that the choice 
of the method was of major infl uence, with different studies favoring different 
pre-processing methods (9, 11, 13). Our results do not conclusively confi rm one 
or more studies, although results partially overlap. One major difference with 
other studies is the size of the used datasets, where one of the datasets used in this 
study is considerably larger. It is to be expected that with the evolution of the array 
technology, the number of profi led samples in any single patient-cohort study is 
likely to increase. 
The effects of the choice of pre-processing method are far more profound in the 
CNS dataset than in the AML dataset. Several possible explanations can be given 
for this, but it is not possible to single any of them out based only on the two 
datasets used in this study. The AML dataset contains more samples, which allows 
for better parameter estimates in the analysis methods presented in this work. 
Furthermore, Affymetrix technology has evolved over time, resulting in a more 
stable platform for the AML dataset (HG-U133A) than the CNS dataset (HuGeneFL). 
Biological differences also play a role in the two datasets. The amount of viable 
cells obtained from bone marrow is also likely to be higher compared to solid 
tumors, which often show necrotic areas, leading to difference in RNA-quality and 
-degradation. Also, tumor cells can be purifi ed from bone marrow samples using 
Ficoll-centrifugation, a technique which is not available for the solid tumors which 
were hybridized in the CNS dataset, resulting in less contamination with other cell 
types in hybridized samples, which is known to be an important factor (34). We 
recommend that the emphasis in setting up a large microarray-based study should 
therefore be on the quality of the biological sample and the quality of RNA rather 
than on the choice of the pre-processing procedure. However, we do believe that 
an inverse relation exists, with the importance of the method of normalization and 
expression summarization increasing when the quality of the biological sample 
and the number of studied samples decrease. Although we base this on a limited 
number of pre-processing methods and data sets, we think that taking into account 
more available methods will have no effect on our conclusion.
List of Abbreviations
AML   Acute myeloid leukemia
CNS  Central nervous system
PNET  Primitive neuro-ectodermal tumors
MED  Medullablastoma
GLIO   Malignant glioma
RHAB  Rhabdoid tumors
SAM  Signifi cance analysis of microarrays
CDF  Cumulative distribution function
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CCR  Continuous complete remission
PAM   Prediction analysis of microarrays
k-NN  k-Nearest neighbour
NC   Nearest centroid
SVC-P  Support vector classifi er with polynomial kernel of degree d
SVC-R  Support vector classifi er with radial basis function kernel of width 
σ
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4.1 Abstract
Mutations in nucleophosmin NPM1 are the most frequent acquired molecular 
abnormalities in acute myeloid leukemia (AML). We determined the NPM1 
mutation status in a clinically and molecularly well-characterized patient cohort 
of 275 patients with newly diagnosed AML by denaturing high performance 
liquid chromatography (dHPLC). We show that NPM1 mutations are signifi cantly 
underrepresented in patients younger than 35yr. NPM1 mutations positively 
correlate with AML with high white blood cell counts, normal karyotypes and 
FLT3 internal tandem duplication (ITD) mutations. NPM1 mutations associate 
inversely with the occurrence of CEBPα- and N-RAS mutations. With respect to gene 
expression profi ling, we show that AML cases with an NPM1 mutation cluster in 
specifi c subtypes of AML with previously established gene expression signatures, 
are highly associated with a homeobox gene-specifi c expression signature and can 
be predicted with high accuracy. We demonstrate that patients with intermediate 
cytogenetic risk AML without FLT3 ITD mutations but with NPM1 mutations have 
a signifi cantly better OS and EFS than those without NPM1 mutations. Finally, in 
multivariable analysis NPM1 mutations express independent favorable prognostic 
value with regard to overall-, event free- and disease free survival.
4.2 Introduction
Acute myeloid leukemia (AML) is a heterogeneous disease with diverse genetic 
abnormalities and variable responsiveness to therapy. Cytogenetic analyses and 
molecular analyses are currently used to risk-stratify AML. For instance, the 
translocations inv(16), t(8;21), and t(15;17) herald a favorable prognosis, whereas 
certain other cytogenetic aberrations indicate leukemia with intermediate or 
high risk of relapse (1-5). Nevertheless, the classifi cation of AML on the basis 
of karyotyping is still far from satisfactory. In recent years extended molecular 
analyses have yielded novel molecular markers important for proper diagnostics 
of AML. The ITD in the fms-like tyrosine kinase-3 gene (FLT3) (6, 7), partial tandem 
duplication (PTD) (8, 9) of the mixed lineage leukemia gene (MLL) and increased 
expression of the transcription factor EVI1 (10), are indicative of poor prognosis. 
In contrast, mutations in the transcription factor CEBPα have been associated with 
a favorable response to therapy (11, 12). A recent study showed mutations in exon 
12 of the gene encoding nucleophosmin NPM1 in approximately 35% of cases of 
de novo AML (13). Mutations of NPM1 were found to be mutually exclusive with 
certain common recurrent chromosomal aberrations, and are predominantly seen 
in AML with normal karyotypes and FLT3 ITD mutations. 
NPM1 is predominantly localized in the nucleolus and is thought to function 
as a molecular chaperone of proteins, facilitating the transport of ribosomal 
proteins through the nuclear membrane (14-16). Disruption of NPM1, either by 
chromosomal translocation or by mutation, results in the cytoplasmic dislocation 
of NPM1. The high frequency of NPM1 mutations in AML with normal karyotypes 
and the observation that cytoplasmic NPM1 cannot exert its normal functions as 
binding partner and transporter protein lead to the notion that NPM1 mutation 
may be an early event in leukemogenesis. 
An important role for NPM1 in leukemias and lymphomas has been proposed 
previously. NPM1 has been found to be part of several fusion proteins, which are 
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formed as a result of chromosomal translocation and in which only the NPM1 N-
terminal region is conserved. A t(2;5)(p23;q35) chromosomal translocation occurs 
in approximately 8% of non-Hodgkin lymphomas in children and young adults 
and results in the chimeric fusion of NPM1 to ALK (17). In rare cases of acute 
promyelocytic leukemia (APL), characterized by chromosomal translocations that 
disrupt the gene encoding the retinoic acid receptor (RARα), fusion of NPM1 to 
RARα was shown (18). A t(3;5)(q25.1;q34) chromosomal translocation, infrequently 
seen in myelodysplastic syndrome and AML gives rise to a fusion transcript of 
NPM1 and MLF1 (19). 
Gene expression profi ling is a powerful way to comprehensively classify individuals 
with AML and to further resolving the heterogenous nature of AML (20). Using this 
technique, new prognostically relevant AML subtypes have been identifi ed, while 
the presence of recurrent chromosomal abnormalities such as inv(16), t(15;17) and 
t(8;21) as well as other molecular aberrations, e.g., C- and N-terminal mutations in 
CEBPα, could be predicted with high accuracy by unique expression patterns (21-
23). In recent study, novel subtypes of AML have also been defi ned based on gene 
expression profi ling, however, the common molecular abnormalities in these AML 
subtypes are largely unknown (22). Since NPM1 is mutated in approximately one 
third of AML patients, this molecular abnormality may drive the clustering of these 
AML subtypes. The effect of mutant NPM1 has been studied using gene expression 
profi ling and revealed a distinctive signature of NPM1 mutations (24). Amongst 
players in this signature were several homeodomain-containing family members 
of HOX transcription factors and CD34, both observations being indicative of 
hematopoietic development (24). However, it is currently not known whether 
NPM1 mutations are predictable on the basis of a gene expression signature.
Cytoplasmic NPM1 has been positively associated with remission rate (13), 
however, the relation of mutant NPM1 with survival outcome parameters remains 
to be elucidated.
We have studied a well-characterized cohort of 275 cases of de novo AML for 
the presence of a NPM1 mutations to (I) validate dHPLC as a rapid approach to 
determine NPM1 mutations, (II) investigate the relation of NPM1 mutations with 
regard to clinical parameters, cytogenetics and various molecular abnormalities, 
(III) determine the relation of NPM1 mutations in subtypes of AML, recently 
identifi ed by gene expression profi ling (22), (IV) derive NPM1 mutation specifi c 
and predictive gene expression signatures and (V) determine the prognostic value 
of mutated NPM1.
4.3 Patients and methods
4.3.1 Patients and cell samples
Patients had a diagnosis of primary AML, confi rmed by cytological examination 
of blood and bone marrow (median age 44 (range 15-78), median bone marrow 
blast count 65 percent (range 0 (for APL) -98), median white blood cell (WBC) 
count 32 (x109/l) (range 0.3-263)). All patients had been treated according to the 
HOVON (Dutch-Belgian Hematology-Oncology Co-operative group) protocols 
(http://www.hovon.nl) (25-27). After informed consent, bone marrow aspirates 
or peripheral blood samples were taken at diagnosis. Blasts and mononuclear 
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cells were purifi ed by Ficoll-Hypaque (Nygaard, Oslo, Norway) centrifugation 
and cryopreserved. The AML samples contained 80-100 percent blast cells after 
thawing, regardless of the blast count at diagnosis. 
4.3.2 PCR, WAVE and sequence analyses
RNA isolation and cDNA synthesis were performed as described (22, 28). 
cDNA prepared from 50ng of RNA was used for all PCR amplifi cations. NPM1 
mutations in exon 12 were determined by cDNA amplifi cation using the primers 
NPM1-FOR 5’-CTTCCGGATGACTGACCAAGAG-3’ and primer NPM1-REV 5’-
CCTGGACAACATTTATCAAACACG-3’ (25mM dNTP, 15 pmol primers, 2mM 
MgCl2, Taq polymerase and 10xbuffer (Invitrogen Life Technologies, Breda, The 
Netherlands)). Cycling conditions for NPM1 mutation detection were as follows: 
1 cycle 5’ 940C, 30 cycles 1’ 940C, 1’ 580C, 1’ 720C, and 1 cycle 7’ 720C. PCR products 
were subsequently subjected to dHPLC using a Transgenomics (Omahah, NE) 
WAVE dHPLC system (29). Samples were run at 560C and 580C. The exact NPM1 
mutant sequence was confi rmed for all samples showing an abnormal dHPLC 
profi le. PCR products were purifi ed using the Multiscreen-PCR 96-well system 
(Millipore, Bedford, MA) followed by direct sequencing with NPM1-REV using an 
ABI-PRISM3100 genetic analyzer (Applied Biosytems, Foster City, CA).  
Sequence analyses for mutations in FLT3 (ITD and tyrosine kinase domain mutation 
(TKD)), N-RAS, K-RAS and CEBPα performed as described previously.(12, 30, 31). 
4.3.3 Gene expression profi ling and unsupervised cluster analyses 
285 AML cases were analyzed using Affymetrix HGU133A GeneChips (22). 
Unsupervised cluster analysis on the basis of the gene expression profi les of the 285 
cases of AML was performed using the Correlation Visualization tool of Omniviz 
(Maynard, MA (version 3.6)) (22). The Pearson’s correlation values calculated in 
Omniviz were subsequently imported into the MicroArray Data Explorer (MADEx), 
which was developed in our laboratory. MADEx was used to visualize the relations 
between the Omniviz unsupervised clustering results and other parameters, such 
as clinical and molecular characteristics of the AML patients (Figure 1).  MADEx 
is a database system that stores, mines and visualizes microarray data in a secure 
and scalable manner. 
4.3.4 Signifi cance Analysis of Microarrays (SAM) 
All supervised analyses were performed using Signifi cance Analysis of Microarrays 
(SAM) (version 1.21) (32). A threshold was set for a minimum change in expression 
of at least 1.5-fold. A false discovery rate of 0.01 was used to select the differentially 
expressed genes. 
4.3.5 Prediction Analysis of Microarrays (PAM) 
All supervised class prediction analyses were performed by applying Prediction 
Analysis of Microarrays (PAM) (version 2.0) (33). The gene signature was selected 
based on the smallest prediction error in the training set and was subsequently 
tested using the test set. The positive predictive value was calculated with (true 
positives/(true positives + false positives)).
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4.3.6 Statistical analyses of survival
Cytogenetic abnormalities were categorized in 3 cytogenetic groups for statistical 
analyses. Patients with inv(16)/t(16;16), t(8;21), and t(15;17) abnormalities 
were considered as being in the favorable-risk category. The unfavorable-risk 
category was defi ned by the presence of -5/del(5q), -7/del(7q), t(6;9), t(9;22), 3q26 
abnormality or complex karyotype (more than 3 abnormalities). All other patients 
were classifi ed as intermediate risk. Statistical analyses were performed with Stata 
Statistical Software, Release 7.0 (Stata, College Station, TX). Actuarial probabilities 
of overall survival (OS) (with failure defi ned as death due to any cause) and event-
free survival (EFS) (with failure defi ned as not achieving complete remission (set 
at day 1), relapse, or death in fi rst complete remission) were estimated by the 
method of Kaplan and Meier. The Cox proportional hazards model was applied 
to determine the association of NPM1 mutation with OS, EFS and disease-free 
survival (DFS), without and with adjustment for other factors such as cytogenetic 
risk, age, white blood cell count and FLT3 ITD. All tests were 2-sided, and a P of 
less than .05 was considered statistically signifi cant.
4.4 Results
4.4.1 Different NPM1 variant mutations in AML 
The presence of NPM1 mutations in 275 cases of primary AML was rapidly and 
reliably detected by dHPLC WAVE. Nucleotide sequencing was performed on 
those cases with an abnormal dHPLC profi le (Table 1). Each NPM1 mutation variant 
reveals a specifi c dHPLC WAVE profi le. Thus, each type of NPM1 mutation could 
be predicted on the basis of a specifi c dHPLC WAVE profi le. 
In addition, three novel NPM1 mutant variants were identifi ed (NPM1 mutants I to 
K (Table 1)). These rare variants have comparable 4-base pair insertions, like NPM1 
variant mutations A to D (13), resulting in a frame shift and replacement of the 7 
C-terminal amino acids of the NPM1 protein by 11 different residues (Table 1).
4.4.2 NPM1 mutations in relation to clinical and molecular features in AML 
The NPM1 mutation frequencies of the 275 cases of primary AML with regard to 
clinical parameters, morphology, cytogenetics and molecular characteristics are 
shown in Table 2. NPM1 mutations are signifi cantly less frequently present in 
patients of younger age (<35 yr, p<0.001). The mean age of patients with AML and 
NPM1 mutations is 47.3 (±10.7), whereas the mean age of patients with AML and 
wild-type NPM1 is 39,7 (±13.3). NPM1 mutations are seen in AML FAB subtypes 
M1 to M6, but are absent in AML FAB M0. The mutations are relatively frequently 
found in AML FAB M5 as well as in all three cases of AML FAB M6. In AML with 
recurrent translocations, i.e., t(8;21), inv(16) and t(15;17), no NPM1 mutations were 
demonstrated. In cases with various other cytogenetic abnormalities, mutations 
in NPM1 were also rare. As a result, there appears a positive correlation between 
NPM1 mutations and AML with normal karyotypes (p<0.001). The analysis 
of NPM1 mutations reveals interesting relationships with particular common 
molecular abnormalities. The presence of NPM1 mutations signifi cantly correlates 
with the presence of FLT3 ITD mutations (p<0.001). A correlation between NPM1 
mutations and FLT3 TKD mutations is not apparent. AML with N-RAS mutations 
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No. No. of NPM1 mutants (%) P
Sex                                    .100
  Male 135 40 (30)
  Female 140 55 (39)
Age,  y                                  < .001
  Younger than 35 74 11 (15)
  35 to 60 169 69 (14)
  60 and older 32 15 (47)
WBC count, x 109/L                                   <.001
  20 or below 113 28 (25)
  Above 20 157 66 (42)
  ND 5  1 (20)
FAB
  M0 6 0 (0) ND
  M1 62 21 (34) > .999
  M2 63 18 (29) .296
  M3 17 1 (6) .008
  M4 49 15 (31) .062
  M5 65 32 (49) .007
  M6 3 3 (100) ND
Cytogenetic abnormalities*
  t(15;17) 16 0 (0) .002
  t(8;21) 21 0 (0) < .001
  inv(16/t(16;16) 17 0 (0) .001
  +8 24 5 (21) ND
  +11 5 0 (0) ND
  +21 1 1 (100) ND
  -5 2 0 (0) ND
  -5(q) 1 0 (0) ND
  -7 13 0 (0) .005
  -7(q) 7 0 (0) ND
  3q 5 1 (20) ND
  t(6;9) 4 0 (0) ND
  t(9;22) 2 1 (50) ND
  t(11q23) 16 1 (6) .014
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No. No. of NPM1 mutants (%) P
  Complex; 
more than 3 
abnormalities
11 0(0) .018
  Other 55 10 (18) .004
  Normal 116 74 (64) < 0.001
  ND 10 6 (60) ND
Molecular abnormalities
  FLT3 ITD 78 47 (60) < .001
  FLT3 TKD 32 14 (44) .243
  NRAS 25 3 (12) .024
  KRAS 8 5 (63) .130
  CEBPα 17 0 (0) .001
  P values were calculated using the Fisher exact test (2-tailed; ND 
  indicates not determined).
*All patients with a specifi c abnormality were considered irrespective of the
  presence of additional abnormalities.
Table 2. NPM1 mutation frequencies in relation to clinical parameters, morphology, 
cytogenetics, and molecular characteristics of the 275 patients with de novo 
AML.
Figure 1 (facing page). Adapted Omniviz Correlation View of 285 AML patients 
(2856 probe sets) (22). The Correlation View displays pair-wise correlations between AML 
patients. The cells in the visualization are colored by Pearson’s correlation coeffi cient values 
with deeper colors indicating higher positive (red) or negative (blue) correlations. The scale 
bar indicates maximum positive correlation (red) towards maximum negative correlation 
(blue). The 16 clusters identifi ed in the cohort of 285 AML patients on the basis of the 
Correlation View are indicated (1 to 16) (22). Clinical and molecular data are depicted in 
the columns along the original diagonal of the Correlation View (22). FAB classifi cation 
and karyotype based on cytogenetics are depicted in the fi rst two columns (FAB M0-red, 
M1-green, M2-purple, M3-orange, M4-yellow, M5-blue, M6-grey; karyotype: normal-
green, inv(16)-yellow, t(8;21)-purple, t(15;17)-orange, 11q23 abnormalities-blue, 7(q) 
abnormalities-red, +8-pink, complex-black, other-gray). FLT3 ITD and NPM1 mutations 
are depicted in the same set of columns (red bar: positive and green bar: negative). The 
expression levels of CD34 (probe set: 209543_s_at) in the 285 AML patients are plotted 
in the last column (bars are proportional to the level of expression). The percentages of the 
most common (>40 percent) abnormalities, NPM1 mutations as well as normal karyotypes 
(NN) for each cluster are indicated. 
A full-color version of this fi gure is provided on the CD.
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Probe set id Gene symbol Fold change
Up-regulated in AML with mutant NPM1
  213844_at HOXA5 4.2
  205366_s_at HOXB6 2.6
  208414_s_at HOXB3 1.8
  204082_at PBX3 2.8
  205600_x_at HOXB5 2.1
  206289_at HOXA4 2.1
  205453_at HOXB2 2.1
  213150_at HOXA10 2.6
  204069_at MEIS1 2.6
  209905_at HOXA9 2.8
  201664_at SMCL4 2.1
  20943_s_at PHKA2 1.6
  206847_s_at HOXA7 1.5
  63825_at ABHD2 1.6
  219304_s_at PDGFD 1.9
  212820_at RC3 2.4
  213110_s_at COL4A5 2.9
  207111_at EMR1 2.1
  208557_at HOXA6 1.6
  203471_s_at PLEK 1.6
  203680_at PRKAR2B 2.3
  202729_s_at LTBP1 3.6
  210145_at PLA2G4A 1.6
 220162_s_at CARD9 1.5
  206298_at ARHGAP22 2.0
  219602_s_at FAM38B 1.9
Down-regulated in AML with mutant NPM1
  209543_s_at CD34 -5.4
  206896_s_at GNG7 -1.7
  209583_s_at MOX2 -3.1
  200953_s_at CCND2 -2.1
  221004_s_at ITM2C -3.0
  205330_at MN1 -4.3
  200602_at APP -2.6
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Probe set id Gene symbol Fold change
  200665_s_at SPARC -3.8
  201015_s_at JUP -3.1
  218899_s_at BAALC -4.3
  209679_s_at LOC57228 -1.9
 219694_at FLJ11127 -2.1
  206042_x_at SNRPN -2.5
  211535_s_at FGFR1 -2.6
  214582_at PDE3B -1.8
  221523_s_at RRAGD -1.8
  213618_at CENTD1 -1.7
  218589_at P2RY5 -3.3
  202016_at MEST -2.9
  208116_s_at MAN1A1 -3.1
  205240_at GPSM2 -1.9
  202747_s_at ITM2A -4.1
  206622_at TRH -9.1
  206726_at PGDS -4.7
Table 3. NPM1 mutation-associated gene expression in 275 patients with de novo 
AML. The top 50 unique most discriminating genes and fold change in expression with 
regard to NPM1 mutation as determined by SAM (up-regulated: increased expression in 
NPM1 mutant cases; down-regulated: decreased expression in NPM1 mutant cases).
4.4.3 NPM1 mutations occur within specifi c AML subtypes defi ned by gene 
 expression profi ling
Of the cohort of 285 cases of primary AML which had previously been profi led 
using the Affymetrix HGU133 GeneChip (22) and for which 16 distinct  expression 
signatures had been defi ned following unsupervised cluster analyses, we have 
now examined 275 cases for the presence of NPM1 mutations. Among these pre-
established signatures, the AML cases with NPM1 mutations aggregate within 
particular clusters (Figure 1). The majority of AML cases in clusters #2, #3, #5 and 
#7 carry NPM1 mutations. As a matter of fact, all cases of AML of clusters #6 (100% 
FLT3 ITD) and #11 (78% normal karyotypes) carried mutations in NPM1. Although, 
clusters #7 and #8 have comparable expression profi les (Figure 1), 13 out of the 18 
AML cases in cluster #7 (72%) and only 1 of 12 cases of cluster #8 (8%) reveal NPM1 
mutations. The clusters merely consisting of AML with inv(16) (#9), t(15;17) (#12) 
or t(8;21) (#13) as well as the clusters predominantly containing cases with CEBPα 
mutations (#4 and #15) all lack NPM1 mutations. The subset of AML patients in 
cluster #10, with adverse prognosis and an expression profi le comparable to CD34-
positive cells (22), did not present with NPM1 mutations. 
Falini and colleagues (13) had shown a negative correlation between the presence 
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                            Predicted genotype
                                   10-CV error*                              Error validation set*
Genotype WT Mutant WT Mutant
WT NPM1 98 24 48 10
Mutant NPM1 0 62 0 33
*10-fold CV error: 10-fold cross validation prediction error on training set (n=184), Error 
validation set: prediction error on validation set (n=91). 10-Fold cross validation works as 
follows: the model is fi tted on 90% of the samples and the class of the remaining 10% is 
predicted. This procedure is repeated 10 times, with each part playing the role of the test 
samples and the error of all 10 parts added together to compute the overall error. The error 
within the validation set refl ects the number of samples wrongfully predicted in this set.
Table 4.  NPM1 mutation prediction by using PAM. Most optimal result for NPM1 
mutation prediction using a cohort of 275 cases of AML divided in a training and test set 
(22). 22 probe sets were used in this prediction, representing 18 unique genes. 
Figure 2. The most predictive molecular signature with regard to NPM1 mutation 
in AML assessed with 22 probe sets representing 18 unique genes. The levels of 
expression of the probe sets in the 275 cases of AML are depicted (scale bar indicates an 
increase (red) or a decrease (green) in the level of expression of at least 4 relative to the 
geometric mean) (22). The three probe sets representing the NPM1 gene are also depicted.
A full-color version of this fi gure is provided on the CD.
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of NPM1 mutations and CD34 expression levels. In fact, by plotting the CD34 mRNA 
expression levels of the 285 AML cases, as determined by the GeneChip analyses, 
along the NPM1 mutation status (Figure 1), a distinguishable association of CD34 
mRNA expression and NPM1 mutation is apparent, i.e., CD34 mRNA expression 
is low or absent in cases of AML with NPM1 mutations, while CD34 mRNA levels 
are high in AML cases without NPM1 mutations.
4.4.4 HOX gene-specifi c gene expression signature of NPM1 mutant cases
To identify genes with signifi cant differential expression between primary AML 
samples with NPM1 mutations (n=95) and samples without NPM1 mutations 
(n=180) the SAM algorithm was used (32). A fold change threshold of 1.5 for 
upregulation of gene expression and 0.667 for downregulation of gene expression 
was applied. With a False Discovery Rate (FDR) of 0.01, 569 probe sets representing 
440 unique genes, were identifi ed as being signifi cantly differentially expressed 
(Supplementary Figure 1 and Table 1). The identity of the Top-50 genes, in some 
cases represented by multiple probe sets, are depicted in Table 3. 
A dominant homeobox (HOX) gene-specifi c signature is strongly associated with 
AML carrying an NPM1 mutation. Moreover, the expression of members of the 
HOXA- and HOXB-gene families, but also the HOX gene-related TALE genes, PBX3 
and MEIS1 are increased. In contrast, the CD34 gene is the strongest signifi cantly 
down regulated gene with regard to NPM1 mutation in the AML patient cohort. 
4.4.5 NPM1 mutant cases are predicted with high accuracy based on their 
 gene expression signature 
NPM1 mutation prediction analyses were performed using the PAM algorithm 
(33). All 275 primary AML samples were randomly assigned to a training set, 
 consisting of 122 samples without NPM1 mutations and 62 samples with NPM1 
mutations, and a validation series, consisting of 58 samples lacking the NPM1 
mutation and 33 samples with mutations in NPM1.  Cross validation to predict the 
mutation status of NPM1 on the training set resulted in 100% correct predictions 
on presence of mutation (sensitivity) and 80.3% correct predictions on absence of 
mutation (specifi city) (Table 4). Prediction of an independent validation set also 
resulted in 100% correct prediction of presence of mutation and 82.7% correct 
prediction on absence of mutation. The positive predictive value in this cohort is 
72% in the training set and 74% overall. As expected, the genes included in the 
PAM gene signature were among the most signifi cant differentially expressed 
genes as determined by SAM, thereby validating both algorithms. Of note, NPM1 
mRNA expression did not correlate with mutation status (Figure 2). The NPM1 
mutant AML cases have a distinct signature with regard to the 18 selected genes 
(Figure 2) and are therefore predicted with high accuracy (Table 4). However, these 
18 genes seem to be expressed at comparable levels in a subset of AML cases with 
wild type NPM1 (Figure 2). 
4.4.6 NPM1 mutation is an independent favorable prognostic marker 
To investigate the prognostic value of NPM1 mutation 252 AML patients with long 
term follow up following therapy completion were included for survival analysis. 
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The EFS, OS and probability of relapse at 60 months for the AML patients with or 
without NPM1 mutations were similar (Figures 3A and 3B). Likewise, among the 
subgroup with cytogenetics of intermediate prognostic risk EFS, OS and probability 
of relapse at 60 months were not different either (Figures 3C and 3D), although 
there appears a trend for more favorable outcome for patients with AML with 
NPM1 mutations. Since NPM1 mutations are signifi cantly associated with both 
normal karyotype and presence of a FLT3 ITD (Table 2), we wished to investigate 
the prognostic value of NPM1 mutations within the intermediate cytogenetic risk 
group in relation to FLT3 ITD status. Patients in the intermediate cytogenetic risk 
group without FLT3 ITD mutations but with NPM1 mutations have a signifi cantly 
better OS and EFS than those without NPM1 mutations (p=0.05) (Figures 4A and C). 
In intermediate cytogenetic risk AML with FLT3 ITD mutations NPM1 mutations 
do not signifi cantly distinguish prognosis (Figures 4B and D).
NPM1 mutations are asynchronously associated with particular karyotypes 
and molecular abnormalities that might express additional positive or negative 
prognostic value and therefore might obscure the prognostic signifi cance of NPM1 
mutations (Table 2 and Figure 1). Therefore we investigated the prognostic value 
of NPM1 mutations in both univariable and multivariable analyses. Univariable 
and multivariable Cox regression analysis were applied to assess the prognostic 
Figure 3. Survival analyses of AML patients with and without NPM1 mutations. 
Kaplan-Meier estimates of overall survival (A) and event free survival (B) among patients 
with AML, overall survival (C) and event free survival (D) among patients with AML with 
intermediate risk karyotypes. 
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signifi cance of NPM1 mutation, cytogenetic risk class, WBC below or above 20, 
age and FLT3 ITD mutation for OS, DFS and EFS (Table 5).  In univariable analyses 
NPM1 mutation showed no statistical signifi cance with respect to the endpoints. 
However, in multivariable analyses mutated NPM1 was signifi cantly associated 
with a much lower hazard ratio, which was statistically signifi cant for all endpoints 
(EFS: HR = 0.59, p = 0.005; DFS: HR = 0.52, p = 0.003 and OS: HR = 0.49, p = 
0.0003). Mutant NPM1 appeared as independent prognostic marker in addition to 
cytogenetic risk, age and FLT3 ITD mutations.
Figure 4. Survival analyses of intermediate cytogenetic risk AML patients with 
and without FLT3 ITD and/or NPM1 mutations. Kaplan-Meier estimates of overall 
survival (A and B) and event free survival (C and D) for patients with intermediate risk 
AML and FLT3 ITD mutations (FLT3 ITD+ (B and D)) versus those with intermediate 
risk AML without FLT3 ITD mutations (FLT3 ITD- (A and C)) 
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4.5  Discussion
Recently, we established a comprehensive classifi cation of AML based on whole-
genome expression profi ling (22). In this classifi cation several clusters of AML 
signatures correlated with distinct (cyto)genetic abnormalities, such as t(8;21), 
t(15;17), inv(16) and C- and N-terminal mutations in CEBPα. However, the common 
underlying molecular abnormality for the other subtypes of AML was unknown. 
In the present study we show that two clusters consist entirely of AML cases with 
NPM1 mutations, i.e., clusters #6 and #11, whereas clusters #2, #3, #5 and #7 
predominantly include patients with NPM1 mutations. Thus, we identify mutant 
NPM1 as a common molecular abnormality in these subtypes of AML.
Falini and colleagues (13) have shown that mutations in NPM1 are present in 
35% of patients with AML. In this study, we confi rm that NPM1 mutations are 
frequently present in AML, i.e., in 35% of all cases. NPM1 mutant is less frequently 
represented in patients with AML of age less than 35 yr. This seems consistent with 
the tendency of the NPM1 mutation to be more frequently present in older children 
with AML (34). Furthermore, NPM1 mutations are signifi cantly associated with 
AML with high WBC. 
We detected the various mutation variants of NPM1 at similar frequencies as was 
described recently (13), and also identifi ed three novel mutant variants. These novel 
variants carry, like the other NPM1 mutant variants in our study, an insertion of 4 
bp, resulting in a protein with an altered C-terminus (Table 1). Falini and colleagues 
(13) suggested that the disruption of one of the two C-terminal tryptophan residues 
and the last fi ve residues, i.e., VSLRK, are important for NPM1 mutant function. 
Our study suggests that the fi nal 9 aminoacids, i.e., AVEEVSLRK, may in general 
be required for mutant NPM1 function.
NPM1 mutations often coincide with mutations in FLT3, in particular with the ITD-
type mutations. Our data may suggest an association of mutations in K-RAS and 
NPM1, but the study has limited power because of the small number of mutant 
K-RAS AML. In contrast, mutations in N-RAS were not associated with mutant 
NPM1, since N-RAS mutations are found in AML with inv(16) (22, 30), a subclass of 
AML which lacks NPM1 mutations. In addition, we did not fi nd NPM1 mutations 
in clusters of AML patients, previously identifi ed by gene expression profi ling (22), 
characterized by C- and N-terminal mutations in CEBPα. These observations might 
perhaps suggest that constitutive active FLT3 or K-RAS provide the proliferative 
signal, whereas mutant NPM1 might serve to impair differentiation in the multistep 
pathogenesis model of AML (35).
It is of note that, the discriminative genes identifi ed by SAM and PAM revealed a 
strong HOX- and TALE- gene-specifi c signature associated with AML cases with 
mutant NPM1, as was published very recently (24). Thus, although CD34 has 
generally been used as marker for immature hematopoietic progenitor cells, the 
NPM1 mutant CD34-negative cells display a molecular signature similar to that 
of hematopoietic stem cells (HSC). Recent studies have shown that CD34-negative 
HSCs exist as well (36, 37). These CD34-negative cells also posses HSC-specifi c 
characteristics, including the ability for hematopoietic engraftment (36, 37). This 
brings up the question whether the NPM1 mutant AML cells in fact represent a 
more primitive population of HSCs with a HOX-gene signature. 
The sharp distinction between CD34-positivity and NPM1 mutations in AML 
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cases based on the HOX-gene signature is notable since 22 of the 39 HOX genes are 
expressed in human CD34-positive cells, whereas during normal differentiation 
HOX gene expression declines (38). Extensive studies have demonstrated for 
a number of HOX-genes that sustained overexpression in murine bone marrow 
results in perturbations in the stem cell pools, and co-expression of certain HOX-
gene family members with their protein binding partner, such as MEIS1, results in 
leukemia (38). Thus, in AML with NPM1 mutations the hematopoietic progenitor 
cells may have arrested at a differentiation stage with endogenous co-expression 
of the HOX-genes, i.e., HOXA5, -A9, -A10, -B2, -B3, -B5 and -B6, and their TALE 
partner genes, i.e., MEIS1 and PBX3, or as a result of the increased expression of 
these genes.
SAM and PAM analyses were highly concordant for the genes identifi ed with 
differential expression between AML with mutant and AML with wild type NPM1, 
where, in both cases, CD34 was the most discriminating gene, downregulated 
in NPM1 mutants. Patients harboring an NPM1 mutation can be predicted with 
high accuracy, however, a subset of patients with wild type NPM1 is wrongly 
predicted. Interestingly, within this subgroup the percentage of patients with 11q23 
abnormalities is signifi cantly increased. In fact, this may not be surprising since 
MLL has been implicated as a HOX gene regulator (39) and selective expression of 
HOX genes in ALL cases with mutant MLL has been shown (40). 
By univariate analyses we show that there is a tendency that the presence of an 
NPM1 mutation, and concomitant low CD34 mRNA expression, is a favorable 
marker for clinical outcome (Figure 3). This is in agreement with CD34 expression 
as an indicator for poor response to induction therapy (41-43). In addition, 
we demonstrate by multivariate analyses that NPM1 mutations are a strong 
independent favorable predictive marker for EFS, DFS and OS in AML. The fi nding 
that the effect of NPM1 mutation is much more pronounced in multivariable than 
in univariable analyses can be explained by the strong correlation between NPM1 
and FLT3 ITD mutations, and additionally by the association with high WBC and 
age. NPM1 mutations are more frequently present in AML patients with FLT3 ITD, 
high WBC and older age. These factors are unfavorable determinants of prognosis 
(44), while NPM1 mutation seems to express a favorable prognostic impact. 
This implies that in univariable analysis the positive effect of NPM1 mutations, 
as measured by the method of Kaplan-Meier or by the HR, is less pronounced, 
since the adverse effects of FLT3 ITD, high WBC and age might mask this effect. 
In fact, NPM1 mutations distinguish a favorable subgroup among intermediate 
cytogenetic risk FLT3 ITD negative AML, that shows comparatively better OS and 
EFS (Figure 4). In addition, we note that in the multivariable analyses the effect of 
NPM1 mutations is more pronounced than is apparent in the univariable analyses. 
This is not only true for NPM1 mutations, but also for the independent prognostic 
effect of FLT3 ITD mutations, age and cytogenetic risk (Table 5).
The data presented here demonstrate that the frequent C-terminal insertion 
mutations in NPM1 correlate with favorable outcome for patients with AML. 
Since NPM1 mutations are predominantly found in patients with standard risk 
AML, determination of the NPM1 mutation status, in combination with other 
prognostically relevant markers, will be useful for further risk stratifi cation of 
adult patients with de novo AML.
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5.1 Abstract
Retroviral insertion mutagenesis is considered a powerful tool to identify cancer 
genes in mice, but its signifi cance for human cancer has remained elusive. 
Moreover, it has recently been debated whether common virus integrations are 
always a hallmark of tumor cells and contribute to the oncogenic process. Acute 
myeloid leukemia (AML) is a heterogeneous disease with a variable response to 
treatment. Recurrent cytogenetic defects and acquired mutations in regulatory 
genes are associated with AML subtypes and prognosis. Recently, gene expression 
profi ling (GEP) has been applied to further risk-stratify AML. Here, we show that 
mouse leukemia genes identifi ed by retroviral insertion mutagenesis are more 
frequently differentially expressed in distinct subclasses of adult and pediatric 
AML than randomly selected genes or genes located more distantly from a virus 
integration site. The candidate proto-oncogenes showing discriminative expression 
in primary AML could be placed in regulatory networks mainly involved in signal 
transduction and transcriptional control. Our data support the validity of retroviral 
insertion mutagenesis in mice for human disease and indicate that combining these 
murine screens for potential proto-oncogenes with GEP in human AML may help 
to identify critical disease genes and novel pathogenetic networks in leukemia. 
5.2 Introduction
Retroviral insertion mutagenesis in mice is used to discover genes involved in 
leukemia and lymphoma (1). Recent advances in high through-put sequencing and 
genome-wide BLAST searches and methods to amplify genomic sequences fl anking 
the virus integration site (VIS) resulted in a catalogue of potential cancer genes (2-
6). VIS-fl anking genes in independent tumors, i.e., common VIS or CIS genes, are 
considered bona fi de disease genes. VIS genes not yet found common often also 
belong to gene classes associated with cancer and may qualify as disease genes (2, 
4, 6, 7). Finally, genes located more distantly from a virus integration may also be 
deregulated and contribute to disease, but the likelihood of this is unknown (7). 
Some genes identifi ed in murine screens have been implicated in human cancer, 
but for the majority this has not yet been demonstrated. Moreover, it has recently 
been debated whether clustering of proviral insertions, previously considered a 
hallmark of cancer-related integrations, are selected for during the oncogenic 
process, or to a signifi cant extent refl ect the nonrandom nature of integrations in 
the genome not necessarily linked with tumor outgrowth (7). To establish their 
signifi cance for clinical disease, we studied expression of VIS and CIS genes in 
human AML. Gene expression profi ling (GEP) has highlighted the heterogeneous 
nature of human AML and resulted in the identifi cation of leukemia subsets based 
on gene expression signatures (8-10). Here, we show that VIS genes from different 
leukemia models contribute signifi cantly to the expression signatures of both adult 
and pediatric AML. In contrast, no signifi cant correlations were found with the 2 
adjacent genes of the VIS or with other genes within a distance of 1Mb, suggesting 
that genes directly fl anking the virus integrations are the principle candidate disease 
genes. Finally, we provide data suggesting that regulatory networks, predicted by 
the VIS genes, may discriminate between biologically distinct AML subsets. 
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5.3 Materials and methods
5.3.1 GEP data from AML patients
Data from Affymetrix HGU133A GeneChip analysis in 285 adult AML patients are 
available at http://www.ncbi.nlm.nih.gov/geo/, accession number GSE1159 (10). 
Patients were categorized as favorable and unfavorable risk based on cytogenetic 
parameters. The favorable risk group comprised cases with t(8;21), inv(16) and t(15;17) 
without additional unfavorable cytogenetic abnormalities. The unfavorable group 
comprised cases with complex karyotype abnormalities, -5 or 5q-, -7 or 7q-, t(6;9), 
t(9;22), 11q23 abnormalities but no favorable risk abnormalities. GEP data from 130 
childhood AML samples are available at website http://www.stjuderesearch.org/
data/AML1/(9). Data were normalized by global scaling (Affymetrix Microarray 
Suite version 5.0; MAS5.0) with target average intensity values of 100 for the adult 
AML and 500 for the pediatric AML dataset, respectively (9, 10). Because these 
methods reliably identify signals with average intensity values above 30 and 100, 
minimum thresholds were set at those values for the adult and pediatric AML 
data sets, respectively. Expression levels from each probe set in every sample were 
calculated relative to the geometric mean and logarithmically transformed (base 
2) to ascribe equal weight to gene-expression levels with equal relative distance to 
the geometric mean. Signifi cance analysis of microarrays (SAM) (11) was used to 
identify genes contributing to the unsupervised clustering of patients in the adult 
and pediatric AML groups. In the adult AML dataset, 16 classes resulting from 
unsupervised clustering (10) were evaluated. In the juvenile AML dataset, 5 classes 
defi ned according to cytogenetic aberrations (9) were analyzed. This analysis was 
performed for all probe sets represented on the HGU133A GeneChip (n=22283). 
Patients from a specifi c class were tested compared to all remaining samples using 
an S-test and sample-class permutations to assess statistical signifi cance. Probe sets 
were considered differential when Fold Change values exceeded 1.5 or were lower 
than 0.67, scores were over 4 or less than -4 and q-values were below 0.05, where 
False Discovery Rate was lower than 0.05.
5.3.2 Signifi cance of difference in number of differentially expressed probe 
 sets
To calculate the signifi cance of difference in the number of differentially expressed 
probe sets in two groups, i.e. VIS representing probe sets versus probe sets not 
representing a VIS, Pearson’s Chi-square with one degree of freedom was calculated 
using 2x2 contingency tables. As some probe sets were differential in multiple 
clusters, all possibilities on differential expression were taken into account. For 
instance, 16 SAM analyses were performed on the adult AML dataset; therefore the 
sum of the numbers used in the contingency table was 16 * 22283 (the total number 
of probe sets). All occurrences of differential expression were counted, meaning 
that if a probe set is differential in n clusters, it is counted n times. 
5.3.3 Virus fl anking genes in mouse leukemia 
Genes affected by virus integrations in Graffi  1.4 (Gr-1.4), BXH2 and AKxD murine 
leukemia virus (MuLV) models have been previously reported (3, 12) (http://
genome2.ncifcrf.gov/RTCGD/).
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5.3.4 Network and principal component analyses 
Ingenuity Pathway Analysis (http://www.ingenuity.com) was used in combination 
with the Ingenuity Pathways Knowledge Base (IPKB). Genes selected from 
experimental data, called focus genes, are used for the generation of networks with 
a maximal size of 35 genes/proteins. Focus genes were VIS genes that signifi cantly 
contributed to the unsupervised clustering of 285 AML cases. Principal component 
analysis (PCA) was performed (Spotfi re, Inc. Somerville, MA).
5.4 Results
5.4.1 Gr-1.4 VIS genes and adult AML
To assess the relevance of Gr-1.4 VIS and CIS genes for human AML, we 
determined their expression in different classes of adult AML patients (9, 10). 
Based on unsupervised cluster analysis of GEP data, 285 adult AML cases were 
grouped in 16 subclasses (10). With SAM, specifi c gene sets were linked to these 
subclasses, by comparing each subclass to the remaining cases. In total, 5193 probe 
sets, representing 3644 genes, contributed to the signature of the 16 subclasses 
(Suppl. Table 1a). We calculated that the probability that a randomly selected gene 
is differentially expressed in one or more subclasses is 0.28 (Table 1) and performed 
Pearson’s Chi-square analysis to test whether VIS and CIS genes have a higher than 
random probability to be differentially expressed in one of the subclasses. Four 
gene lists derived from the Gr-1.4-induced leukemia model and represented on 
the HGU133A GeneChip were analyzed: (I) VIS + CIS genes (n=115, represented 
by 234 probe sets), (II) CIS genes (n=51, 116 probe sets), (III) direct neighbors of 
CIS genes (n=53, 81 probe sets) (IV) genes located within a region of 1 Mb of the 
CIS genes, with a maximum of 5 genes up- or downstream (n=279, 468 probe sets) 
(Figure 1; Suppl. Table 2a-d). The VIS and CIS genes have a signifi cantly increased 
probability (0.46, p=000.1 and 0.43, p=0.002, respectively) to be differentially 
expressed in subclasses of adult AML compared to unselected genes (I and II in 
Table 1, genes are listed in supplementary Table 3a and 3b). In contrast, no such 
correlation was found for gene lists III and IV (Table 1). 
5.4.2 Gr-1.4 VIS genes and pediatric AML
To determine the validity of these results for an independent AML GEP data set, 
correlation analysis was performed on 130 childhood AML samples (9). Patients 
were grouped in 5 subclasses, i.e., cases with inv(16), t(15;17), t(8;21), translocations 
involving MLL and cases with megakaryoblastic leukemia (Supplementary Table 
1b). In total, 2736 probe sets,  representing 2093 genes, contributed to the signature 
of the 5 subclasses. The probability that a randomly selected gene is differentially 
expressed in one or more subclasses of the childhood AML dataset was 0.16 (Table 
1). Similar to adult AML, Gr-1.4 CIS and VIS genes had a signifi cantly increased 
probability (0.31, p=0.0127 and 0.25, p=0.005, respectively) to be differentially 
expressed in the distinct patient clusters, while again no such correlation was seen 
with more distantly located genes (Supplementary Tables 3e and 3f).
103
Signifi cance of Mouse Cancer Genes for Human AML
N
um
be
r 
of
 u
ni
qu
e 
ge
ne
s 
(p
ro
be
 
se
ts
)
N
um
be
r o
f u
ni
qu
e 
SA
M
 g
en
es
 in
 
ad
ul
t A
M
L 
(p
ro
be
 s
et
s)
Pr
ob
ab
ili
ty
 
¥
P-
va
lu
e 
*
N
um
be
r o
f 
un
iq
ue
 S
A
M
 
ge
ne
s 
in
 
pe
di
at
ri
c 
A
M
L 
(p
ro
be
 s
et
s)
Pr
ob
ab
ili
ty
 
P-
va
lu
e 
*
A
ll 
ge
ne
s
12
84
8 
(2
22
83
)
36
44
 (5
19
3$
)
0.
28
--
20
93
 (2
73
6$
)
0.
16
--
(I)
 G
r-
1.
4 
C
IS
 g
en
es
51
 (1
16
)
22
 (3
2)
0.
43
0.
00
2
16
 (2
1)
0.
31
0.
01
27
(II
) G
r-
1.
4 
V
IS
 g
en
es
11
5 
(2
34
)
53
 (7
4)
0.
46
<0
.0
00
1
29
 (4
2)
0.
25
0.
00
50
(II
I) 
2 
ad
ja
ce
nt
 
ge
ne
s
53
 (8
1)
15
 (1
8)
0.
28
0.
49
 
(n
.s
.)
7 
(9
)
0.
13
0.
93
61
 (n
.s
.)
(IV
) 1
0 
ad
ja
ce
nt
 
ge
ne
s
27
9 
(4
68
)
91
 (1
23
)
0.
33
0.
19
 
(n
.s
.)
50
 (6
6)
0.
18
0.
20
71
 (n
.s
.)
C
an
di
da
te
 le
uk
em
ia
 g
en
es
 fr
om
 o
th
er
 m
ou
se
 m
od
el
s
BX
H
2 
C
IS
/V
IS
53
 (1
11
)
33
 (5
1)
0.
62
<0
.0
00
1
21
 (2
5)
0.
40
0.
00
01
A
K
xD
 C
IS
/V
IS
11
9 
(2
32
)
72
(1
04
)
0.
61
<0
.0
00
1
43
 (6
0)
0.
36
<0
.0
00
1
A
ll 
C
IS
/V
IS
23
7 
(4
70
)
12
2 
(1
78
)
0.
51
<0
.0
00
1
69
 (9
7)
0.
29
<0
.0
00
1
$  B
ec
au
se
 so
m
e p
ro
be
 se
ts
 c
on
tr
ib
ut
ed
 to
 m
ul
tip
le 
cl
as
se
s, 
th
e t
ot
al
 n
um
be
r o
f s
et
s u
se
d 
in
 C
hi
-s
qu
ar
e a
na
ly
sis
 w
as
 8
73
9 
fo
r a
du
lt 
A
M
L 
an
d 
29
55
 fo
r t
he
 p
ed
ia
tr
ic
 A
M
L 
ca
se
s. 
Fo
r d
et
ai
ls 
se
e s
up
pl
em
en
ta
ry
 T
ab
les
 1
a 
an
d 
1b
.
* P
-v
al
ue
 d
et
er
m
in
ed
 b
y 
a 
tw
o-
ta
ile
d 
ch
i-s
qu
ar
e t
es
t w
ith
 9
5%
 co
nfi
 d
en
ce
 in
te
rv
al
s.
¥ 
Pr
ob
ab
ili
ty
 re
pr
es
en
ts
 th
e l
ik
eli
ho
od
 th
at
 a
 p
ro
be
 se
t i
s d
iff
er
en
tia
lly
 ex
pr
es
se
d 
(n
um
be
r o
f S
A
M
 g
en
es
/to
ta
l n
um
be
r o
f g
en
es
).
n.
s: 
no
t s
ig
ni
fi c
an
t
Ta
bl
e 
1.
 V
ir
us
 in
te
gr
at
io
n 
si
te
s 
pr
oj
ec
te
d 
on
 2
85
 a
du
lt
 A
M
L 
an
d 
13
0 
pe
di
at
ri
c 
A
M
L 
sa
m
pl
es
104
Chapter 5
5.4.3 BXH2 and AKxD virus VIS genes and AML 
Candidate leukemia genes identifi ed in two other models, BXH2 and AKxD 
(Supplementary Tables 2e and 2f; http://genome2.ncifcrf.gov/RTCGD/ also 
correlated signifi cantly with the gene sets responsible for clustering of adult (0.62, 
p<0.0001 and 0.61, p<0.0001, for BXH2 and AKxD CIS/VIS, respectively) and 
pediatric AML cases (0.40, p=0.0001 and 0.36, p<0.0001, respectively) (Table 1; 
Supplementary Tables 3c-f). The combined data from the three models indicate that 
genes directly fl anking the virus integrations are signifi cantly more differentially 
expressed than random genes in both adult and pediatric AML subtypes. 
5.4.4 No correlation between proviral integration and actively transcribed 
 genes in normal hematopoietic precursors 
To investigate whether correlations between murine VIS genes and human AML 
clustering are biased by preferential integrations in genes that are highly expressed 
in nonleukemic hematopoietic precursors, we calculated the numbers of VIS 
genes in 5 categories of genes, classifi ed on the basis of their expression levels in 
normal CD34+ cells (Supplementary Table 4). We found that the greatest portion 
of integrations occurred in the low to intermediate expression categories and not 
in highly expressed genes. We also calculated that VIS genes correlated with AML 
clustering with a signifi cantly higher probability than the nonVIS genes in the 
different expression categories in CD34+ cells. Together, these results argue against 
bias due to preferential integration in highly expressed genes (Supplementary 
Table 5). 
Figure 1. Genomic region of VIS. Four gene lists were derived from the Gr-1.4–induced 
leukemia model: (I ) genes directly fl anking virus integration sites; (II ) genes commonly 
targeted by virus integrations (CIS genes), (III ) two direct neighbors of CIS genes, and (IV) 
genes located within a region of 1 Mbp of CIS genes, with a maximum of 10 (IV). Virus 
integrations can be located upstream or downstream or within the target gene.
A full-color version of this fi gure is provided on the CD.
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5.4.5 Networks based on VIS genes
We imported all VIS/CIS genes from Gr-1.4, BXH2 and AKxD MuLV models 
that were differentially expressed in the adult AML panel into the Ingenuity 
application to place them in regulatory networks. From this list (n=125), 110 
genes present in the IPKB (focus genes) were used for the generation of networks. 
Five highly signifi cant networks, associated with cell growth and proliferation, 
hematopoietic cell development, cell cycle, and gene expression were identifi ed 
(Table 2, Supplementary Figures 1-5). Network 1 existed exclusively of focus genes 
(n=35), suggesting that genes within this network are commonly deregulated in 
AML. Multiple genes in this network, i.e. IL2RG, STAT5A, STAT5B, IL4R, HCK and 
IRS2 are involved in cytokine signaling. The SOX4 gene encodes a transcriptional 
Figure 2. Principal component analysis showing clustering of AML patients, based 
on their expression signature of genes in network 5. A comparison is shown of cases 
from good cytogenetic risk categories (red symbols) versus cases from poor cytogenetic risk 
categories (blue symbols).  
A full-color version of this fi gure is provided on the CD.
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regulator implicated in the pathogenesis of neuronal tumors and lymphoma 
(13, 14) ZNF145, which is involved in t(11;17) in acute promyelocytic leukemia 
(APL), encodes a transcriptional repressor also known as promyelocytic leukemia 
zinc fi nger (PLZF) that has recently been implicated as a regulator of stem cell 
renewal (15, 16). We also asked whether networks might be differentially affected 
in prognostic subgroups of AML. To this end, we applied principal component 
analysis (PCA), by which AML samples are clustered in a three-dimensional space 
based on expression correlations of genes of each of the separate networks. Thus 
far, only network 5 clearly discriminated between AML patients with favorable and 
unfavorable cytogenetic risk indication (Fig. 2). SAM analysis indicated that this 
distinction is predominantly based on differential expression of HOXA9, MEIS1 
and CCND3, which are upregulated in the unfavorable group and BCOR and GFI1, 
which are downregulated in the unfavorable group (Supplementary Tables 6a and 
6b). 
5.5 Discussion
Genes commonly fl anking MuLV provirus integration sites in murine leukemia 
and lymphoma are generally considered disease genes (12), although this idea has 
recently been challenged (7). Moreover, retroviruses may affect gene expression 
over several hundreds of Kb, which makes assignment of the relevant target gene 
ambiguous (7). We have systematically compared different groups of potential 
target genes, located within, near or more distantly from the insertion site with 
differentially expressed genes in subtypes of human AML, classifi ed based on gene 
expression profi les. Our key fi nding is that genes located in direct proximity of the 
virus integration have a signifi cantly higher probability to contribute to the gene 
expression-based clustering of both pediatric and adult AML than random genes, 
or than genes located more distantly from the site of integration. The data thus 
suggest that genes directly fl anking MuLV integrations are most suspicious for 
their involvement in disease, although they do not preclude that in some instances 
deregulation of more distant genes may contribute to leukemic cell growth. 
Conceivably, in extended screenings, a signifi cant proportion of such genes would 
also be found as VIS or CIS genes. 
Thus far, only about 50% of VIS genes were differentially expressed in subsets 
of human adult AML classifi ed by GEP (10). This may have multiple, not 
mutually exclusive, reasons. First, because the subsets of AML were identifi ed by 
unsupervised clustering analysis based on gene expression relative to the mean 
of all samples (10), some disease genes may not be recognized because they are 
deregulated in samples that are not clustered with this approach. This may be 
addressed by extending GEP on more patients, which may allow defi nition of 
additional patient clusters. Secondly, a virus-fl anking gene may be involved in 
murine, but not human AML. This may apply to genes encoding transcription 
factors that activate promoter and enhancer elements in the virus LTR (17, 18). 
Finally, some genes identifi ed in mice may not be deregulated in human AML 
at the transcriptional but at the translational/posttranslational level, or may be 
functionally altered due to mutations. 
Consistent with previous molecular and cytogenetic studies, the networks affected 
in AML mainly comprise signaling molecules and transcription regulators involved 
in growth factor-controlled cell proliferation and survival and the transcriptional 
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control of myeloid differentiation (19). However, Gr1.4 VIS genes deregulated in 
AML also include genes involved in other mechanisms (Table 2 and supplementary 
Tables 3a and 3b). For instance, TXNIP and PRDX2 act in cellular responses to 
oxidative stress, whereas CTNNA1 has been implicated in cell differentiation. 
CTNNA1 is a candidate tumor suppressor gene located at chromosome 5q3.1 in a 
region that is frequently deleted in myelodysplasia and AML (20). 
An important implication of this work is that disease genes and non-pathogenic 
genes, e.g., related to differentiation status of the cells, may be distinguished in 
clinical AML data sets. With the VIS gene lists in the various mouse leukemia 
models not yet saturated and the possibilities of GEP of AML still growing, the 
power of this strategy may increase. This may allow further refi nement of currently 
identifi ed and presumably disclose additional pathogenetic networks underlying 
AML. Such information would be useful for further refi nement of diagnosis and 
for identifi cation of key targets for therapeutic intervention. 
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6.1 Abstract
6.1.1 Background
Accurate interpretation of data obtained by unsupervised analysis of large 
scale expression profi ling studies is currently frequently performed by visually 
combining sample-gene heatmaps and sample characteristics. This method is not 
optimal for comparing individual samples or groups of samples. Here, we describe 
an approach to visually integrate the results of unsupervised and supervised cluster 
analysis using a correlation plot and additional sample metadata. 
6.1.2 Results 
We have developed a tool called the HeatMapper that provides such visualizations 
in a dynamic and fl exible manner and is available from 
http://www.erasmusmc.nl/hematologie/heatmapper/.
6.1.3 Conclusions
The HeatMapper allows an accessible and comprehensive visualization of the 
results of gene expression profi ling and cluster analysis.
6.2 Background
Gene expression profi ling by applying microarrays followed by cluster analyses is a 
powerful way to defi ne pathobiologically relevant relations between the expression 
of sets of genes and disease classes. Unsupervised methods such as cluster analysis 
(1) and principal component analysis (2) are often applied to calculate and visualize 
these relations. Interpretation of results obtained by cluster analysis is frequently 
performed by visual inspection of a so-called heatmap; a matrix of genes versus 
samples in which gene expression levels or ratios are indicated using colors. Green 
often indicates low expression or down-regulation while red is frequently used to 
indicate high expression or up-regulation of genes (1, 3). A dendrogram, which 
is typically produced by unsupervised cluster analysis, provides further insights 
into sample-to-sample or gene-to-gene relations (1). These visualizations are useful 
when small numbers of samples and genes are analyzed, but are insuffi cient when 
studying larger datasets. Similarities and differences between samples or genes are 
easily lost due to the large size of these visualizations. This shortcoming particularly 
affects patient-cohort studies, since these analyses include increasing numbers of 
samples to allow comprehensive analyses. 
A second type of heatmap that is frequently used is a matrix of pair-wise sample 
correlations in which anti-correlation or correlation is indicated by a color-scale, 
e.g. blue to red (4-6). Although details on individual gene expression measurements 
are lost, similarity between any pair of samples can easily be inspected. 
To be able to correctly interpret both the sample versus gene expression heatmap 
and the sample versus sample correlation plot, data of the type of samples 
profi led, e.g. clinical parameters, karyotypes, mutations in particular genes, or 
gene expression data should be available. This information might then be included 
in a visual overview, as is frequently seen with sample versus gene heatmaps (7, 
8). Such presentation would be a useful addition to the sample-sample heatmaps, 
which are frequently shown without metadata. Here we developed a tool, called the 
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HeatMapper, which can generate such combined visualizations. The tool is simple 
in use and allows dynamic and fl exible display of a correlation plot in combination 
with sample characteristics. 
6.3 Implementation
The HeatMapper, written in JAVA (version 1.4.2), uses comma-separated or tab-
delimited text-fi les as input. It requires two fi les: one fi le containing a matrix 
of sample-sample similarity, i.e. Pearson correlation, Spearman correlation or 
Euclidean distance, and one fi le with sample related data. In both fi les, similar 
sample ID’s are used. Correlation fi les can be generated using tools such as 
Omniviz, GeneMaths and R/BioConductor, while sample data fi les can for 
instance be created in Microsoft Excel. Example fi les are available from the website. 
Alternatively, the tool can be adapted to communicate with a database. In our 
laboratory, the HeatMapper is connected to a MySQL database which further 
optimizes the workfl ow. This version is available on request.
6.4 Results & Discussion
As the upper right part of a traditional sample versus sample heatmap is in fact 
a mirror image of the lower left part, it is redundant. Therefore, when data are 
loaded, the HeatMapper only displays a triangular heatmap (Figure 1). Sample-
sample (dis-) similarity, i.e. Pearson correlation, Spearman correlation or Euclidean 
distance, is mapped to a color scale ranging from blue to red. Dark blue relates 
to the negative extreme value of the metric, i.e. -1 for Pearon correlation, where 
dark red refers to the positive extreme value, i.e. 1 for Pearson correlation. Sample 
related data, can be simply added via the menu and is subsequently plotted 
alongside the heatmap diagonal. Different entries in one sample characteristic 
are mapped to different colors, or, in the case of numeric data, shown as bars 
of which the size is proportional to the value.  Several options are available to 
customize the resulting visualization, such as zoom functionality and options to 
change the colors used in histograms or bars to indicate phenotypic or genotypic 
differences. Further customization options include the possibility to change the 
sample order, allowing a user for instance to visualize the results of a different 
clustering algorithm, or to sort the data according to any user-defi ned order. This 
can be accomplished via selecting the ‘Change sample order’ menu-option, after 
which the order of the sample ids can be inserted by typing them or using copy-
paste. Subsets of the original data can be created and viewed in any sequence. 
Importantly, high-resolution images of the produced fi gures can be exported using 
the Portable Network Graphics (PNG) format.
Our tool provides several advantages over more traditional means of presenting 
results obtained gene expression profi ling and clustering analysis (7, 8). The 
pair-wise display of samples clearly indicates similarity in expression profi les. 
By combined visualization of sample versus sample similarities and sample 
characteristics, subclasses of samples sharing a commonality, such as a mutation 
in a particular gene, and a high similarity in expression profi le can be readily 
identifi ed. Cluster assignments, made manually by the user, can then be added via 
the ‘Add special values’ menu option and displayed as sample characteristic. 
As an example, Figure 1 shows the results of a cluster analysis of 285 acute myeloid 
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leukemia (AML) samples. Clusters are recognized as red triangles near the plot 
diagonal. Sample related data are presented in the adjacent bars, where the same 
color indicates the same characteristic. The last bar indicates the expression levels 
of CD34, in which the level of expression is proportional to the length of the bar. 
By visual inspection of this plot, one can immediately conclude that (1)AML 
samples can be separated into several subtypes, such as cases with a t(8;21), based 
on expression profi ling (9), (2) several clusters are related to a single distinguished 
abnormality (for instance nucleophosmin (NPM1) mutations), indicated in red in 
the fi fth column and (3) mRNA levels of CD34 are low in samples with NPM1 
mutations.
In our laboratory the HeatMapper code has been coupled to a database containing 
gene expression profi ling results, from which gene expression levels can 
dynamically be obtained. This allows the quick and accurate visual inspection of 
the distribution of expression levels in different clusters, and making the tool even 
more powerful. The database implementation, is available on request.
Our visualization method has been successfully applied in several studies (6, 9-
12). 
6.5 Conclusion
With the increase of the number of samples profi led, particularly in patient-cohort 
studies, specialized visualization methods for microarray studies are indispensable. 
Our tool allows the accurate inspection of combinations of dataset characteristics, i.e. 
correlations and clustering results and sample related characteristics, i.e. survival 
time and gene expression levels. Summarizing, the HeatMapper tool results in 
powerful visualization tool that allows the accurate and rapid interpretation of the 
data obtained by large scale gene expression profi ling. The HeatMapper tool has 
already proven to be very useful in several studies (6, 9-12).
Availability & Requirements
Project name: HeatMapper
Project homepage: http://www.erasmusmc.nl/hematologie/heatmapper/
Operating system: Platform independent
Programming language: JAVA
Figure 1 (facing page). HeatMapper screenshot. The fi gure shows pairwise correlations 
between 285 samples of patients with Acute Myeloid Leukemia, as described previously 
(6). The cells in the visualization are colored by Pearson’s correlation coeffi cient values 
with deeper colors indicating higher positive (red) or negative (blue) correlations. Clinical 
and molecular data are depicted in the columns along the original diagonal of the heatmap. 
Karyotype and FAB classifi cation based on cytogenetics are depicted in the fi rst two 
columns (karyotype: normal-green, inv(16)-yellow, t(8;21)-purple, t(15;17)-orange, 11q23 
abnormalities-blue, 7(q) abnormalities-red, +8-pink, complex-black, other-gray; FAB M0-
red, M1-green, M2-purple, M3-orange, M4-yellow, M5-blue, M6-grey). FLT3 ITD, CEBPα 
and NPM1 mutations are depicted in the same set of columns (red bar: positive and green 
bar: negative). The expression levels of CD34 (probe set: 209543_s_at) in the 285 AML 
patients are plotted in the last column (bars are proportional to the level of expression).
A full-color version of this fi gure is provided on the CD.
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Other requirements: JAVA 1.4.2 or higher.
License: The tool is available free of charge. Source code is available upon request.
Any restrictions to use by non-academics: None
List of Abbreviations
AML   Acute Myeloid Leukemia
PNG   Portable Network Graphics
NPM1   Nucleophosmin
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7.1 Diagnostics of acute myeloid leukemia through gene expression 
profi ling
Acute myeloid leukemia (AML) is a heterogeneous disease from various points 
of view. Leukemia develops through a series of accumulating genetic changes. 
As a result, the clinical phenotype of leukemia is diverse.  This has an impact on 
the development, the choice and management of therapy of patients with AML. 
This thesis dealt with various aspects of genome-wide expression profi ling, an 
approach that holds promise for developmental therapeutics in cancer in general 
and leukemia in particular. 
7.1.1 Recognition and prediction of known AML subtypes using gene 
 expression profi ling
Recently, gene expression profi ling using microarrays has become a popular 
method to identify and predict known prognostically and clinically relevant 
subclasses in cancer (1-3). A well-known example is the study of Golub et al, in 
which AML and ALL samples could be distinguished based on their expression 
profi les (1). In another more recent study, a large number of 937 samples, including 
chronic and acute lymphoid and myeloid leukemia, and normal controls, were 
analyzed using gene expression profi ling (4). This study dealt with establishing 
the diagnosis of global categories of acute and chronic leukemia using expression 
profi ling and confi rmed that apart from other hematologic malignancies, acute and 
chronic myeloid and lymphoid leukemia can be distinguished. 
Another challenge is to verify whether expression profi ling can also be applied to 
recognize distinct subtypes within a particular hematologic malignancy, like AML. 
In recent years, it has become evident that microarrays are suitable for distinguishing 
certain subclasses of AML from others. For instance, AML with a trisomy of 
chromosome 8 could be distinguished from samples with normal cytogenetics 
(n=27) (5);  cases of AML with mixed leukemia lineage gene (MLL) rearrangements 
could be discerned from both other ALL and AML cases (n=65) (6).  Samples with 
reciprocal translocations (inv(16), t(15;17) and t(8;21)) could be distinguished from 
other AML samples (n=37) (7), and  AML with MLL- and reciprocal rearrangements 
could be separated from AML carrying normal karyotypes (n=28) (8). 
These conclusions were derived in studies including cases with a limited spectrum 
of subtypes of AML. In Chapter 2, we used a broad, more representative cross-
section of AML and analyzed cellular gene expression profi les of a patient-cohort 
of 285 patients, i.e., without excluding any particular subtype of AML, and 
investigated whether known subtypes could be identifi ed (Chapter 2).  We found 
that recurrent reciprocal translocations such as inv(16), t(15;17) and t(8;21) each 
have highly distinct expression profi les, while MLL translocations aggregated in 
two separate clusters. Thus, it appears that certain common karyotypic aberrations 
can indeed be recognized using gene expression profi ling.
During the last decade many novel small molecular aberrations have been identifi ed 
(Table 1B, Chapter 1). Several efforts have been made to derive their characteristic 
gene expression signatures. It was found that the expression signature of AML 
with FLT3 internal tandem duplication and FLT3 tyrosine kinase point mutations 
can be predicted with high accuracy (9, 10). On the other hand, AML with N-RAS 
mutations could not be predicted according to a distinctive expression signature 
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in studies by us and others (10). In our study, FLT3 internal tandem duplication 
mutations were correctly predicted in 79% of samples in a validation dataset. 
In contrast, we were unable to predict FLT3 tyrosine kinase mutations through 
a specifi c expression pattern in our study. The discrepancy between the latter 
results with those of Neben et al (10) could be due to the greater numbers of 
samples with tyrosine kinase mutations in the Neben et al (10) study, allowing 
the detection of a more subtle signature. Other molecular abnormalities were 
found to be associated with specifi c gene expression signatures in our study, such 
as CEBPα mutations, which segregated into two separate gene expression groups 
with different cytological FAB-types. Likewise, AML cases with NPM1 mutations 
(Chapter 4) clustered in various subgroups, some of which co-associated with the 
presence of FLT3 internal tandem duplication mutations. AML cases with high 
EVI1 expression were also found to be associated with particular gene expression 
patterns. Thus, molecular abnormalities have pronounced effects on genome-wide 
mRNA expression, although not always as prominently as balanced cytogenetic 
translocations such as inv(16), t(15;17) and t(8;21).
Comparing several malignancies including AML, Haferlach et al (4) recently 
showed that six AML subgroups, respectively with inv(16), t(15;17), t(8;21), complex 
karyotypes, 11q23 and normal karyotypes/other, were predictable through gene 
expression profi ling with sensitivities and specifi cities comparable to our results 
(Chapter 2). The results of these representative studies show that gene expression 
profi ling can be used to identify distinct molecular subtypes of AML, such as AML 
with inv(16), t(15;17), t(8;21), mutant CEBPα or high EVI1 expression. Several other 
AML subclasses, i.e. those with N-RAS, K-RAS, trisomy(8), FLT3 tyrosine kinase 
point mutations, do not relate with a distinct signature. We assume that the latter 
AML types are too heterogeneous to be predicted by means of gene expression 
profi ling, e.g. due to effects of additional cooperative mutations with stronger 
signatures. 
7.1.2 Identifi cation of unknown subtypes of AML using gene expression 
 profi ling
 Gene expression profi ling in AML has further highlighted the extraordinarily 
heterogeneous nature of the disease (4-7, 9-11). Although the majority of leukemia 
cases are associated with one or more genetic abnormalities, not all of these 
abnormalities are prognostically useful (Table 2, Chapter 1). In fact, 15-20% of 
patients lack any prognostically relevant molecular abnormality. Gene expression 
profi ling might be useful for the identifi cation of novel subtypes of AML with 
prognostic variations. Currently, the number of studies dealing with this issue is 
still limited. Using semi-supervised clustering of 116 samples, profi led on Stanford 
dual-channel microarrays, Bullinger et al. were able to distinguish  patients with 
a normal karyotype with a good from those with an adverse prognosis, based 
on a signature of 133 genes (11). Their signature was recently validated in an 
independent dataset (n=64) (12). Several factors, such as mutations in FLT3 and 
particular FAB subtypes, were unevenly distributed between the two groups.  
Multivariate analysis, for which a larger number of samples is required, will have 
to show whether the signature also harbors independent prognostic value. In our 
study, we identifi ed a subset of AML cases  (cluster #10) with a common gene 
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expression signature that was associated with a variety of known poor prognostic 
markers, such as high EVI1 expression, t(9;22) and monosomies 5 and 7 (Chapter 
2). Using a training- and a validation-set, we found that this cluster #10 subtype 
of AML could be predicted with high accuracy. Interestingly, the gene expression 
profi le of “cluster #10 AML” resembles the gene expression signature of normal 
CD34-positive hematopoietic precursor cells. Recently, Heuser et al showed that 
poor responders to induction chemotherapy also cluster together with normal 
CD34-positive cells, indicating a possible overlap between these two groups (13). 
The co-clustering of “cluster #10 AML” and CD34-positive cells might indicate 
that the phenotypes of these types of leukemia resemble early hematopoietic 
progenitors and are less responsive to therapy. 
The “cluster #10 AML” represents a new subgroup of AML with a poor prognosis, 
that is of similar frequency as, for instance, the t(8;21) or inv(16) subgroups. 
Identifi cation of new AML subtypes using microarrays deserves further 
investigations, e.g. when extended series of cases are examined.  
7.1.3 Prediction of prognosis 
An important goal of gene expression profi ling research in AML is to establish 
a individualized classifi cation into good and poor prognosis. This is as yet not 
possible, due to insuffi cient resolution of the heterogeneity of AML. In an effort 
to derive prognostic information from gene expression patterns, we have also 
tried to classify our cohort into AML with poor or good prognosis, by comparing 
the profi les of patients in continuous complete remission with those of patients 
with a relapse of leukemia. The result of this analysis revealed an unacceptable 
misclassifi cation error of 40%, using a training- and a validation dataset. A similarly 
negative result was obtained when the same experiment was restricted to cases of 
AML with a normal karyotype only. It appears that AML is too heterogeneous 
to accurately predict prognosis with only one classifi er. Several clusters show up 
with a clear gene expression profi le but do not correlate with distinctive survival 
characteristics. The number of cases of some of these clusters was too small for 
reliable survival estimates.  
We foresee that in the future, useful prognostic classifi ers will be defi ned within 
particular genotypic subtypes of AML. Indeed, within AML with t(15;17), a subset 
with a FLT3 ITD and concordantly a high white blood cell count, appear to cluster 
separately (Figure 1, Chapter 2). FLT3 ITD and high white blood cell count in APL 
with t(15;17) tend to have a comparatively worse prognosis (14). 
7.1.4 Aggregation of microarray data 
To increase the number of samples, efforts have been made to aggregate data from 
various expression profi ling studies to increase the number of samples. We used 
Affymetrix HG-U133A GeneChips whereas Bullinger et al (11), used a different 
biochip platform, i.e. Stanford dual channel arrays. The limited overlap of genes 
of these two types of arrays prohibits a thorough concurrent analysis. In another 
profi ling study, the investigators used the same Affymetrix HG-U133A GeneChip 
that we have employed (4). Since the data of the latter study have not been released 
in the public domain, a comparative analysis or meta-analysis has not been directly 
possible. In a third study, pediatric AML was profi led on the same Affymetrix 
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HG-U133A microarray platform (15). In this case, we have taken advantage of the 
opportunity and analyzed their and our 415 adult and pediatric samples using 
the same bioinformatics approach in direct comparison (Figure 1). Subtypes with 
specifi c chromosomal abnormalities such as inv(16), t(8;21) or t(15;17) in both the 
pediatric and adult series revealed distinct and similar gene expression profi les. It 
is of note that while pediatric and adult samples aggregated together, they formed 
adjacent subclusters within each cluster. It is unclear whether this small difference 
between the pediatric and adult AML genotypes is due to the age differences of 
both cohorts, or differences in processing of samples in the two laboratories.  
7.1.5 Perspectives of expression profi ling in AML
Our results demonstrate that the clustering of the AML cases based on gene 
expression profi ling is driven by two phenomena: (I) the common karyotypic or 
molecular abnormalities, such as balanced translocations, and (II) differences in 
cytological maturation status of the primary AML. At this point, particular genetic 
subgroups, e.g. AML with internal tandem duplications in FLT3, cannot yet be 
identifi ed at the accuracy level required for clinical applications. By including 
genes currently not present on the arrays, or prediction in larger subsets of AML 
patients this problem may potentially be overcome. Analyzing such datasets will 
reveal not only additional, but also more specifi c genes that relate to particular 
AML subtypes. 
By selecting the distinctive and informative probe sets, a specialized microarray for 
AML diagnostics can be developed. Subsequently specialized GeneChips can be 
used for proper diagnosis of AML using one assay. Interestingly, such microarrays 
have been developed for lymphoid leukemia and breast cancer (16, 17). 
7.2 Technical improvements of oligonucleotide array research
Until recently, microarrays did not represent the whole genome but a fraction 
of 40-45% of the genes. It is likely that genes critical in the leukemogenic process 
are missed. With further technological advancements, for instance due to further 
shrinking of feature size, a whole genome microarray is foreseen to become available 
in the future. Currently, commercial platforms such as Affymetrix represent 60-
65% of the genome. In addition, the sensitivity of microarrays, which are currently 
less effi cient in measuring low expression values (18), is also likely to improve. 
The quality of probe set design can probably be increased through the use of more 
accurate information in sequence databases. Better understanding of alternative 
splicing of mRNA transcripts and higher coverage of alternative splice variants on 
microarrays will further contribute to an increased insight into cellular processes. 
Affymetrix exon arrays, containing probe sets for exons rather than genes, are 
currently being tested (54). 
From a statistical viewpoint, other methods to estimate noise and background- 
and cross hybridization, such as quantile normalization and variation stabilizing 
normalization (19, 20), have been developed. Similarly, alternative procedures for 
estimating expression levels, such as dChip and robust multi-array average (RMA) 
were demonstrated (21, 22). Affymetrix has recently released a new algorithm 
designated PLIER, which applies a similar approach as RMA to measure expression 
(23).  However, although the new algorithms have advantages, no single algorithm 
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Figure 1. Unsupervised cluster analyses of 130 pediatric (15) and 285 adult 
(Chapter 2) acute myeloid leukemia (AML) patients . Patients were clustered using 
2,175 Affymetrix probe sets which are representative for the 2,856 probe sets used for the 
most optimal clustering of the adult AML with regard to known molecular abnormalities. 
French-American-British (FAB) classifi cation and karyotype based on cytogenetics are 
depicted in the fi rst two columns along the original diagonal of the Correlation View (FAB 
M0, red; M1, green; M2, purple; M3,orange; M4, yellow; M5, blue; M6, gray; M7, red. 
Karyotype: normal, green; inv(16), yellow; t(8;21), purple; t(15;17), orange; t(11q23)/MLL 
abnormalities. Blue; 7(q) abnormalities, red; trisomy8, pink; complex, black; other, gray). In 
the third column, pediatric AML cases are indicated in green and adult AML cases in red.
A full-color version of this fi gure is provided on the CD.
123
Discussion
has yet shown to be fully able to distinguish between noise and signal under all 
circumstances (24). We showed that the outcome of analysis of microarray data is 
infl uenced by the choice of the pre-processing method. This effect is most obvious 
as demonstrated by the analysis at the probe set level, i.e. individual expression 
levels and identifi cation of differentially expressed genes (Chapter 3). As the data 
compared in our study could not be compared with data representing the ground 
truth, the “golden standard” pre-processing method could not be identifi ed. 
With further improvements as regards for instance technical design of 
oligonucleotide arrays, sophisticated algorithms for normalization and expression 
measurement adapted to size and type of study, closer estimates of true gene 
expression will be obtained with oligonucleotide arrays. 
In another approach for improving analysis outcomes in large datasets, the 
variability between probes within a probe set is tested and probe sets are 
disqualifi ed if variation exceeds a certain threshold. The quality of the dataset on 
which all further analyses are performed can thus be improved, as less effective 
probe sets are omitted. This approach, which is called factor analysis, is still largely 
experimental (25).
7.3 AML pathogenesis
The large quantities of data produced in microarray experiments may also be useful 
for elucidating the molecular pathogenesis of leukemia. We have proposed a novel 
approach towards classifying samples based on pathogenesis, by combining genes 
present in the signature of the 16 clusters of clinical leukemia with sets of leukemia 
genes identifi ed in retroviral insertional mutagenesis experiments in experimental 
animals (Chapter 5). We found that genes found close to virus integrations sites 
are more frequently differentially expressed in human AML, supporting their 
involvement in leukemogenesis. 
Using retroviral insertional mutagenesis, predominantly activated genes, i.e. proto-
oncogenes, have been detected. Retroviral insertional mutagenesis may besides 
activating genes also repress genes that play a role in leukemogenesis. The fact that 
integration of virus may be followed by methylation of the integration site may 
provide a key to the identifi cation of repressed genes (26). Experiments that take 
advantage of the methylation of integration sites result in a higher detection rate of 
genes involved in murine leukemogenesis. Furthermore, more accurate gene lists 
differentially expressed in AML will be obtained due to advances in microarray 
research, e.g. larger datasets and microarrays containing more genes. Combined 
with the increasing possibilities of pathway analysis software, increasingly 
accurate and complete biochemical interaction networks will be constructed. As 
these networks represent the candidate pathogenetic networks involved in AML, 
these advances potentially allow a classifi cation of AML based on pathogenesis. 
Genes that are differentially expressed in a particular cluster or class of AML can 
either be disease genes, i.e. involved in the development of the disease, or just 
downstream marker genes. Bioinformatics tools, such as Toucan (27, 28), have been 
developed to detect statistical overrepresentation of transcription factor binding 
sites in the promoter regions of a list of genes. By applying the Toucan software, 
transcription factor target genes were identifi ed (29). To identify direct target genes 
of transcription factors involved in AML, we have applied this methodology on lists 
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of genes differentially regulated in AML. Toucan was employed on the expression 
signatures of clusters with core binding factor complex abnormalities, i.e., cluster 
9 (inv(16)) and cluster 13 (t(8;21)). The core binding transcription factor complex is 
constituted of several proteins, one of them being AML1. AML1 can bind specifi c 
DNA sequences, also called AML1 binding sites. Genes deregulated in core binding 
factor leukemia cases are potential targets of the core binding factor complex. 
Promoter sites of these targets are likely to contain one or more AML1 binding 
sites. However, using Toucan, we did not fi nd any signifi cant overrepresentation 
of AML1 binding sites in promoters of core binding factor target genes. The lack 
of AML1 binding sites could be due to the small size of the AML1 binding site (6 
bp) resulting in high background levels.  The fact that active binding sites may be 
present at large distance of a gene might contribute to this problem. Furthermore, it 
is possible that the lists of genes used as input contain downstream targets, which 
lack AML1 binding sites. The failure to fi nd evidence for binding sites could also 
be due to the lack of knowledge of binding site sequences, or the amount of noise 
present in both lists of differentially expressed genes (genes that are associated 
with a particular subgroup but are not a target of one particular transcription 
factor) and promoter sequences (short binding site sequences randomly occurring 
due to chance). However, a list consisting of known AML1 target genes also failed 
to reveal AML1 binding sites that were statistically overrepresented. 
Research aimed at elucidating the pathogenesis of AML may take advantage of 
data generated by expression profi ling of clinical material. For instance, our gene 
expression profi ling study (Chapter 2) revealed two clusters (cluster #4 and cluster 
#15) dominantly containing cases of AML with mutations in CEBPα. In fact, cluster 
15 consists exclusively of CEBPα mutated AML samples, while cluster 4 contains 
9 samples with and 6 samples without CEBPα mutations. Interestingly, AML cells 
with CEBPα mutations display high expression levels of CEBPα mRNA, while cell 
samples from AML cases without mutation do not show any measurable mRNA 
expresssion. A possible explanation for the lack of CEBPα mRNA expression may 
relate to promoter methylation. By assessing methylation status of the CEBPα 
promoter in all 15 samples we could indeed show that hypermethylation of the 
CEBPα promoter was only apparent in those AML cases with no CEBPα mutations 
and no measurable expression of CEBPα transcripts (30). Whether methylation is 
the cause or the result of mutated CEBPα remains subject of further research. Yet, 
this example of two gene expression signatures in relation to CEBPα mutations 
illustrates that gene expression profi ling may open ways towards deconstructing 
the molecular basis of leukemogenesis.
Sophisticated bioinformatics approaches have been developed to derive 
pathogenetic relevant relations from microarray data. Several groups have tried to 
identify sets of genes that correlate in aggregated microarray datasets. Correlations 
between expression levels potentially indicate functional interaction of gene 
products (31-33). By compiling a database of signatures of different tumor- and 
tissue types, machine-learning techniques can be applied to fi nd commonalities 
amongst the expression profi les. Sets or modules of genes that show comparable 
trends in different datasets are suggested to be functionally connected. Enlarged 
datasets and data available from other sources will contribute to a more complete 
understanding of biomolecular interactions (34, 35). 
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Data mining of scientifi c literature provides an interesting approach for gaining 
information on intracellular reactions. Lists of genes, for instance generated through 
microarray research, are used as input to retrieve information on interactions 
between genes, and potential biochemical networks are generated. Several 
commercial and academic approaches have been presented, such as Ingenuity® 
(36), MetaCore™ (37) and ACS (38). A limitation of this approach is that at the 
current state of development, knowledge about interactions is only in part available 
in literature or moreover, not all published data may be accurate. It is therefore not 
possible to confi dently construct complete networks of cellular processes using this 
approach. These applications will gain in value along with ongoing development 
and increased understanding. 
7.4 High-throughput techniques in cancer research
Originally, oligonucleotide arrays have been developed for high-throughput DNA 
and even peptide research (39-41).  Although expression profi ling is widely applied, 
DNA profi ling is still an emerging fi eld at an early stage of development. Further 
development of the early arrays for targeting DNA sequences have now resulted in 
the production of microarrays for probing single nucleotide polymorphisms (SNP), 
so-called SNP-arrays. Such arrays target 10.000 to 500.000 common SNP’s, which are 
more or less equally divided over the genome. Not only genomic polymorphisms 
are established, but also DNA copy numbers. This technique can thus be used to 
get information on chromosomal gains or losses. The genotype calls provide data 
of loss of heterozygosity. An alternative approach to DNA profi ling is array-based 
comparative genomic hybridization (array-CGH). As dual-channel microarrays, 
array CGH uses DNA from a test and a reference sample to assess copy numbers, 
but this technique cannot by applied to assess genotypes (42). Current resolutions 
are comparable to those of SNP-chips. Interestingly, SNP-array analyses of AML 
have revealed the presence of uniparental disomy, probably as a result of mitotic 
recombination, in about 20% of AML patients (43, 44). 
Losses or gains of chromosomal materials detected with DNA-profi ling may 
have effects on mRNA transcript levels and prognostically relevant chromosomal 
abnormalities could therefore also be identifi ed through expression profi ling. 
However, genome-wide SNP-array analyses in AML may facilitate the identifi cation 
of common abnormalities underlying distinct expression clusters. 
Several other high-throughput techniques are currently in development or have 
recently been applied. Chromatin immunoprecipitation (ChIP) is a technique to 
study protein-DNA interactions (45) to assess e.g. the binding of transcription 
factors to particular DNA regions or the epigenetic status of a gene and its regulatory 
regions. . To facilitate large-scale analyses, ChIP has been combined with microarray 
technology (46). This allows the identifi cation of target sites for a certain protein 
on a genome-wide level. In AML, target genes of disrupted transcription factors 
such as the core binding factor complex (involved in inv(16) and t(8;21)) or the 
PML-RARα fusion protein (involved in t(15;17)) could as such be identifi ed. ChIP-
on-Chip profi ling in combination with gene expression profi ling could be useful fo 
elucidating regulatory networks involved in leukemogenesis (47).
Methylation of CpG-islands in the genome is frequently seen and is known to 
play a role in regulating gene expression (48). Methylation profi ling of cancer 
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may reveal specifi c patterns of CpG island methylation resulting from clonal 
selection of cells with growth advantages, e.g. due to silencing of associated tumor 
suppressor genes (49).  For instance, methylation of genes associated with CEBPα 
mutations, possibly through the upregulation of methyl transferase enzymes such 
as DNMT3B, has been demonstrated (30). It is thought that this epigenetic event 
plays a role in leukemogenesis. Therefore, methylation profi ling of AML might 
be of use in identifying critical regulatory genes that are silenced as a result of 
molecular abnormalities.
Alternative splicing of primary RNA transcripts results in different mRNA 
transcripts of the same gene and plays an important role in cell homeostasis (50-52). 
For instance, different splice forms of EVI1 with different oncogenic characteristics 
have been shown to be present in AML (53). To identify the infl uence of alternative 
splicing, exon arrays have been developed targeting over 300.000 different 
Ensembl transcripts (54). Arrays targeting different splice variants can be used to 
identify particular active splice forms and specifi c combinations of co-occurring 
abnormalities that are involved in AML pathogenesis.
MicroRNA’s are short length RNAs (22 bp) that represent a class of mRNA 
translation regulators (55). They have been postulated to have a role in the 
control of cell development, growth, maturation and other cellular processes. A 
single microRNA can have up to hundreds of target mRNAs, which are subject to 
mRNA degradation and translation repression. A variety of microRNAs have been 
identifi ed in recent years. Profi ling tumors for expression of a series of microRNAs 
has been shown to characterize and to distinguish different sorts of cancer (56). 
Profi ling of microRNAs will in the future be applied to distinguish microRNAs 
that are associated with different subtypes of AML. Some of these microRNAs may 
be involved in pathogenesis of leukemia (57). 
On the protein level, mass spectrometry is a promising technique for assessing 
protein content and protein levels in cells (58). However, this technique has to be 
further developed to reliably identify the proteome present in a biological sample. 
Currently, mass spectrometry reliably identifi es only one to fi ve percent of most 
abundant proteins present. Protein levels may correlate with mRNA levels but it is 
clear that there is no direct relationship between mRNA and protein levels, e.g. due 
to variations of cellular processing of mRNA (59). Mass spectrometry furnishes 
a more specifi c way of identifying the active components that play a role in the 
cellular processes in leukemia cells.
A key challenge in current high-throughput research is the identifi cation of the 
most relevant targets for further investigation. Due to the large amounts of data 
Figure 2 (facing page). Screenshot of the JAVA heatmap explorer, which is part 
of MADEx. The right upper half of the (mirror image) heatmap is left out and several 
histograms, indicating different sample characteristics, have been added. In this example, 
the fi rst bar indicates FAB status ; the second bar indicates karyotype. Different colors 
indicate different patient class. The third and fourth bar indicate presence of AML specifi c 
acquired mutations in the genes FLT3 and NPM1. Green indicates absence of a mutation 
while red indicates presence of a mutation. The fi fth bar displays relative expression levels 
of the CD34 gene. All data is retrieved dynamically from the MADEx database. 
A full-color version of this fi gure is provided on the CD.
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involved, the number of false-positive and false-negative results will be signifi cant 
even at low rates.  It is therefore necessary that results are confi rmed using other 
techniques. Combining data from different high-throughput sources, like SNP-
arrays, methylation profi ling and gene expression analyses, allows a technique-
independent validation of results (Figure 3). As an example of the potential use of 
integrative genomic analyses, a prognostically relevant mutation in Microphthalmia-
associated transcription factor was identifi ed by comparing expression data 
with DNA copy number changes (60). From this example, we can learn that the 
complementary use of different techniques for complete characterization of patient 
samples can add to the understanding of tumorigenic and pathogenetic processes. 
7.5 Managing large data volumes in cancer research
To be able to compare experiments and exchange data between applications, 
standardization of analysis and data is important. To this end, many journals 
require the publication of microarray data supporting research in a specifi c format 
called Microarray and Gene Expression Markup Language (MAGE-ML). It is an 
XML-format based on the Minimum Information About Microarray Experiments 
(MIAME) standard (61), developed by a consortium of academic and commercial 
research investigators called MGED (62). Several large public data-repositories 
such as ArrayExpress and the Gene Expression Omnibus accept MAGE-ML. 
The archiving of raw data has facilitated research of gene expression profi les on 
an aggregated level (31-33). Many academic and commercial efforts have been 
undertaken to develop database systems for storing and analyzing microarray 
experiments, such as Bioarray Software Environment (BASE), the Stanford 
Microarray Database (SMD) and the TIGR Microarray Suite 4 (TM4) (63-65).  Also, 
applications have been developed that are available for local installation. These are 
used to analyze data, such as Cluster/Treeview and BRB ArrayTools (66, 67). An 
important contribution has been made through the development of the statistical 
Figure 3. Applying multiple high-throughput techniques on a cohort of de novo AML 
samples will further improve diagnosis but will also be useful for fundamental 
research of AML.
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programming environment R (68), a open-source implementation of the S-plus 
statistical programming language (69). Together with Bioconductor, an extended 
library of predefi ned analysis methods, the R programming environment can be 
applied to analyze microarray data with any method required. A disadvantage of 
these applications is that they require a basic knowledge of data-analysis methods 
and that in general they are not easy in use. Furthermore, integrated visualization 
of large series of specimens in relation to various other sets of data, e.g. clinical 
parameters, other molecular data, is not available. In Chapter 6, we propose an 
approach to visualize sample-sample correlations in an integrated view with 
sample-specifi c characteristics, such as karyotype or survival. An implementation 
of this visualization has been made available in the HeatMapper, as described in 
Chapter 6.
The latter visualization has been implemented in the MicroArray Data Explorer 
(MADEx). In MADEx, we have combined the HeatMapper tool  with a database 
application that stores expression data and analysis results from microarray 
experiments and allows access to these data via a user-friendly and fl exible web-
interface (Figure 2). By storing expression data together with results of different 
types of analysis, such as cluster analysis or tests for differential expression, 
MADEx functions as a central repository for microarray studies.  The central 
storage of these types of data combined with several dynamic analysis- and 
visualization functionalities within MADEx, allows researchers to quickly access 
data of microarray experiments at different levels in a web-based manner. To date, 
MADEx has been successfully applied in several studies (70-73). 
7.6 Conclusions 
The investigations reported in this thesis furnish evidence as regards the potential 
utility of expression profi ling using oligonucleotide arrays for the diagnosis of AML. 
Most likely, in the near future further improvements both in statistical methods and 
array technology will be introduced. Based on this, one may forecast that within 
several years expression profi ling will replace, at least in part, certain current routine 
diagnostic approaches (immunophenotyping, cytogenetics, molecular diagnostics) 
and offer added informative value. The discovery of additional prognostically 
relevant mutations, such as mutations in FLT3, CEBPα and NPM1, will further 
contribute to the refi nement of AML classifi cation. Identifi cation of such molecular 
changes will be greatly enhanced by applying high-throughput techniques that 
have recently become available, such as SNP profi ling, microRNA profi ling and 
methylation site profi ling (Figure 3) .
Moreover, integration of data available from different data sources will allow for 
in depth analysis and contribute to the elucidation of the molecular pathogenesis 
of AML. As we showed, microarray data, in combination with data from murine 
virus integration models, can already be used to generate pathogenetic networks 
that defi ne different classes of myeloid leukemia. Future research will result 
in extended list of murine AML genes, more complete sets of differentially 
expressed genes and more accurate defi nitions of protein-protein and gene-protein 
interactions in scientifi c literature, which will eventually facilitate the elucidation 
of the leukemogenic process. 
While data from these sources will probably facilitate a complete and accurate 
130
Chapter 7
classifi cation of AML and advance the elucidation of AML pathogenesis, it is to 
be kept in mind that due to the heterogeneity of AML, the number of samples 
concurrently analyzed is a critical factor and will remain a limiting step in this 
explorative process.
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Hematopoïese, of de vorming van functionele bloedcellen, is een proces wat 
plaats vindt in het beenmerg. Hematopoïetische stamcellen ondergaan cycli van 
deling en differentiatie waarin de functionele eindcellen, zoals rode bloedcellen, 
bloedplaatjes en witte bloedcellen, worden gevormd. Leukemie is een ziekte waarbij 
de stamcellen abnormale processen van deling in combinatie met een stop van de 
differentiatie ondergaan, waardoor er de vorming van functionele eindcellen wordt 
belemmerd. In het geval van acute myeloïde leukemie (AML) is er een afwijking in 
de tak van bloedcelvorming waar onder andere rode bloedcellen, bloedplaatjes en 
granulocyten worden gevormd.
De ontsporing van hematopoïetische stamcellen met AML als gevolg wordt 
veroorzaakt door abnormaliteiten in het genoom, zoals chromosomale fusies, 
deleties en mutaties. De klinische prognose wordt momenteel bepaald aan de hand 
van de aan- of afwezigheid van (combinaties van) abnormaliteiten. 
Het belangrijkste gevolg van genomische afwijkingen is de abnormale transcriptie 
van genen naar mRNA. Met behulpvan gen expressie profi lering, door middel 
van microarrays,  kunnen de transcriptie niveaus van duizenden genen simultaan 
worden bepaald. In hoofdstuk 2 is een onderzoek beschreven waarin met gen 
expressie profi lering is toegepast op 285 beenmerg monsters van de novo AML 
patiënten, voor het bepalen van prognose. Verschillende bekende prognostische 
groepen, zoals t(8;21) en inv(16) konden worden geidentifi ceerd, alsmede een 
nieuwe prognostisch relevante groep van patiënten met een relatief slechte 
prognose (cluster 10).Hoofdstuk 2 laat zien dat gen expressie profi lering in staat 
is om de huidige technieken voor het bepalen van prognose te vervangen, en 
prognose te verbeteren.
Om expressie niveaus te bepalen en te normalizeren met behulp van microrarrays 
worden verschillende statistische technieken toegepast. Deze kunnen leiden tot 
verschillende analyse uitkomsten. In hoofdstuk 3 wordt ingegaan op het effect van 
verschillende statistische technieken op de uitkomst van analyse. Methoden die 
een globale indruk van de data geven, zoals clustering en predictie analyse, worden 
niet erg beïnvloedt. Methoden die op de individuele data werken, zoals detectie 
van differentiële expressie, zijn daarentegen wel gevoelig voor de verschillende 
manieren van pre-processen. Door het ontbreken van een gouden standaard kan 
niet worden vastgesteld welke pre-processing methode het meest accuraat is. 
Mutaties in het gen nucleophosmine (NPM1) zijn aanwezig in 35% van AML 
patiënten. Mutaties in NPM1 correleren met hoge witte bloedcel aantallen, een 
normaal karyotype en mutaties in het gen FLT3 (hoofdstuk 4). NPM1 mutaties 
worden zelden gevonden in combinatie met mutaties in de genen CEBPα en NRAS, 
en zijn negatief gecorreleerd met een leeftijd onder de 35 jaar. Mutaties in NPM1 
zijn geassocieerd met een specifi ek expressie profi el en multivariate analyse toont 
aan dat patiënten met mutaties in NPM1 een relatief gunstige prognose hebben. 
Retrovirale insertionele mutagenese is een krachtige techniek voor het identifi ceren 
van genen betrokken bij de ontwikkeling van kanker in muizen. De relevantie van 
de gevonden genen voor humane ziekten is echter onduidelijk. Hoofdstuk 5 laat 
zien dat genen geïdentifi ceerd met behulp van retrovirale insertionele mutagenese 
signifi cant vaker differentieel tot expressie komen, dan overige genen. Genen die 
op grotere afstand van de plaats van de insertie liggen, tot 1 megabase,  komen niet 
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signifi cant vaker differentieel tot expressie. Onze data ondersteunen de validiteit 
van retrovirale insertionele mutagenese voor het detecteren van genen betrokken 
bij humane ziekten.
Gen expressie profi elen wordt traditioneel weergegeven in sample versus gen 
heatmaps, waarin expressie niveaus worden weergegeven op een groen tot rode 
schaal. In een dergelijke weergave is er geen overzicht van gecorreleerde profi elen 
en is het moeilijk om sample karakteristieken weer te geven. Hoofdstuk 6 beschrijft 
een methode voor de effi ciënte en accurate visuele weergave van de resultaten 
van een clusteranalyse. In deze weergave worden correlaties gecombineerd met 
sample karakteristieken. 
Conclusies
Genoom-brede gen expressie studies zijn veelbelovend voor het verbeteren het van 
prognose, en deze techniek zal in de toekomst de bestaande technieken grotendeels 
vervangen. Door het combineren van data uit gen expressie profi lering studies 
met data van andere studies, zoals studies van mutaties of integraties in specifi eke 
genen, danwel high-througput studies, zoals studies waarin SNP profi elen worden 
geanalyzeerd, kunnen belangrijke nieuwe inzichten in de pathogenese van leukemie 
worden verkregen.  
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